Also O
, O
the O
potential O
for O
hepatic O
injury O
should O
be O
considered O
when O
Rebif B-brand
is O
used O
in O
combination O
with O
other O
products O
associated O
with O
hepatic O
injury O
, O
or O
when O
new O
agents O
are O
added O
to O
the O
regimen O
of O
patients O
already O
on O
Rebif B-brand
. O

- O
a O
steroid B-group
medicine I-group
such O
as O
prednisone B-drug
( O
Deltasone B-brand
, O
Orasone B-brand
, O
others O
) O
, O
methylprednisolone B-drug
( O
Medrol B-brand
, O
others O
) O
, O
prednisolone B-drug
( O
Prelone B-brand
, O
Pediapred B-brand
, O
others O
) O
, O
and O
others O
; O

also O
, O
concurrent O
use O
of O
this O
medication O
may O
antagonise O
the O
anti-glaucoma O
and O
miotic O
actions O
of O
ophthalmic O
cholinesterase B-group
inhibitors I-group
. O

If O
any O
signs O
or O
symptoms O
occur O
physicians O
should O
consider O
discontinuation O
of O
either O
one O
or O
both O
agents O
( O
ZYVOX B-brand
or O
concomitant O
serotonergic B-group
agents I-group
) O
. O

This O
time O
window O
is O
different O
than O
for O
other O
oral O
formulations O
of O
ciprofloxacin B-drug
, O
which O
are O
usually O
administered O
2 O
hours O
before O
or O
6 O
hours O
after O
antacids B-group
. O

Lithium B-drug
: O
NSAIDs B-group
have O
produced O
an O
elevation O
of O
plasma O
lithium B-drug
levels O
and O
a O
reduction O
in O
renal O
lithium B-drug
clearance O
. O

No O
pharmacokinetic O
data O
are O
available O
. O

pregnancies O
have O
been O
reported O
. O

On O
the O
basis O
of O
the O
estimated O
number O
of O
regular O
users O
of O
intravenous O
amphetamine B-drug
in O
Ontario O
, O
the O
mortality O
rate O
in O
such O
users O
is O
at O
least O
four O
times O
as O
high O
as O
in O
the O
general O
population O
of O
the O
same O
age O
, O
and O
is O
comparable O
to O
that O
in O
alcoholics O
and O
heroin B-drug_n
addicts O
. O

The O
effects O
of O
L-CCG-1 B-drug_n
were O
not O
so O
strong O
. O

A O
400 O
mg O
once-daily O
dose O
was O
not O
studied O
but O
would O
be O
expected O
to O
increase O
aliskiren B-drug
blood O
levels O
further O
. O

SSRIs B-group
: O
Weakness O
hyperreflexia O
, O
and O
incoordination O
have O
been O
reported O
rarely O
when O
5-HT1 B-group
agonists I-group
have O
been O
co-administered O
with O
SSRIs B-group
( O
e. O
g O
. O

Because O
moderate O
CYP3A4 O
inhibitors O
( O
e.g. O
, O
diltiazem B-drug
) O
result O
in O
2-fold O
increase O
in O
plasma O
concentrations O
of O
aprepitant B-drug
, O
concomitant O
administration O
should O
also O
be O
approached O
with O
caution O
. O

Exemestane B-drug
is O
extensively O
metabolized O
by O
CYP O
3A4 O
, O
but O
coadministration O
of O
ketoconazole B-drug
, O
a O
potent O
inhibitor O
of O
CYP O
3A4 O
, O
has O
no O
significant O
effect O
on O
exemestane B-drug
pharmacokinetics O
. O

Phenytoin B-drug
: O
Altered O
serum O
levels O
of O
phenytoin B-drug
( O
increased O
and O
decreased O
) O
have O
been O
reported O
in O
patients O
receiving O
concomitant O
ciprofloxacin B-drug
. O

Since O
iloprost B-drug
inhibits O
platelet O
function O
, O
there O
is O
a O
potential O
for O
increased O
risk O
of O
bleeding O
, O
particularly O
in O
patients O
maintained O
on O
anticoagulants B-group
. O

Therefore O
, O
caution O
is O
advised O
if O
the O
concomitant O
administration O
of O
loxapine B-drug
and O
CNS-active O
drugs O
is O
required O
. O

Consequently O
, O
drugs O
with O
a O
low O
therapeutic O
margin O
, O
such O
as O
vitamin B-group
K I-group
antagonists I-group
, O
phenytoin B-drug
, O
and O
theophylline B-drug
, O
could O
have O
a O
delayed O
elimination O
and O
increases O
in O
their O
serum O
half-life O
leading O
to O
a O
toxic O
level O
. O

Therefore O
, O
caution O
should O
be O
exercised O
when O
using O
these O
drugs O
together O

Phenytoin B-drug
: O
Amphetamines B-group
may O
delay O
intestinal O
absorption O
of O
phenytoin B-drug
; O

Anticoagulants B-group
: O
Flurbiprofen B-drug
like O
other O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
, O
has O
been O
shown O
to O
affect O
bleeding O
parameters O
in O
patients O
receiving O
anti-coagulants B-group
, O
and O
serious O
clinical O
bleeding O
has O
been O
reported O
. O

propranolol B-drug
to O
healthy O
volunteers O
under O
steady-state O
conditions O
had O
no O
relevant O
effect O
on O
either O
drug O
s O
bioavailability O
, O
AUC O
and O
Cmax O
, O
differences O
were O
20 O
% O
between O
isradipine B-drug
given O
singly O
and O
in O
combination O
with O
propranolol B-drug
, O
and O
between O
propranolol B-drug
given O
singly O
and O
in O
combination O
with O
isradipine B-drug
. O

ocular O
effects O
; O

The O
concomitant O
administration O
of O
bosentan B-drug
and O
cyclosporine B-drug
A I-drug
is O
contraindicated O
. O

This O
oxidation O
, O
which O
is O
catalyzed O
by O
xanthine O
oxidase O
, O
inactivates O
mercaptopurine B-drug
. O

Ethinyl B-drug
estradiol I-drug
: O
Substrate O
of O
CYP3A4 O
( O
major O
) O
, O
3A5-7 O
( O
minor O
) O
; O

4 O
. O

The O
mean O
clearances O
of O
dofetilide B-drug
were O
16 O
% O
and O
15 O
% O
lower O
in O
patients O
on O
thiazide B-group
diuretics I-group
and O
inhibitors O
of O
tubular O
organic O
cation O
transport O
, O
respectively O
. O

In O
addition O
, O
levetiracetam B-drug
does O
not O
affect O
the O
in O
vitro O
glucuronidation O
of O
valproic B-drug
acid I-drug
. O

Specifically O
, O
they O
have O
focused O
on O
aspects O
of O
learning O
and O
memory O
that O
are O
impaired O
( O
vs. O
spared O
) O
by O
lesions O
of O
the O
hippocampal O
formation O
. O

The O
concentrations O
of O
SN38 B-drug_n
, O
the O
active O
metabolite O
of O
irinotecan B-drug
, O
were O
on O
average O
33 O
% O
higher O
in O
patients O
receiving O
bolus-IFL O
in O
combination O
with O
AVASTIN B-brand
when O
compared O
with O
bolus-IFL O
alone O
. O

All O
vasopressors B-group
should O
be O
used O
cautiously O
in O
patients O
taking O
monoamine B-group
oxidase I-group
( I-group
MAO I-group
) I-group
inhibitors I-group
. O

If O
an O
alternative O
treatment O
is O
unavailable O
, O
a O
TARCEVA B-brand
dose O
greater O
than O
150 O
mg O
should O
be O
considered O
for O
NSCLC O
patients O
, O
and O
greater O
than O
100 O
mg O
considered O
for O
pancreatic O
cancer O
patients O
. O

Vitamin B-group
D I-group
: O
The O
coadministration O
of O
any O
of O
the O
vitamin B-group
D I-group
analogues I-group
should O
be O
avoided O
as O
this O
could O
create O
possible O
additive O
effects O
and O
hypercalcemia O
. O

Check O
serum O
potassium O
levels O
at O
frequent O
intervals O
; O

Twenty-four O
healthy O
male O
subjects O
were O
randomized O
to O
one O
of O
two O
cohorts O
. O

Androgens B-group
may O
increase O
sensitivity O
to O
oral O
anticoagulahts O
. O

The O
serum O
concentration O
of O
phenytoin B-drug
increased O
dramatically O
from O
16.6 O
to O
49.1 O
microg/mL O
when O
fluvoxamine B-drug
was O
coadministered O
, O
although O
the O
daily O
dosage O
of O
phenytoin B-drug
and O
other O
drugs B-drug
had O
not O
changed O
. O

Acetazolamide B-drug
may O
increase O
the O
effects O
of O
other O
folic B-group
acid I-group
antagonists I-group
. O

If O
replacing O
clonidine B-drug
by O
beta-blocker B-group
therapy O
, O
the O
introduction O
of O
beta B-group
blockers I-group
should O
be O
delayed O
for O
several O
days O
after O
clonidine B-drug
administration O
has O
stopped O
. O

Grapefruit O
juice O
Co-administration O
of O
felodipine B-drug
with O
grapefruit O
juice O
resulted O
in O
more O
than O
2-fold O
increase O
in O
the O
AUC O
and O
Cmax O
, O
but O
no O
prolongation O
in O
the O
half- O
life O
of O
felodipine B-drug
. O

Renal O
clearance O
measurements O
of O
PAH B-drug
can O
not O
be O
made O
with O
any O
significant O
accuracy O
in O
patients O
receiving O
sulfonamides B-group
, O
procaine B-drug
, O
or O
thiazolesulfone B-drug
. O

Co-administration O
with O
other O
drugs O
that O
are O
metabolized O
by O
CYP O
3A4 O
( O
e.g. O
, O
indinavir B-drug
, O
erythromycin B-drug
) O
may O
increase O
their O
clearance O
, O
resulting O
in O
decreased O
plasma O
concentration O
. O

Drug O
/ O
Laboratory O
Test O
Interactions O
As O
a O
result O
of O
administration O
of O
Keflex B-brand
, O
a O
false-positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
. O

Marked O
symptomatic O
orthostatic O
hypotension O
has O
been O
reported O
when O
calcium B-group
channel I-group
blockers I-group
and O
organic O
nitrates B-group
were O
used O
in O
combination O
. O

There O
were O
no O
clinically O
relevant O
alterations O
in O
the O
pharmacokinetics O
of O
either O
agent O
. O

MAO B-group
inhibitors I-group
: O
MAOI B-group
antidepressants I-group
, O
as O
well O
as O
a O
metabolite O
of O
furazolidone B-drug
, O
slow O
amphetamine B-group
metabolism O
. O

A O
host O
of O
other O
medical O
considerations O
are O
discussed O
in O
chapter O
8 O
, O
including O
persistent O
ovarian O
follicles O
; O

Aprepitant B-drug
increased O
the O
AUC O
of O
midazolam B-drug
by O
25 O
% O
on O
Day O
4 O
and O
decreased O
the O
AUC O
of O
midazolam B-drug
by O
19 O
% O
on O
Day O
8 O
relative O
to O
the O
dosing O
of O
Aprepitant B-drug
on O
Days O
1 O
through O
3 O
. O

1 O
. O

Drug O
Interactions O
: O
a O
. O
Drugs O
Enhancing O
Heparin B-drug
Effect O
: O
Oral O
anticoagulants B-group
: O
Heparin B-drug
sodium I-drug
may O
prolong O
the O
one-stage O
prothrombin O
time O
. O

Seventeen O
percent O
of O
CHOP-HAART O
patients O
developed O
severe O
autonomic O
neurotoxicity O
, O
whereas O
none O
of O
the O
CHOP O
patients O
developed O
neurotoxicity O
( O
P O
= O
0.002 O
) O
. O

metabolic O
interference O
has O
sometimes O
been O
observed O
and O
the O
behaviour O
of O
the O
biological O
indicators O
differs O
from O
what O
would O
be O
expected O
. O

The O
different O
responses O
in O
locomotor O
activity O
induced O
by O
cocaine B-drug
suggest O
that O
genetic O
factors O
may O
play O
a O
role O
in O
determining O
the O
magnitude O
of O
response O
to O
this O
drug O
. O

Acetylcysteine B-drug
interference O
with O
urine O
ketone O
test O
. O

Patients O
with O
renal O
insufficiency O
or O
renal O
failure O
may O
be O
at O
risk O
for O
further O
kidney O
damage O
as O
well O
as O
complications O
related O
to O
interactions O
of O
herbal O
remedies O
with O
complex O
renal O
therapy O
regimens O
. O

nitrosourea B-group
AUC O
, O
with O
the O
extent O
of O
the O
reduction O
depending O
on O
the O
minimum O
effective O
concentration O
( O
MEC O
) O
chosen O
. O

Probenecid B-drug
: O
Probenecid B-drug
interferes O
with O
renal O
tubular O
secretion O
of O
ciprofloxacin B-drug
and O
produces O
an O
increase O
in O
the O
level O
of O
ciprofloxacin B-drug
in O
serum O
. O

Cholinesterase B-group
Inhibitors I-group
: O
Dipyridamole B-drug
may O
counteract O
the O
anticholinesterase O
effect O
of O
cholinesterase B-group
inhibitors I-group
, O
thereby O
potentially O
aggravating O
myasthenia O
gravis O
. O

At O
steady O
state O
, O
VIOXX B-brand
50 O
mg O
once O
daily O
had O
no O
effect O
on O
the O
anti-platelet O
activity O
of O
low-dose O
( O
81 O
mg O
once O
daily O
) O
aspirin B-brand
, O
as O
assessed O
by O
ex O
vivo O
platelet O
aggregation O
and O
serum O
TXB2 O
generation O
in O
clotting O
blood O
. O

Cardiovascular O
: O
Hypotension O
( O
0-9 O
% O
) O
. O

antihistamines B-group
; O

No O
significant O
drug-drug O
pharmacokinetic O
( O
or O
pharmacodynamic O
) O
interactions O
have O
been O
found O
in O
interaction O
studies O
with O
hydrochlorothiazide B-drug
, O
digoxin B-drug
, O
warfarin B-drug
, O
and O
nifedipine B-drug
. O

WelChol B-brand
decreased O
the O
Cmax O
and O
AUC O
of O
sustained-release O
verapamil B-drug
( O
Calan B-brand
SR I-brand
) O
by O
approximately O
31 O
% O
and O
11 O
% O
, O
respectively O
. O

Pharmacokinetic O
profile O
of O
etodolac B-drug
in O
special O
populations O
. O

- O
Lithium B-drug
: O
Lithium B-drug
should O
generally O
not O
be O
given O
with O
diuretics B-group
( O
such O
as O
bumetanide B-drug
) O
because O
they O
reduce O
its O
renal O
clearance O
and O
add O
a O
high O
risk O
of O
lithium B-drug
toxicity O
. O

Alternatives O
to O
clarithromycin B-drug
, O
such O
as O
azithromycin B-drug
, O
should O
be O
considered O
. O

Administration O
of O
eplerenone B-drug
with O
other O
CYP3A4 O
inhibitors O
( O
e.g. O
, O
erythromycin B-drug
500 O
mg O
BID O
, O
verapamil B-drug
240 O
mg O
QD O
, O
saquinavir B-drug
1200 O
mg O
TID O
, O
fluconazole B-drug
200 O
mg O
QD O
) O
resulted O
in O
increases O
in O
Cmax O
of O
eplerenone B-drug
ranging O
from O
1.4- O
to O
1.6- O
fold O
and O
AUC O
from O
2.0- O
to O
2.9- O
fold O
. O

These O
alterations O
in O
digoxin B-drug
pharmacokinetics O
produced O
by O
amiodarone B-drug
explain O
the O
increase O
in O
serum O
digoxin B-drug
level O
that O
has O
been O
observed O
when O
this O
drug O
combination O
has O
been O
used O
clinically O
. O

co-administration O
of O
phenobarbital B-drug
may O
produce O
a O
synergistic O
anticonvulsant O
action O
. O

Carbamazepine B-drug
: O
Steady-state O
trough O
plasma O
carbamazepine B-drug
and O
carbamazepine B-drug_n
10 I-drug_n
, I-drug_n
11 I-drug_n
epoxide I-drug_n
concentrations O
were O
not O
affected O
by O
concomitant O
gabapentin B-drug
( O
400 O
mg O
TID O
; O

Restoration O
of O
female O
fertility O
to O
values O
similar O
to O
controls O
was O
evident O
following O
a O
29-day O
withdrawal O
period O
after O
dosing O
at O
2 O
mg/kg/day O
( O
twice O
the O
human O
dose O
based O
on O
BSA O
) O
. O

Cardiac B-group
glycosides I-group
could O
exaggerate O
the O
depression O
of O
AV O
nodal O
conduction O
observed O
with O
bepridil B-drug
hydrochloride I-drug
. O

The O
harmonic O
mean O
elimination O
half-life O
was O
45.7 O
and O
43.4 O
hours O
for O
rofecoxib B-drug
+ O
digoxin B-drug
and O
placebo O
+ O
digoxin B-drug
treatments O
, O
respectively O
. O

Most O
who O
take O
EPA B-drug
supplements O
and O
the O
above O
drugs O
or O
herbs O
do O
not O
suffer O
from O
these O
problems O
and O
if O
they O
occur O
, O
they O
are O
rare O
. O

Rifampin B-drug
: O
Coadministration O
of O
rifampin B-drug
and O
VIRACEPT B-brand
resulted O
in O
an O
82 O
% O
decrease O
in O
nelfinavir B-drug
plasma O
A.C O
. O

Animal O
studies O
also O
suggest O
an O
increased O
potential O
for O
seizures O
when O
these O
two O
drugs O
are O
given O
concomitantly O
. O

and O
overdose O
. O

Tadalafil B-drug
dose O
should O
not O
exceed O
a O
maximum O
of O
10 O
mg O
in O
a O
72- O
hour O
period O
in O
patients O
receiving O
concomitant O
indinavir B-drug
therapy O
. O

It O
is O
recommended O
that O
glucose O
tests O
based O
on O
enzymatic O
glucose O
oxidase O
reactions O
be O
used O
. O

The O
uptake O
inhibitors O
cocaine B-drug
and O
desipramine B-drug
( O
3 O
mumol/liter O
) O
potentiated O
the O
positive O
inotropic O
effects O
of O
norepinephrine B-drug
in O
nonfailing O
myocardium O
( O
p O
< O
0.05 O
) O
but O
not O
in O
functional O
class O
IV O
myocardium O
. O

In O
clinical O
studies O
performed O
with O
Fondaparinux B-drug
, O
the O
concomitant O
use O
of O
oral O
anticoagulants B-group
( O
warfarin B-drug
) O
, O
platelet B-group
inhibitors I-group
( O
acetylsalicylic B-drug
acid I-drug
) O
, O
NSAIDs B-group
( O
piroxicam B-drug
) O
, O
and O
digoxin B-drug
did O
not O
significantly O
affect O
the O
pharmacokinetics/pharmacodynamics O
of O
fondaparinux B-drug
sodium I-drug
. O

The O
half-life O
of O
ketamine B-drug
in O
plasma O
and O
brain O
was O
longer O
in O
the O
presence O
of O
halothane B-drug
than O
when O
ketamine B-drug
was O
given O
alone O
. O

Tacrolimus B-drug
: O
Co-administration O
of O
tacrolimus B-drug
and O
bosentan B-drug
has O
not O
been O
studied O
in O
man O
. O

Animal O
studies O
indicate O
that O
dobutamine B-drug
may O
be O
ineffective O
if O
the O
patient O
has O
recently O
received O
a O
b-blocking B-group
drug I-group
. O

Avoid O
dong O
quai O
and O
black O
cohosh O
( O
have O
estrogen O
activity O
) O
. O

Administration O
of O
reserpine B-drug
during O
therapy O
with O
a O
tricyclic B-group
antidepressant I-group
has O
been O
shown O
to O
produce O
a O
stimulating O
effect O
in O
some O
depressed O
patients O
. O

Nonetheless O
, O
they O
have O
been O
observed O
with O
macrolide B-group
products I-group
. O

Drugs O
That O
Should O
Not O
Be O
Coadministered O
with O
CRIXIVAN B-brand

Nephrotoxicity O
has O
been O
reported O
following O
concomitant O
administration O
of O
other O
cephalosporins B-group
with O
potent O
diuretics B-group
such O
as O
furosemide B-drug
. O

Drug/Laboratory O
Interactions O
No O
formal O
drug O
interaction O
studies O
have O
been O
performed O
with O
Campath B-brand
. O

Drug O
interaction O
studies O
were O
performed O
with O
azithromycin B-drug
and O
other O
drugs O
likely O
to O
be O
co-administered O
. O

No O
dosage O
adjustment O
of O
either O
drug O
is O
recommended O
when O
azithromycin B-drug
is O
co O
administered O
with O
any O
of O
the O
above O
agents O
. O

Naproxen B-drug
, O
naproxen B-drug
sodium I-drug
and O
other O
NSAIDs B-group
have O
been O
reported O
to O
reduce O
the O
tubular O
secretion O
of O
methotrexate B-drug
in O
an O
animal O
model O
, O
possibly O
increasing O
the O
toxicity O
of O
methotrexate B-drug
. O

Adrenergic B-group
blockers I-group
: O
Adrenergic B-group
blockers I-group
are O
inhibited O
by O
amphetamines B-group
. O

+109 O
% O

Warfarin B-drug
: O
A O
single O
125-mg O
dose O
of O
Aprepitant B-drug
was O
administered O
on O
Day O
1 O
and O
80 O
mg/day O
on O
Days O
2 O
and O
3 O
to O
healthy O
subjects O
who O
were O
stabilized O
on O
chronic O
warfarin B-drug
therapy O
. O

RESULTS O
: O
Bombesin B-drug_n
significantly O
increased O
the O
incidence O
of O
intestinal O
tumors O
and O
cancer O
metastasis O
to O
the O
peritoneum O
. O

The O
gastrointestinal O
absorption O
of O
digoxin B-drug
also O
appears O
to O
be O
inhibited O
. O

. O

The O
physician O
should O
be O
cautious O
when O
administering O
flurbiprofen B-drug
to O
patients O
taking O
anticoagulants B-group
. O

Interactions O
may O
occur O
with O
the O
following O
: O
adrenocorticoids O
( O
cortisone-like O
medicine O
) O
, O
anticoagulants B-group
( O
blood B-group
thinners O
) O
, O
carbamazepine B-drug
, O
corticotropin B-drug
( O
barbiturates B-group
may O
decrease O
the O
effects O
of O
these O
medicines O
) O
, O
central B-group
nervous I-group
system I-group
( I-group
CNS I-group
) I-group
depressants I-group
( O
using O
these O
medicines O
with O
barbiturates B-group
may O
result O
in O
increased O
CNS O
depressant O
effects O
) O
, O
divalproex B-drug
sodium I-drug
, O
valproic B-drug
acid I-drug
( O
using O
these O
medicines O
with O
barbiturates B-group
may O
change O
the O
amount O
of O
either O
medicine O
that O
you O
need O
to O
take O
) O
, O
and O
oral O
contraceptives B-group
containing O
estrogens B-group
( O
barbiturates B-group
may O
decrease O
the O
effectiveness O
of O
these O
oral O
contraceptives B-group
, O
and O
you O
may O
need O
to O
change O
to O
a O
different O
type O
of O
birth O
control O
) O
. O

Other O
CNS B-group
depressant I-group
drugs I-group
( O
e.g O
. O
barbiturates B-group
, O
tranquilizers B-group
, O
opioids B-group
and O
general O
anesthetics B-group
) O
have O
additive O
or O
potentiating O
effects O
with O
INAPSINE B-brand
. O

Because O
of O
the O
small O
effect O
on O
half-life O
, O
the O
coadministration O
with O
probenecid B-drug
to O
extend O
the O
half-life O
of O
ertapenem B-drug
is O
not O
recommended O
. O

[ O
The O
effect O
of O
sandimmune B-brand
on O
the O
activity O
of O
mixed-function O
mono-oxidases O
in O
the O
liver O
microsomes O
] O
The O
effects O
of O
the O
immunodepressant B-group
-- O
the O
drug O
sandimmune B-brand
-- O
on O
hepatic O
microsomal O
monooxygenase O
activities O
were O
studied O
. O

In O
large O
, O
well O
controlled O
trials O
in O
patients O
with O
schizophrenia O
or O
related O
psychoses O
, O
olanzapine B-drug
5 O
to O
20 O
mg/day O
was O
significantly O
superior O
to O
haloperidol B-drug
5 O
to O
20 O
mg/day O
in O
overall O
improvements O
in O
psychopathology O
rating O
scales O
and O
in O
the O
treatment O
of O
depressive O
and O
negative O
symptoms O
, O
and O
was O
comparable O
in O
effects O
on O
positive O
psychotic O
symptoms O
. O

In O
vitro O
studies O
have O
shown O
that O
the O
metabolism O
of O
docetaxel B-drug
may O
be O
modified O
by O
the O
concomitant O
administration O
of O
compounds O
that O
induce O
, O
inhibit O
, O
or O
are O
metabolized O
by O
cytochrome O
P450 O
3A4 O
, O
such O
as O
cyclosporine B-drug
, O
terfenadine B-drug
, O
ketoconazole B-drug
, O
erythromycin B-drug
, O
and O
troleandomycin B-drug
. O

Maximal O
exercise O
testing O
, O
a O
maneuver O
often O
applied O
to O
cardiac O
patients O
, O
does O
not O
significantly O
alter O
the O
serum O
digoxin B-drug
level O
. O

Potential O
interactions O
between O
TAXOL B-brand
, O
a O
substrate O
of O
CYP3A4 O
, O
and O
protease B-group
inhibitors I-group
( O
ritonavir B-drug
, O
saquinavir B-drug
, O
indinavir B-drug
, O
and O
nelfinavir B-drug
) O
, O
which O
are O
substrates O
and/or O
inhibitors O
of O
CYP3A4 O
, O
have O
not O
been O
evaluated O
in O
clinical O
trials O
. O

( O
41 O
) O
but O
returned O
to O
normal O
levels O
when O
the O
nerves O
were O
rewarmed O
. O

Animal O
experience O
indicates O
that O
clorazepate B-drug
dipotassium I-drug
prolongs O
the O
sleeping O
time O
after O
hexobarbital B-drug
or O
after O
ethyl B-drug
alcohol I-drug
, O
increases O
the O
inhibitory O
effects O
of O
chlorpromazine B-drug
, O
but O
does O
not O
exhibit O
monoamine O
oxidase O
inhibition O
. O

and O
calcium B-group
channel I-group
antagonists I-group
e.g. O
, O
verapamil B-drug
) O
, O
CYP1A2 O
inducers O
( O
omeprazole B-drug
) O
and O
CYP1A2 O
inhibitors O
( O
furafylline B-drug
and O
clarithromycin B-drug
) O
. O

Digoxin B-drug
and O
verapamil B-drug
use O
may O
be O
rarely O
associated O
with O
ventricular O
fibrillation O
when O
combined O
with O
Adenocard B-brand
. O

Nelfinavir B-drug
steady-state O
Cmax O
, O
A.C. O
and O
Cmin O
were O
increased O
by O
12 O
% O
, O
15 O
% O
, O
and O
14 O
% O
, O
respectively O
, O
by O
concomitant O
amprenavir B-drug
. O

Phase O
II O
clinical O
trial O
data O
, O
where O
IRESSA B-brand
and O
vinorelbine B-drug
have O
been O
used O
concomitantly O
, O
indicate O
that O
IRESSA B-brand
may O
exacerbate O
the O
neutropenic O
effect O
of O
vinorelbine B-drug
. O

Weak O
inhibitory O
effects O
toward O
other O
isoforms O
( O
CYP2C8 O
, O
2C9 O
, O
2C19 O
, O
2D6 O
, O
3A4 O
) O
were O
found O
, O
but O
Ki O
values O
were O
in O
excess O
of O
plasma O
concentrations O
achieved O
following O
dosing O
. O

- O
Drugs O
that O
may O
decrease O
plasma O
phenytoin B-drug
concentrations O
include O
: O
carbamazepine B-drug
, O
chronic O
alcohol B-drug
abuse O
, O
reserpine B-drug

The O
majority O
of O
patients O
in O
RA O
clinical O
studies O
received O
one O
or O
more O
of O
the O
following O
concomitant O
medications O
with O
ORENCIA B-brand
: O
MTX B-drug
, O
NSAIDs B-group
, O
corticosteroids B-group
, O
TNF B-group
blocking I-group
agents I-group
, O
azathioprine B-drug
, O
chloroquine B-drug
, O
gold B-drug
, O
hydroxychloroquine B-drug
, O
leflunomide B-drug
, O
sulfasalazine B-drug
, O
and O
anakinra B-drug
. O

Indinavir B-drug
steady-state O
Cmax O
, O
A.C. O
and O
Cmin O
were O
decreased O
by O
22 O
% O
, O
38 O
% O
, O
and O
27 O
% O
, O
respectively O
, O
by O
concomitant O
amprenavir B-drug
. O

In O
contrast O
, O
the O
potency O
of O
norepinephrine B-drug
was O
increased O
in O
failing O
hearts O
( O
New O
York O
Heart O
Association O
functional O
class O
IV O
) O
in O
relation O
to O
the O
concentrations O
producing O
50 O
% O
of O
the O
maximal O
effect O
( O
EC50 O
) O
. O

No O
clinically O
significant O
adverse O
interactions O
with O
commonly O
used O
preanesthetic O
drugs O
, O
or O
drugs O
used O
during O
anesthesia O
( O
muscle B-group
relaxants I-group
, O
intravenous O
agents O
, O
and O
local O
anesthetic B-group
agents I-group
) O
were O
reported O
in O
clinical O
trials O
. O

Monitor O
prothrombin O
levels O
and O
adjust O
anticoagulant B-group
dosage O
accordingly O
. O

Further O
, O
if O
guanfacine B-drug
is O
to O
be O
discontinued O
in O
such O
patients O
, O
careful O
tapering O
of O
the O
dosage O
may O
be O
necessary O
in O
order O
to O
avoid O
rebound O
phenomena O
. O

Activation O
of O
an O
effector O
immediate-early O
gene O
arc O
by O
methamphetamine B-drug
. O

CYP450 O
Metabolized O
Drugs O
Results O
from O
in O
vitro O
and O
in O
vivo O
studies O
suggest O
that O
enfuvirtide B-drug
is O
unlikely O
to O
have O
significant O
drug O
interactions O
with O
concomitantly O
administered O
drugs O
metabolized O
by O
CYP450 O
enzymes O
. O

The O
antihypertensive O
effects O
of O
methyldopa B-drug
, O
mecamylamine B-drug
, O
reserpine B-drug
, O
and O
veratrum B-drug
alkaloids I-drug
may O
be O
reduced O
by O
sympathomimetics B-group
. O

The O
clinical O
relevance O
of O
these O
increases O
is O
not O
known O
. O

Omeprazole B-drug
should O
be O
taken O
as O
directed O
and O
Proquin B-brand
XR I-brand
should O
be O
taken O
with O
a O
main O
meal O
of O
the O
day O
, O
preferably O
the O
evening O
meal.. O

Certain O
drugs O
, O
including O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
( O
NSAIDs B-group
) O
, O
salicylates B-group
, O
monoamine B-group
oxidase I-group
inhibitors I-group
, O
and O
non-selective B-group
beta-adrenergic-blocking I-group
agents I-group
may O
potentiate O
the O
hypoglycemic O
action O
of O
Starlix B-brand
and O
other O
oral O
antidiabetic B-group
drugs I-group
. O

Corticosteroids B-group
: O
Concomitant O
administration O
with O
aspirin B-brand
may O
increase O
the O
risk O
of O
gastrointestinal O
ulceration O
and O
may O
reduce O
serum O
salicylate O
levels O
. O

Of O
particular O
importance O
, O
sufficient O
time O
must O
elapse O
before O
initiating O
TCA O
treatment O
in O
a O
patient O
being O
withdrawn O
from O
fluoxetine B-drug
, O
given O
the O
long O
half-life O
of O
the O
parent O
and O
active O
metabolite O
( O
at O
least O
5 O
weeks O
may O
be O
necessary O
) O
. O

Concomitant O
treatment O
with O
potassium-sparing B-group
diuretics I-group
may O
be O
associated O
with O
increased O
serum O
potassium O
levels O
. O

Valproate B-drug
500 O
mg O
twice O
daily O
did O
not O
modify O
the O
rate O
or O
extent O
of O
levetiracetam B-drug
absorption O
or O
its O
plasma O
clearance O
or O
urinary O
excretion O
. O

However O
, O
in O
a O
follow-up O
study O
in O
normal O
subjects O
, O
single-dose O
administration O
of O
colestipol B-drug
hydrochloride I-drug
and O
propranolol B-drug
and O
twice-a-day O
administration O
for O
5 O
days O
of O
both O
agents O
did O
not O
affect O
the O
extent O
of O
propranolol B-drug
absorption O
, O
but O
had O
a O
small O
yet O
statistically O
significant O
effect O
on O
its O
rate O
of O
absorption O
; O

Sexual O
intercourse O
with O
a O
steady O
partner O
causes O
no O
more O
cardiovascular O
risk O
than O
normal O
daily O
activities O
such O
as O
ironing O
, O
2 O
kilometers O
of O
walking O
without O
climbing O
, O
paperhanging O
, O
playing O
golf O
or O
gardening O
. O

Probenecid B-drug
may O
decrease O
renal O
tubular O
secretion O
of O
cephalosporins B-group
when O
used O
concurrently O
, O
resulting O
in O
increased O
and O
more O
prolonged O
cephalosporin B-group
blood O
levels O
. O

Warfarin B-drug
: O
In O
subjects O
receiving O
warfarin B-drug
, O
no O
significant O
change O
in O
clotting O
time O
was O
observed O
when O
grepafloxacin B-drug
was O
coadministered O
. O

Bismuth B-drug
: O
Bismuth B-drug
subsalicylate I-drug
, O
given O
concomitantly O
with O
enoxacin B-drug
or O
60 O
minutes O
following O
enoxacin B-drug
administration O
, O
decreased O
enoxacin B-drug
bioavailability O
by O
approximately O
25 O
% O
. O

hepatotoxic O
drugs O
; O

For O
the O
calcium-entry B-group
blocking I-group
agents I-group
now O
available O
in O
the O
United O
States O
( O
verapamil B-drug
, O
nifedipine B-drug
and O
diltiazem B-drug
) O
, O
these O
data O
appeared O
well O
after O
clinical O
patterns O
of O
use O
evolved O
. O

However O
, O
prudent O
evaluation O
of O
individual O
cases O
is O
warranted O
in O
the O
clinical O
setting O
. O

When O
used O
concurrently O
with O
such O
drugs O
, O
the O
dose O
of O
butorphanol B-drug
should O
be O
the O
smallest O
effective O
dose O
and O
the O
frequency O
of O
dosing O
reduced O
as O
much O
as O
possible O
when O
administered O
concomitantly O
with O
drugs O
that O
potentiate O
the O
action O
of O
opioids B-group
. O

Most O
events O
were O
reported O
to O
occur O
when O
contrast O
media O
was O
given O
within O
4 O
weeks O
after O
the O
last O
dose O
of O
interleukin-2 B-drug
. O

Cimetidine B-drug
: O
Cimetidine B-drug
does O
not O
affect O
the O
pharmacokinetics O
of O
fosfomycin B-drug
when O
coadministered O
with O
MONUROL B-brand
. O

C57BL/6N O
demonstrated O
large O
numbers O
of O
two O
of O
the O
three O
types O
of O
liver O
tumors O
seen O
in O
livers O
of O
genetically O
predisposed O
mice O
, O
one O
of O
which O
required O
the O
additional O
stimulus O
of O
dietary O
phenobarbital B-drug
for O
growth O
. O

May O
interact O
with O
thyroid O
medication O
( O
e.g. O
, O
levothyroxine B-drug
) O
, O
iodine-containing B-drug
products O
, O
antacids B-group
, O
H2-antagonists B-group
( O
e.g. O
, O
famotidine B-drug
, O
ranitidine B-drug
) O
, O
and O
proton B-group
pump I-group
inhibitors I-group
( O
e.g. O
, O
lansoprazole B-drug
, O
omeprazole B-drug
) O
. O

Photic O
evoked O
potentials O
were O
recorded O
from O
the O
visual O
cortex O
of O
chronically O
implanted O
albino O
rats O
. O

SETTING O
: O
Clinical O
research O
center O
. O

Concomitant O
medications O
were O
grouped O
as O
ACE B-group
inhibitors I-group
, O
oral O
anticoagulants B-group
, O
calcium B-group
channel I-group
blockers I-group
, O
beta B-group
blockers I-group
, O
cardiac B-group
glycosides I-group
, O
inducers O
of O
CYP3A4 O
, O
substrates O
and O
inhibitors O
of O
CYP3A4 O
, O
substrates O
and O
inhibitors O
of O
P-glycoprotein O
, O
nitrates B-group
, O
sulphonylureas B-group
, O
loop B-group
diuretics I-group
, O
potassium B-group
sparing I-group
diuretics I-group
, O
thiazide B-group
diuretics I-group
, O
substrates O
and O
inhibitors O
of O
tubular O
organic O
cation O
transport O
, O
and O
QTc-prolonging O
drugs O
. O

Recombinant O
shuttle O
vectors O
containing O
a O
vanH O
promoter-vanA O
antisense O
gene O
cassette O
fully O
restored O
vancomycin B-drug
susceptibility O
through O
a O
combined O
transcriptional O
activator O
binding O
domain O
decoy O
and O
inducible O
vanA O
antisense O
RNA O
effect O
. O

3 O
. O

A O
single O
tonic O
convulsion O
was O
seen O
in O
each O
of O
2 O
male O
dogs O
( O
one O
treated O
at O
10 O
mg/kg/day O
and O
one O
at O
120 O
mg/kg/day O
) O
in O
a O
2-year O
study O
. O

+82 O
% O

Gemfibrozil B-drug
Other O
fibrates B-group
Niacin B-drug
( O
nicotinic B-drug
acid I-drug
) O
( O
=1 O
g/day O
) O

Angiomax B-brand
does O
not O
exhibit O
binding O
to O
plasma O
proteins O
( O
other O
than O
thrombin O
) O
or O
red O
blood O
cells O
. O

therefore O
, O
doses O
greater O
than O
the O
normal O
antiasthmatic O
dose O
of O
beta-agonist B-group
bronchodilator I-group
drugs I-group
may O
be O
required O
. O

Co-administration O
of O
ketoconazole B-drug
, O
a O
strong O
inhibitor O
of O
CYP3A4 O
, O
increased O
cinacalcet B-drug
exposure O
following O
a O
single O
90 O
mg O
dose O
of O
Sensipar B-brand
by O
2.3 O
fold O
. O

If O
resumed O
during O
captopril B-drug
therapy O
, O
such O
agents O
should O
be O
administered O
cautiously O
, O
and O
perhaps O
at O
lower O
dosage O
. O

allopurinol B-drug
; O

Certain O
antibiotic B-group
, O
cisplatin B-drug
, O
cyclosporine B-drug
, O
diuretic B-group
, O
foscarnet B-drug
, O
and O
vaccines B-group
. O

With O
some O
agents O
, O
the O
metabolism O
may O
be O
induced O
, O
resulting O
in O
decreased O
concentrations O
. O

Beta-blockers B-group
, O
clonidine B-drug
, O
lithium B-drug
salts O
, O
and O
alcohol B-drug
may O
either O
potentiate O
or O
weaken O
the O
blood-glucose-lowering O
effect O
of O
insulin B-drug
. O

Antimicrobial O
activity O
of O
Ganoderma B-drug_n
lucidum I-drug_n
extract I-drug_n
alone O
and O
in O
combination O
with O
some O
antibiotics B-group
. O

Alcohol B-drug
, O
in O
particular O
, O
has O
been O
found O
to O
exhibit O
additive O
effects O
of O
this O
variety O
. O

Due O
to O
the O
possibility O
of O
antagonism O
in O
vivo O
, O
particularly O
when O
bactericidal O
activity O
is O
desired O
, O
this O
drug O
combination O
should O
be O
avoided O
. O

If O
this O
is O
not O
possible O
, O
the O
starting O
dose O
should O
be O
reduced O
and O
the O
patient O
should O
be O
observed O
closely O
for O
several O
hours O
following O
an O
initial O
dose O
and O
until O
blood O
pressure O
has O
stabilized O
( O
see O
DOSAGE O
AND O
ADMINISTRATION O
. O
) O

Cyclosporin B-drug
: O
Reports O
indicate O
that O
cyclosporine B-drug
levels O
may O
be O
increased O
during O
concomitant O
treatment O
with O
allopurinol B-drug
sodium I-drug
for O
injection O
. O

Adequate O
monitoring O
of O
theophylline B-drug
plasma O
concentrations O
should O
be O
considered O
when O
therapy O
with O
VIOXX B-brand
is O
initiated O
or O
changed O
in O
patients O
receiving O
theophylline B-drug
. O

If O
midazolam B-drug
is O
administered O
parenterally O
, O
special O
precaution O
is O
required O
since O
the O
sedative O
effect O
may O
be O
prolonged O
. O

The O
effect O
of O
Keppra B-brand
on O
probenecid B-drug
was O
not O
studied O
. O

Lopinavir/ritonavir B-drug

It O
is O
structurally O
distinct O
from O
the O
other O
currently O
available O
HMGCoA B-group
reductase I-group
inhibitors I-group
( O
lovastatin B-drug
, O
simvastatin B-drug
, O
and O
pravastatin B-drug
) O
, O
leading O
to O
unique O
biopharmaceutical O
properties O
relative O
to O
the O
other O
agents O
of O
this O
class O
. O

Digoxin B-drug
: O
In O
patients O
with O
hypercholesterolemia O
, O
concomitant O
administration O
of O
lovastatin B-drug
and O
digoxin B-drug
resulted O
in O
no O
effect O
on O
digoxin B-drug
plasma O
concentrations O
. O

There O
have O
been O
isolated O
reports O
of O
patients O
experiencing O
increases O
in O
their O
prothrombin O
times O
when O
etidronate B-drug
was O
added O
to O
warfarin B-drug
therapy O
. O

ulcerans O
infection O
. O

isoflurane B-drug
; O

INDOCIN B-brand
has O
been O
reported O
to O
decrease O
the O
tubular O
secretion O
of O
methotrexate B-drug
and O
to O
potentiate O
its O
toxicity O
. O

The O
mean O
minimum O
lithium B-drug
concentration O
increased O
15 O
% O
and O
the O
renal O
clearance O
was O
decreased O
by O
approximately O
20 O
% O
. O

The O
behavioral O
changes O
of O
mice O
induced O
by O
acute O
and O
repeated O
i.p O
. O

An O
intravenous O
injection O
of O
perchlorate B-drug_n
given O
later O
also O
produces O
a O
complete O
and O
immediately O
beginning O
depletion O
of O
pertechnetate B-drug
already O
accumulated O
in O
the O
thyroid O
, O
within O
a O
period O
of O
195 O
min O
after O
99m-TcO-4-injection O
with O
a O
corresponding O
increase O
in O
blood O
levels O
. O

The O
development O
of O
clinical O
vancomycin-resistant O
strains O
of O
enterococci O
( O
VRE O
) O
is O
a O
major O
cause O
for O
concern O
. O

In O
human O
heart O
failure O
, O
there O
is O
a O
presynaptic O
defect O
in O
the O
sympathetic O
nervous O
system O
, O
leading O
to O
reduced O
uptake-1 O
activity O
. O

Administering O
InsP B-drug_n
( I-drug_n
3 I-drug_n
) I-drug_n
together O
with O
RR B-drug_n
( O
100-500 O
microM O
) O
inhibited O
InsP O
( O
3 O
) O
-induced O
responses O
( O
both O
Ca O
( O
2+ O
) O
and O
current O
responses O
) O
in O
a O
dose-dependent O
fashion O
. O

Therefore O
, O
the O
potential O
exists O
for O
interaction O
between O
carbamazepine B-drug
and O
any O
agent O
metabolized O
by O
one O
( O
or O
more O
) O
of O
these O
enzymes O
. O

Seizure O
, O
associated O
with O
increased O
lidocaine B-drug
concentrations O
, O
has O
been O
reported O
with O
concomitant O
administration O
of O
intravenous O
amiodarone B-drug
. O

Evaluation O
of O
its O
efficacy O
and O
toxicity O
. O

Azithromycin B-drug
did O
not O
affect O
the O
prothrombin O
time O
response O
to O
a O
single O
dose O
of O
warfarin B-drug
. O

Preliminary O
investigations O
indicate O
that O
icodextrin B-drug
and O
its O
metabolites O
interfere O
with O
enzymatic-based O
amylase O
assays O
, O
resulting O
in O
inaccurately O
low O
values O
. O

Drugs O
That O
Inhibit O
CYP3A4 O
CYP3A4 O
is O
a O
minor O
metabolic O
pathway O
for O
the O
elimination O
of O
zaleplon B-drug
because O
the O
sum O
of O
desethylzaleplon O
( O
formed O
via O
CYP3A4 O
in O
vitro O
) O
and O
its O
metabolites O
, O
5-oxo-desethylzaleplon B-drug_n
and O
5-oxo-desethylzaleplon B-drug_n
glucuronide I-drug_n
, O
account O
for O
only O
9 O
% O
of O
the O
urinary O
recovery O
of O
a O
zaleplon B-drug
dose O
. O

Blood O
samples O
also O
were O
taken O
before O
morning O
doses O
on O
the O
3rd O
, O
4th O
, O
and O
5th O
days O
of O
phases O
1 O
and O
3 O
. O

Elevated O
International O
Normalized O
Ratio O
and O
Potential O
Bleeding O
International O
Normalized O
Ratio O
( O
INR O
) O
elevations O
and O
infrequent O
reports O
of O
bleeding O
events O
including O
gastrointestinal O
and O
non-gastrointestinal O
bleedings O
have O
been O
reported O
in O
clinical O
studies O
, O
some O
associated O
with O
concomitant O
warfarin B-drug
administration O
. O

Cimetidine B-drug
has O
been O
shown O
to O
increase O
the O
bioavailability O
of O
labetalol B-drug
HCl I-drug
. O

indomethacin B-drug
; O

- O
In O
isolated O
cases O
, O
a O
pronounced O
though O
reversible O
, O
impairment O
of O
renal O
function O
( O
accompanied O
by O
a O
corresponding O
increase O
in O
the O
serum O
creatinine O
level O
) O
has O
been O
reported O
in O
organ O
transplant O
patients O
receiving O
immuno-suppressant B-group
therapy O
and O
concomitant O
bezafibrate B-drug
. O

Methadonea O

Patients O
taking O
disopyramide B-drug
phosphate I-drug
and O
hepatic O
enzyme O
inhibitors O
concomitantly O
should O
be O
closely O
monitored O
. O

Observe O
the O
patient O
for O
possible O
diminished O
effect O
of O
steroid B-group
and O
increase O
the O
steroid B-group
dosage O
accordingly O
. O

This O
defect O
is O
not O
related O
to O
acute O
insulin O
release O
or O
the O
presence O
of O
glucose B-drug
. O

In O
vitro O
studies O
have O
demonstrated O
that O
efavirenz B-drug
inhibits O
2C9 O
, O
2C19 O
, O
and O
3A4 O
isozymes O
in O
the O
range O
of O
observed O
efavirenz B-drug
plasma O
concentrations O
. O

At O
a O
higher O
dose O
and O
a O
shorter O
withdrawal O
period O
( O
20 O
mg/kg O
, O
daily O
for O
7 O
days O
followed O
by O
a O
3-day O
withdrawal O
) O
, O
the O
SST O
mice O
showed O
behavioral O
sensitization O
similar O
to O
the O
RBC O
mice O
, O
but O
the O
LST O
mice O
did O
not O
develop O
sensitization O
. O

the O
fourth O
group O
served O
as O
control O
and O
received O
an O
equivalent O
volume O
of O
an O
isocaloric O
solution O
of O
dextrose B-drug
. O

When O
the O
dose O
of O
picrotoxin B-drug_n
is O
minimized O
to O
0.5 O
mg/kg O
such O
an O
effect O
is O
not O
observed O
. O

They O
should O
be O
observed O
closely O
, O
particularly O
if O
renal O
function O
is O
impaired O
. O

In O
addition O
, O
the O
frequency O
of O
monitoring O
serum O
lithium B-drug
concentration O
should O
be O
increased O
at O
the O
outset O
of O
such O
combination O
drug O
treatment O
. O

Dose-response O
curves O
( O
derived O
from O
the O
results O
of O
using O
the O
tablets O
as O
well O
as O
pure O
powders O
) O
showed O
that O
tripelennamine B-drug
was O
responsible O
for O
the O
inhibitory O
activity O
, O
which O
was O
partially O
antagonized O
by O
pentazocine B-drug
. O

When O
CANCIDAS B-brand
is O
co-administered O
with O
inducers O
of O
drug O
clearance O
, O
such O
as O
efavirenz B-drug
, O
nevirapine B-drug
, O
phenytoin B-drug
, O
dexamethasone B-drug
, O
or O
carbamazepine B-drug
, O
use O
of O
a O
daily O
dose O
of O
70 O
mg O
of O
CANCIDAS B-brand
should O
be O
considered O

Antidiabetics B-group
: O
Because O
corticosteroids B-group
may O
increase O
blood O
glucose O
concentrations O
, O
dosage O
adjustments O
of O
antidiabetic B-group
agents I-group
may O
be O
required O
. O

Sulfapyridine B-drug
may O
interact O
with O
any O
of O
the O
following O
: O
- O
Acetaminophen B-drug
( O
e.g. O
, O
Tylenol B-brand
) O
( O
with O
long-term O
, O
high-dose O
use O
) O
or O

Patients O
receiving O
beta-blockers B-group
should O
be O
warned O
of O
this O
potential O
hazard O
. O

Diltiazem B-drug
is O
both O
a O
substrate O
and O
an O
inhibitor O
of O
the O
cytochrome O
P-450 O
3A4 O
enzyme O
system O
. O

Recommendations O
were O
to O
avoid O
administration O
of O
diffusible O
anti-helminthic B-group
treatment O
during O
the O
cure O
, O
and O
to O
improve O
the O
general O
conditions O
of O
patients O
before O
the O
cure O
of O
melarsoprol B-drug
. O

Estrogen-containing B-group
therapies O
should O
not O
be O
used O
with O
ARIMIDEX B-brand
as O
they O
may O
diminish O
its O
pharmacologic O
action O
. O

If O
CEFOTAN B-brand
and O
an O
aminoglycoside B-group
are O
used O
concomitantly O
, O
renal O
function O
should O
be O
carefully O
monitored O
, O
because O
nephrotoxicity O
may O
be O
potentiated O
. O

Anticoagulants B-group
: O
Coagulation O
parameters O
should O
be O
tested O
more O
frequently O
and O
monitored O
regularly O
during O
simultaneous O
administration O
of O
high O
doses O
of O
heparin B-drug
, O
oral O
anticoagulants B-group
, O
or O
other O
drugs O
that O
may O
affect O
the O
blood O
coagulation O
system O
or O
the O
thrombocyte O
function O
. O

Amprenavir B-drug
significantly O
increased O
the O
area O
under O
the O
curve O
at O
steady O
state O
( O
AUC O
( O
ss O
) O
) O
of O
rifabutin B-drug
by O
2.93-fold O
and O
the O
AUC O
( O
ss O
) O
of O
25-O-desacetylrifabutin B-drug_n
by O
13.3-fold O
. O

CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and/or O
life-threatening O
reactions O
such O
as O
cardiac O
arrhythmias O
. O

The O
concomitant O
administration O
of O
Exjade B-brand
and O
aluminum-containing B-drug
antacid B-group
preparations I-group
has O
not O
been O
formally O
studied O
. O

Clinical O
experience O
in O
the O
concurrent O
administration O
of O
ECT O
and O
antidepressant B-group
drugs I-group
is O
limited O
. O

Pharmacokinetic O
Interaction O
between O
amprenavir B-drug
and O
rifabutin B-drug
or O
rifampin B-drug
in O
healthy O
males O
. O

Therefore O
, O
we O
investigated O
the O
effects O
of O
biocytin O
inclusion O
on O
opioid B-group
responses O
and O
other O
membrane O
properties O
during O
whole-cell O
, O
tight O
seal O
recordings O
of O
these O
neurons O
. O

Probenecid B-drug
: O
May O
decrease O
renal O
tubular O
secretion O
of O
ampicillin B-drug
resulting O
in O
increased O
blood O
levels O
and/or O
ampicillin B-drug
toxicity O
. O

Tricyclic B-group
antidepressants I-group
may O
potentiate O
the O
cardiovascular O
effects O
of O
adreneric O
agents O
. O

4 O
. O

Many O
drugs O
used O
in O
dentistry O
can O
not O
be O
taken O
concomitantly O
with O
these O
medications O
. O

Fluvastatin B-drug
is O
the O
first O
synthetic B-group
3-hydroxy-3-methylglutaryl I-group
coenzyme I-group
A I-group
( I-group
HMGCoA I-group
) I-group
reductase I-group
inhibitor I-group
to O
be O
approved O
for O
clinical O
use O
, O
and O
has O
been O
studied O
extensively O
in O
humans O
since O
1986 O
. O

Endogenous O
respiration O
was O
unaffected O
by O
the O
drug O
at O
a O
concentration O
as O
high O
as O
100 O
mug/ml O
, O
whereas O
exogenous O
respiration O
was O
markedly O
sensitive O
and O
inhibited O
to O
an O
extent O
of O
85 O
% O
. O

Nonsteroidal B-group
Anti-Inflammatory I-group
Drugs I-group
: O
The O
administration O
of O
diflunisal B-drug
to O
normal O
volunteers O
receiving O
indomethacin B-drug
decreased O
the O
renal O
clearance O
and O
significantly O
increased O
the O
plasma O
levels O
of O
indomethacin B-drug
. O

Analgesic/anti-inflammatory B-group
( O
e.g. O
, O
acetaminophen B-drug
, O
aspirin B-brand
, O
codeine B-drug
and O
codeine B-drug
combinations O
, O
ibuprofen B-drug
, O
indomethacin B-drug
) O
. O

Drugs O
which O
induce O
CYP3A4 O
activity O
( O
eg O
, O
phenobarbital B-drug
, O
rifampin B-drug
, O
rifabutin B-drug
) O
would O
be O
expected O
to O
increase O
the O
clearance O
of O
efavirenz B-drug
resulting O
in O
lowered O
plasma O
concentrations O
. O

Amiodarone B-drug
taken O
concomitantly O
with O
digoxin B-drug
increases O
the O
serum O
digoxin B-drug
concentration O
by O
70 O
% O
after O
one O
day O
. O

Haloperidol B-drug
reduced O
or O
eliminated O
the O
increases O
in O
FI O
responding O
produced O
by O
intermediate O
doses O
of O
either O
( B-drug_n
+ I-drug_n
) I-drug_n
-NANM I-drug_n
or O
PCP B-drug_n
in O
pigeons O
, O
but O
did O
not O
antagonize O
the O
decreases O
in O
FI O
or O
FR O
responding O
produced O
by O
high O
doses O
of O
PCP O
or O
either O
stereoisomer O
of O
NANM B-drug_n
. O

WelChol B-brand
has O
been O
studied O
in O
several O
human O
drug O
interaction O
studies O
in O
which O
it O
was O
administered O
with O
a O
meal O
and O
the O
test O
drug O
. O

Propoxyphene B-drug
: O
In O
cases O
of O
propoxyphene B-drug
overdosage O
, O
amphetamine B-group
CNS O
stimulation O
is O
potentiated O
and O
fatal O
convulsions O
can O
occur O
. O

No O
drug O
interaction O
studies O
have O
been O
conducted O
for O
COLAZAL B-brand
, O
however O
the O
use O
of O
orally O
administered O
antibiotics B-group
could O
, O
theoretically O
, O
interfere O
with O
the O
release O
of O
mesalamine B-drug
in O
the O
colon O
. O

T3 O
resin O
uptake O
is O
decreased O
, O
reflecting O
the O
elevated O
TBG O
. O

Local O
and O
some O
general O
anesthetics B-group
, O
antiarrhythmic B-group
agents I-group
and O
other O
drugs O
that O
interfere O
with O
neuromuscular O
transmission O
should O
be O
used O
cautiously O
, O
if O
at O
all O
, O
in O
patients O
with O
myasthenia O
gravis O
; O

The O
clinical O
significance O
of O
this O
finding O
is O
not O
clear O
. O

If O
intravenous O
pentamidine B-drug
is O
required O
to O
treat O
Pneumocystis O
carinii O
pneumonia O
, O
treatment O
with O
HIVID B-drug
should O
be O
interrupted O
. O

Both O
ibogaine B-drug_n
and O
18-MC B-drug_n
block O
morphine-induced B-drug
and O
nicotine-induced B-drug
dopamine O
release O
in O
the O
nucleus O
accumbens O
; O

Tetracyclines B-group
: O
Since O
both O
acitretin B-drug
and O
tetracyclines B-group
can O
cause O
increased O
intracranial O
pressure O
, O
their O
combined O
use O
is O
contraindicated O
. O

In O
vitro O
, O
buspirone B-drug
may O
displace O
less O
firmly O
bound O
drugs O
like O
digoxin B-drug
. O

Death O
in O
amphetamine B-drug
users O
: O
causes O
and O
rates O
. O

The O
following O
drug O
interactions O
have O
been O
reported O
with O
erythromycin B-drug
products O
. O

The O
goal O
of O
enhancing O
selective O
tumor O
cell O
killing O
relative O
to O
the O
normal O
cells O
that O
are O
dose O
limiting O
may O
be O
achieved O
either O
by O
overcoming O
tumor O
cell O
resistance O
or O
by O
protecting O
normal O
cells O
. O

this O
phenomenon O
was O
not O
observed O
in O
North O
American O
clinical O
trials O
. O

Acetazolamide B-drug
reduces O
urinary O
excretion O
of O
quinidine B-drug
and O
may O
enhance O
its O
effect O
. O

Agents O
that O
may O
enhance O
the O
risk O
of O
hemorrhage O
should O
be O
discontinued O
prior O
to O
initiation O
of O
Fondaparinux B-drug
therapy O
. O

The O
absorption O
of O
lymecycline B-drug
may O
be O
affected O
by O
the O
simultaneous O
administration O
of O
indigestion O
remedies O
, O
iron B-drug
or O
zinc B-drug
supplements O
. O

RESULTS O
: O
Sildenafil B-drug
has O
demonstrated O
effectiveness O
in O
men O
with O
erectile O
dysfunction O
associated O
with O
prostatectomy O
, O
radiation O
therapy O
, O
diabetes O
mellitus O
, O
certain O
neurologic O
disorders O
, O
and O
drug O
therapy O
( O
eg O
, O
selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
[ O
SSRIs B-group
] O
) O
. O

Beta-Blockers B-group
: O
In O
controlled O
clinical O
studies O
, O
adrenergic B-group
beta-receptor I-group
blockers I-group
have O
been O
frequently O
administered O
concomitantly O
with O
nicardipine B-drug
HCl I-drug
. O

Metoprolol B-drug
- O
Administration O
of O
20 O
mg/day O
LEXAPRO B-brand
for O
21 O
days O
in O
healthy O
volunteers O
resulted O
in O
a O
50 O
% O
increase O
in O
Cmax O
and O
82 O
% O
increase O
in O
AUC O
of O
the O
beta-adrenergic B-group
blocker I-group
metoprolol B-drug
( O
given O
in O
a O
single O
dose O
of O
100 O
mg O
) O
. O

Histamine B-group
H2-receptor I-group
antagonists I-group
: O
Histamine B-group
H2-receptor I-group
antagonists I-group
appear O
to O
have O
no O
significant O
effect O
on O
the O
bioavailability O
of O
ciprofloxacin B-drug
. O

( O
200 O
mg O
Q12h O
) O

Usually O
, O
such O
inactivation O
of O
the O
aminoglycoside B-group
is O
clinically O
significant O
only O
in O
patients O
with O
severely O
impaired O
renal O
function.. O

Liver O
Function O
Tests O
: O
Elevations O
of O
AST O
( O
SGOT O
) O
, O
ALT O
( O
SGPT O
) O
or O
LDH O
were O
experienced O
by O
approximately O
1 O
in O
3 O
patients O
treated O
with O
Soriatane B-brand
. O

Phenytoin B-drug

Concomitant O
administration O
of O
Robinul B-brand
Injection O
and O
potassium B-drug
chloride I-drug
in O
a O
wax O
matrix O
may O
increase O
the O
severity O
of O
potassium O
chloride-induced O
gastrointestinal O
lesions O
as O
a O
result O
of O
a O
slower O
gastrointestinal O
transit O
time O
. O

There O
are O
no O
significant O
effects O
on O
cefdinir B-drug
pharmacokinetics O
if O
the O
antacid B-group
is O
administered O
2 O
hours O
before O
or O
2 O
hours O
after O
cefdinir B-drug
. O

Acarbose B-drug
has O
been O
shown O
to O
change O
the O
bioavailabillty O
digoxin B-drug
when O
they O
are O
co-administered O
, O
which O
may O
require O
digoxin B-drug
dose O
adjustment O
. O

In O
such O
cases O
, O
the O
unbound O
( O
free O
) O
hormone O
should O
be O
measured O
. O

- O
Procainamide B-drug
( O
e.g. O
, O
Pronestyl B-brand
) O
or O

4 O
microg O
mL O
( O
-1 O
) O
in O
the O
presence O
of O
galangin B-drug
( O
12.5 O
microg O
mL O
( O
-1 O
) O
) O
or O
3,7-dihydroxyflavone O
( O
6.25 O
microg O
mL O
( O
-1 O
) O
) O
. O

Aspirin B-brand
: O
CELEBREX B-brand
can O
be O
used O
with O
low O
dose O
aspirin B-brand
. O

however O
, O
no O
deleterious O
interactions O
were O
seen O
when O
ROMAZICON B-brand
was O
administered O
after O
narcotics B-group
, O
inhalational O
anesthetics B-group
, O
muscle B-group
relaxants I-group
and O
muscle O
relaxant O
antagonists O
administered O
in O
conjunction O
with O
sedation O
or O
anesthesia O
. O

Opioid B-group
analgesics I-group
Decreased O
antinociceptive O
action O

Both O
digoxin B-drug
and O
COREG B-brand
slow O
AV O
conduction O
. O

Patients O
with O
HACA O
titers O
may O
have O
allergic O
or O
hypersensitivity O
reactions O
when O
treated O
with O
other O
diagnostic B-group
or O
therapeutic B-group
monoclonal I-group
antibodies I-group
. O

Acute O
dosing O
with O
clozapine B-drug
failed O
to O
alter O
the O
behavioral O
effects O
of O
PCP B-drug_n
in O
either O
procedure O
even O
when O
tested O
up O
to O
doses O
that O
produced O
pharmacological O
effects O
alone O
. O

Pharmacodynamic O
Interactions O
: O
The O
CNS-depressant O
action O
of O
the O
benzodiazepine B-group
class I-group
of O
drugs O
may O
be O
potentiated O
by O
alcohol B-drug
, O
narcotics B-group
, O
barbiturates B-group
, O
nonbarbiturate B-group
hypnotics I-group
, O
antianxiety B-group
agents I-group
, O
the O
phenothiazines O
, O
thioxanthene O
and O
butyrophenone B-group
classes I-group
of I-group
antipsychotic I-group
agents I-group
, O
monoamine B-group
oxidase I-group
inhibitors I-group
and O
the O
tricyclic B-group
antidepressants I-group
, O
and O
by O
other O
anticonvulsant B-group
drugs I-group
. O

Massive O
seizures O
may O
be O
encountered O
with O
this O
combination O
. O

This O
article O
reviews O
the O
impact O
of O
renal O
disease O
on O
the O
pharmacokinetics O
of O
cardiovascular O
drugs O
and O
identifies O
clinically O
important O
interactions O
between O
these O
and O
other O
drugs O
commonly O
used O
in O
the O
management O
of O
chronic O
renal O
disease O
. O

In O
diabetic O
patients O
, O
the O
metabolic O
effects O
of O
androgens B-group
may O
decrease O
blood O
glucose O
and O
therefore O
, O
insulin B-drug
requirements O
. O

Some O
early O
studies O
indicated O
that O
EPA B-drug
supplements O
might O
have O
detrimental O
effects O
in O
those O
groups O
. O

Exacerbation O
or O
the O
initial O
presentation O
of O
a O
number O
of O
autoimmune O
and O
inflammatory O
disorders O
has O
been O
observed O
following O
concurrent O
use O
of O
interferon-alfa B-drug
and O
PROLEUKIN B-brand
, O
including O
crescentic O
IgA O
glomerulonephritis O
, O
oculo-bulbar O
myasthenia O
gravis O
, O
inflammatory O
arthritis O
, O
thyroiditis O
, O
bullous O
pemphigoid O
, O
and O
Stevens-Johnson O
syndrome O
. O

3 O
. O

In O
female O
rats O
, O
fulvestrant B-drug
administered O
at O
doses O
0.01 O
mg/kg/day O
( O
approximately O
one-hundredth O
of O
the O
human O
recommended O
dose O
based O
on O
body O
surface O
area O
[ O
BSA O
] O
, O
for O
2 O
weeks O
prior O
to O
and O
for O
1 O
week O
following O
mating O
, O
caused O
a O
reduction O
in O
fertility O
and O
embryonic O
survival O
. O

indinavir I-drug
concentration O

DOXIL B-brand
may O
interact O
with O
drugs O
known O
to O
interact O
with O
the O
conventional O
formulation O
of O
doxorubicin B-drug
HCl I-drug
. O

Ethosuximide B-drug
: O
Amphetamines B-group
may O
delay O
intestinal O
absorption O
of O
ethosuximide B-drug
. O

In O
situations O
in O
which O
concurrent O
therapy O
is O
necessary O
, O
careful O
patient O
monitoring O
is O
essential O
. O

This O
interference O
has O
resulted O
in O
significant O
increases O
in O
half-life O
and O
AUC O
. O

suppression O
of O
midcycle O
gonadotropin O
peaks O
; O

However O
, O
caution O
should O
be O
used O
when O
administering O
CELEBREX B-brand
with O
warfarin B-drug
since O
these O
patients O
are O
at O
increased O
risk O
of O
bleeding O
complications O
. O

Gentamicin B-drug
- O
Methionine B-drug
may O
protect O
against O
the O
ototoxic O
effects O
of O
gentamicin B-drug
. O

Atracurium B-drug
was O
again O
given O
by O
infusion O
to O
maintain O
40 O
% O
twitch O
for O
a O
second O
hour O
, O
then O
2 O
mg O
gentamycin/kg B-drug
bwt O
were O
given O
i.v O
. O

conversely O
, O
diethylpropion B-drug
may O
interfere O
with O
antihypertensive B-group
drugs I-group
( O
i.e. O
, O
guanethidine B-drug
, O
a-methyldopa B-drug
) O
. O

Co-treatment O
with O
the O
potent O
CYP3A4 O
inhibitor O
ketoconazole B-drug
increases O
erlotinib B-drug
AUC O
by O
2/3 O
. O

Platelet B-group
inhibitors I-group
: O
Drugs O
such O
as O
acetylsalicylic B-drug
acid I-drug
, O
dextran B-drug
, O
phenylbutazone B-drug
, O
ibuprofen B-drug
, O
indomethacin B-drug
, O
dipyridamole B-drug
, O
hydroxychloroquine B-drug
and O
others O
that O
interfere O
with O
platelet-aggregation O
reactions O
( O
the O
main O
hemostatic O
defense O
of O
heparinized O
patients O
) O
may O
induce O
bleeding O
and O
should O
be O
used O
with O
caution O
in O
patients O
receiving O
heparin B-drug
sodium I-drug
. O

It O
is O
not O
known O
whether O
the O
concurrent O
use O
of O
these O
agents O
with O
apraclonidine B-drug
can O
lead O
to O
a O
reduction O
in O
IOP O
lowering O
effect O
. O

The O
approach O
is O
applicable O
across O
a O
wide O
variety O
of O
settings O
commonly O
associated O
with O
joint O
action O
data O
, O
including O
continuous O
and O
discrete O
responses O
, O
alternative O
error O
structures O
, O
and O
nonzero O
background O
response O
. O

CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and/or O
life-threatening O
reactions O
such O
as O
cardiac O
arrhythmias O
. O

Methotrexate B-drug
: O
Ibuprofen B-drug
, O
as O
well O
as O
other O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
, O
probably O
reduces O
the O
tubular O
secretion O
of O
methotrexate B-drug
based O
on O
in O
vitro O
studies O
in O
rabbit O
kidney O
slices O
. O

Inducers O
of O
CYP3A4 O

Because O
of O
the O
potential O
for O
additive O
or O
synergistic O
depressant O
effects O
on O
the O
SA O
and O
AV O
nodes O
, O
however O
, O
Adenocard B-brand
should O
be O
used O
with O
caution O
in O
the O
presence O
of O
these O
agents O
. O

Food O
: O
Isoniazid B-drug
should O
not O
be O
administered O
with O
food O
. O

Postoperatively O
, O
45 O
patients O
were O
randomly O
assigned O
in O
a O
double-blind O
fashion O
to O
receive O
ADL B-drug
8-2698 I-drug
( O
4 O
mg O
) O
or O
placebo O
and O
intravenous O
morphine B-drug
( O
0.15 O
mg/kg O
) O
or O
to O
receive O
oral O
and O
intravenous O
placebo O
. O

No O
information O
available O
. O

An O
increased O
incidence O
of O
benign O
ovarian O
granulosa O
cell O
tumors O
and O
testicular O
Leydig O
cell O
tumors O
was O
evident O
, O
in O
females O
dosed O
at O
10 O
mg/rat/15 O
days O
and O
males O
dosed O
at O
15 O
mg/rat/30 O
days O
, O
respectively O
. O

Behavioral O
responses O
to O
repeated O
cocaine B-drug
exposure O
in O
mice O
selectively O
bred O
for O
differential O
sensitivity O
to O
pentobarbital B-drug
. O

Such O
individuals O
are O
referred O
to O
as O
poor O
metabolizers O
of O
drugs O
such O
as O
debrisoquin B-drug
, O
dextromethorphan B-drug
, O
the O
tricyclic B-group
antidepressants I-group
, O
and O
clozapine B-drug
. O

Steady-state O
plasma O
felbamate B-drug
concentrations O
were O
found O
to O
be O
29 O
% O
lower O
than O
the O
mean O
concentrations O
of O
a O
group O
of O
newly O
diagnosed O
subjects O
with O
epilepsy O
also O
receiving O
2400 O
mg O
of O
felbamate B-drug
a O
day O
. O

Cevimeline B-drug
should O
be O
used O
with O
caution O
in O
individuals O
known O
or O
suspected O
to O
be O
deficient O
in O
CYP2D6 O
activity O
, O
based O
on O
previous O
experience O
, O
as O
they O
may O
be O
at O
a O
higher O
risk O
of O
adverse O
events O
. O

see O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

Dasatinib B-drug
and O
its O
metabolites O
are O
minimally O
excreted O
via O
the O
kidney O
. O

Other O
CYP3A4 O
inducers O
include O
, O
but O
are O
not O
limited O
to O
, O
rifabutin B-drug
, O
rifapentine B-drug
, O
phenytoin B-drug
, O
carbamazepine B-drug
, O
phenobarbital B-drug
and O
St. O
Johns O
Wort O
. O

. O

Co-medications O
that O
induce O
CYP O
3A4 O
( O
e.g. O
, O
rifampicin B-drug
, O
phenytoin B-drug
, O
carbamazepine B-drug
, O
phenobarbital B-drug
, O
or O
St. O
John O
s O
wort O
) O
may O
significantly O
decrease O
exposure O
to O
exemestane B-drug
. O

Among O
the O
risk O
factors O
studied O
, O
two O
appear O
to O
increase O
the O
risk O
of O
ARE O
: O
the O
prescription O
of O
thiabendazole B-drug
to O
treat O
strongyloidiasis O
during O
the O
melarsoprol B-drug
cure O
and O
the O
bad O
general O
clinical O
conditions O
of O
patients O
. O

The O
effects O
of O
nonbenzodiazepine O
agonists O
at O
benzodiazepine O
receptors O
, O
such O
as O
zopiclone B-drug
, O
triazolopyridazines O
and O
others O
, O
are O
also O
blocked O
by O
ROMAZICON B-brand
. O

. O

When O
administered O
with O
food O
or O
milk O
, O
there O
is O
more O
rapid O
absorption O
; O

Read O
circulars O
for O
lithium B-drug
preparations O
before O
use O
of O
such O
concomitant O
therapy O
. O

indinavir I-drug
concentration O

= O
decrease O

No O
change O
in O
dose O
of O
either O
drug O
is O
recommended O
. O

INH B-drug
( O
Isoniazid B-drug
) O
is O
also O
reported O
to O
affect O
ketoconazole B-drug
concentrations O
adversely O
. O

In O
vitro O
studies O
demonstrated O
that O
the O
plasma O
protein O
binding O
of O
des-ciclesonide B-drug
was O
not O
affected O
by O
warfarin B-drug
or O
salicylic B-drug
acid I-drug
, O
indicating O
no O
potential O
for O
protein O
binding-based O
drug O
interactions O
. O

The O
following O
drug O
interactions O
have O
been O
identified O
involving O
NIZORAL B-brand
Tablets O
and O
other O
drugs O
metabolized O
by O
the O
cytochrome O
P450 O
3A4 O
enzyme O
system O
: O
Ketoconazole B-drug
tablets O
inhibit O
the O
metabolism O
of O
terfenadine B-drug
, O
resulting O
in O
an O
increased O
plasma O
concentration O
of O
terfenadine B-drug
and O
a O
delay O
in O
the O
elimination O
of O
its O
acid O
metabolite O
. O

Cmax O
and O
t1/2 O
were O
increased O
1.4-fold O
and O
1.3-fold O
, O
respectively O
. O

Pharmacokinetic O
interactions O
between O
nisoldipine B-drug
and O
beta-blockers B-group
( O
atenolol B-drug
, O
propranolol B-drug
) O
were O
variable O
and O
not O
significant O
. O

Theophylline-related B-drug
adverse O
effects O
have O
occurred O
in O
patients O
when O
theophylline B-drug
and O
enoxacin B-drug
were O
coadministered O
. O

Certain O
drugs O
tend O
to O
produce O
hyperglycemia O
and O
may O
lead O
to O
loss O
of O
control O
. O

Example O
inhibitors O
include O
azole B-group
antifungals I-group
, O
ciprofloxacin B-drug
, O
clarithromycin B-drug
, O
diclofenac B-drug
, O
doxycycline B-drug
, O
erythromycin B-drug
, O
imatinib B-drug
, O
isoniazid B-drug
, O
nefazodone B-drug
, O
nicardipine B-drug
, O
propofol B-drug
, O
protease B-group
inhibitors I-group
, O
quinidine B-drug
, O
and O
verapamil B-drug
. O

Effect O
of O
diazepam B-drug
and O
midazolam B-drug
on O
the O
antinociceptive O
effect O
of O
morphine B-drug
, O
metamizol B-drug
and O
indomethacin B-drug
in O
mice O
. O

When O
encountered O
, O
such O
arrhythmias O
may O
respond O
to O
administration O
of O
a O
beta-adrenergic B-group
blocking I-group
drug I-group
. O

The O
clinical O
significance O
is O
unknown O
. O

Cytochrome O
P-450 O
inducers O
, O
such O
as O
phenytoin B-drug
, O
carbamazepine B-drug
and O
phenobarbital B-drug
, O
induce O
clonazepam B-drug
metabolism O
, O
causing O
an O
approximately O
30 O
% O
decrease O
in O
plasma O
clonazepam B-drug
levels O
. O

Binding O
to O
plasma O
protein O
is O
not O
significantly O
altered O
by O
diazepam B-drug
, O
diphenylhydantoin B-drug
, O
or O
phenylbutazone B-drug
. O

Immunogenicity/Re-exposure O
: O
In O
in O
vitro O
studies O
, O
Angiomax B-brand
exhibited O
no O
platelet O
aggregation O
response O
against O
sera O
from O
patients O
with O
a O
history O
of O
HIT/HITTS O
. O

Concomitant O
administration O
of O
other O
sympathomimetic B-group
agents I-group
may O
potentiate O
the O
undesirable O
effects O
of O
FORADIL B-brand
. O

Doxylamine B-drug
may O
enhance O
the O
effects O
of O
epinephrine B-drug
. O

Rare O
instances O
of O
dyspnea O
, O
palpitation O
, O
chest O
pain O
, O
syncope O
. O

Nevertheless O
, O
the O
prothrombin O
time O
or O
other O
suitable O
coagulation O
test O
should O
be O
monitored O
when O
warfarin B-drug
or O
its O
derivatives O
and O
enoxacin B-drug
are O
given O
concomitantly O
. O

These O
agents O
should O
not O
be O
taken O
within O
4 O
hours O
before O
or O
4 O
hours O
after O
grepafloxacin B-drug
administration O
. O

Amiodarone B-drug
taken O
concomitantly O
with O
quinidine B-drug
increases O
quinidine B-drug
serum O
concentration O
by O
33 O
% O
after O
two O
days O
. O

If O
antacid B-group
therapy O
is O
needed O
, O
the O
antacid O
dose O
should O
be O
administered O
at O
least O
2 O
hours O
prior O
to O
or O
2 O
hours O
after O
the O
dose O
of O
SPRYCEL B-brand
. O

Although O
17-hydroxy-corticosteroid O
measurements O
( O
Porter-Silber O
test O
) O
do O
not O
appear O
to O
be O
artifactually O
altered O
, O
it O
is O
suggested O
that O
therapy O
with O
naproxen B-drug
be O
temporarily O
discontinued O
72 O
hours O
before O
adrenal O
function O
tests O
are O
performed O
if O
the O
Porter-Silber O
test O
is O
to O
be O
used O
. O

Rifampin B-drug
, O
an O
inducer O
of O
drug O
metabolism O
, O
decreased O
the O
concentrations O
of O
losartan B-drug
and O
its O
active O
metabolite O
. O

Drugs O
Whose O
Absorption O
Can O
Be O
Affected O
by O
the O
Level O
of O
Acidity O
in O
the O
Stomach O
: O
Drugs O
such O
as O
ketoconazole B-drug
and O
itraconazole B-drug
should O
be O
administered O
at O
least O
2 O
hours O
prior O
to O
dosing O
with O
VIDEX B-brand
. O

Vaccinations O
with O
attenuated O
live O
bacteria O
should O
therefore O
be O
completed O
at O
least O
3 O
days O
before O
the O
first O
dose O
of O
Mefloquine B-drug
. O

Additional O
reductions O
in O
blood O
pressure O
may O
occur O
when O
FLOLAN B-brand
is O
administered O
with O
diuretics B-group
, O
antihypertensive B-group
agents I-group
, O
or O
other O
vasodilators B-group
. O

The O
inhibitor O
, O
on O
the O
other O
hand O
, O
promoted O
significant O
decrease O
of O
nucleolin/C23 O
in O
NIH-3T3 O
cells O
during O
serum O
deprivation O
. O

Candida O
albicans O
, O
one O
of O
the O
pathogenic O
species O
, O
was O
totally O
inhibited O
at O
a O
concentration O
of O
approximately O
10 O
mug/ml O
. O

certain O
antibiotics B-group
, O
especially O
the O
aminoglycosides B-group
and O
polymyxins B-group
; O

The O
extent O
to O
which O
SSRI-TCA B-group
interactions O
may O
pose O
clinical O
problems O
will O
depend O
on O
the O
degree O
of O
inhibition O
and O
the O
pharmacokinetics O
of O
the O
SSRI B-group
involved O
. O

The O
AUC O
of O
eszopiclone B-drug
was O
increased O
2.2-fold O
by O
coadministration O
of O
ketoconazole B-drug
, O
a O
potent O
inhibitor O
of O
CYP3A4 O
, O
400 O
mg O
daily O
for O
5 O
days O
. O

Lopinavir I-drug

Particular O
caution O
is O
necessary O
when O
using O
ROMAZICON B-brand
in O
cases O
of O
mixed O
drug O
overdosage O
since O
the O
toxic O
effects O
( O
such O
as O
convulsions O
and O
cardiac O
dysrhythmias O
) O
of O
other O
drugs O
taken O
in O
overdose O
( O
especially O
cyclic B-group
antidepressants I-group
) O
may O
emerge O
with O
the O
reversal O
of O
the O
benzodiazepine B-group
effect O
by O
flumazenil B-drug
. O

The O
second O
response O
is O
due O
to O
a O
release O
of O
norepinephrine O
from O
nerves O
and O
was O
potentiated O
by O
ouabain B-drug
through O
the O
increase O
in O
the O
norepinephrine O
release O
, O
whereas O
the O
first O
response O
was O
not O
due O
to O
the O
norepinephrine O
release O
but O
presumably O
to O
a O
direct O
action O
on O
smooth O
muscle O
cell O
and O
was O
inhibited O
by O
ouabain B-drug
. O

Oral O
contraceptives B-group
and O
other O
hormonalmethods O
of O
birth O
control O
should O
not O
be O
usedas O
the O
sole O
method O
of O
contraception O
inwomen O
taking O
nevirapine B-drug
, O
since O
nevirapinemay O
lower O
the O
plasma O
levels O
of O
thesemedications O
. O

Therefore O
, O
the O
potential O
for O
such O
drug O
interactions O
should O
be O
considered O
in O
patients O
receiving O
dorzolamide B-drug
. O

Human I-drug
growth I-drug
hormone I-drug
- O
Concomitant O
use O
of O
L-glutamine B-drug
and O
human B-drug
growth I-drug
hormone I-drug
may O
enhance O
nutrient O
absorption O
in O
those O
with O
severe O
short O
bowel O
syndrome O
. O

No O
effects O
on O
plasma O
concentrations O
of O
cimetidine B-drug
or O
ketoconazole B-drug
were O
observed O
. O

amphotericin B-drug
B I-drug
, O
however O
, O
is O
useful O
in O
therapy O
of O
human O
fungal O
infections O
because O
it O
is O
less O
toxic O
. O

Administration O
of O
non-steroidal B-group
anti-inflammatory I-group
drugs I-group
concomitantly O
with O
cyclosporine B-drug
has O
been O
associated O
with O
an O
increase O
in O
cyclosporine-induced B-drug
toxicity O
, O
possibly O
due O
to O
decreased O
synthesis O
of O
renal O
prostacyclin O
. O

No O
studies O
have O
been O
performed O
with O
other O
NNRTIs B-group
. O

Nicotine B-drug
: O
Nicotine B-drug
may O
provoke O
vasoconstriction O
in O
some O
patients O
, O
predisposing O
to O
a O
greater O
ischemic O
response O
to O
ergot B-drug
therapy O
. O

8 O
. O

Because O
of O
the O
broadening O
indications O
for O
immunosuppressive B-group
drugs I-group
, O
and O
the O
prolonged O
survival O
in O
conditions O
for O
which O
they O
are O
being O
used O
, O
many O
patients O
on O
immunosuppression O
are O
now O
cared O
for O
in O
the O
community O
or O
seen O
in O
non-specialist O
hospitals O
, O
usually O
in O
close O
collaboration O
with O
a O
specialist O
. O

A O
causal O
relationship O
has O
not O
been O
established O

Therefore O
, O
there O
is O
a O
potential O
for O
an O
in O
vivo O
drug O
interaction O
with O
drugs O
that O
are O
metabolized O
by O
P450 O
2D6 O
. O

Verapamil B-drug
: O
Concomitant O
use O
of O
verapamil B-drug
is O
contraindicated O
. O

( O
500 O
mg O
Q8h O
) O

Duloxetine B-drug
May O
Have O
a O
Clinically O
Important O
Interaction O
with O
the O
Following O
Other O
Drugs O
: O
Alcohol B-drug
: O
When O
Duloxetine B-drug
and O
ethanol B-drug
were O
administered O
several O
hours O
apart O
so O
that O
peak O
concentrations O
of O
each O
would O
coincide O
, O
Duloxetine B-drug
did O
not O
increase O
the O
impairment O
of O
mental O
and O
motor O
skills O
caused O
by O
alcohol B-drug
. O

On O
the O
basis O
of O
the O
metabolism O
of O
bexarotene B-drug
by O
cytochrome O
P450 O
3A4 O
, O
ketoconazole B-drug
, O
itraconazole B-drug
, O
erythromycin B-drug
, O
gemfibrozil B-drug
, O
grapefruit O
juice O
, O
and O
other O
inhibitors O
of O
cytochrome O
P450 O
3A4 O
would O
be O
expected O
to O
lead O
to O
an O
increase O
in O
plasma O
bexarotene B-drug
concentrations O
. O

- O
Decreased O
pregnanediol O
excretion O

The O
incidence O
of O
upper O
gastrointestinal O
events O
in O
patients O
concomitantly O
taking O
aspirin B-brand
or O
NSAIDs B-group
was O
similar O
in O
patients O
taking O
ibandronate B-drug
2.5 O
mg O
daily O
( O
21.7 O
% O
) O
and O
150 O
mg O
once O
monthly O
( O
22.0 O
% O
) O
. O

Oral O
Contraceptive B-group
: O
Based O
on O
AUC O
and O
half-life O
, O
multiple-dose O
pharmacokinetic O
profiles O
of O
norethindrone B-drug
and O
ethinyl B-drug
estradiol I-drug
following O
administration O
of O
tablets O
containing O
2.5 O
mg O
of O
norethindrone B-drug
acetate I-drug
and O
50 O
mcg O
of O
ethinyl B-drug
estradiol I-drug
were O
similar O
with O
and O
without O
coadministration O
of O
gabapentin B-drug
( O
400 O
mg O
TID O
; O

Drugs O
That O
Are O
Mainly O
Metabolized O
by O
CYP3A4 O

Elevated O
plasma O
levels O
of O
theophylline B-drug
have O
been O
reported O
with O
concomitant O
quinolone B-group
use O
. O

Because O
lithium B-drug
may O
enhance O
the O
serotonergic O
effects O
of O
escitalopram B-drug
, O
caution O
should O
be O
exercised O
when O
LEXAPRO B-brand
and O
lithium B-drug
are O
coadministered O
. O

Drugs O
That O
Should O
Not O
Be O
Coadministered O
With O
VIRACEPT B-brand
Antiarrhythmics B-group
: O
amiodarone B-drug
, O
quinidine B-drug
Antihistamines B-group
: O
astemizole B-drug
, O
terfenadine B-drug
Antimigraine O
: O
ergot B-group
derivatives I-group
Antimycobacterial I-group
agents I-group
: O
rifampin B-drug
Benzodiazepines B-group
midazolam B-drug
, O
triazolam B-drug
GI O
motility O
agents O
: O
cisapride B-drug

Poor O
metabolizers O
have O
higher O
than O
expected O
plasma O
concentrations O
of O
tricyclic B-group
antidepressants I-group
( O
TCAs B-group
) O
when O
given O
usual O
doses O
. O

Cercarial O
encystment O
at O
concentrations O
of O
25000 O
microg/l O
or O
higher O
was O
significantly O
impaired O
by O
all O
test O
metals O
; O

Hyperpyrexia O
has O
been O
reported O
when O
amitriptyline B-drug
HCl I-drug
is O
administered O
with O
anticholinergic B-drug
agents O
or O
with O
neuroleptic B-drug
drugs O
, O
particularly O
during O
hot O
weather O
. O

Some O
clinicians O
have O
noted O
that O
these O
reactions O
resemble O
the O
immediate O
side O
effects O
caused O
by O
interleukin-2 B-drug
administration O
, O
however O
the O
cause O
of O
contrast O
reactions O
after O
interleukin-2 O
therapy O
is O
unknown O
. O

The O
anxiogenic O
effects O
of O
theophylline B-drug
were O
reduced O
by O
pretreatment O
with O
CGS B-drug_n
21680 I-drug_n
, O
an O
A2-selective O
agonist O
, O
but O
not O
by O
N6-cyclopentyladenosine B-drug_n
( O
CPA B-drug_n
) O
, O
an O
A1-selective O
agonist O
. O

CNS O
vascular O
lesions O
, O
characterized O
by O
perivascular O
hemorrhages O
, O
edema O
, O
and O
mononuclear O
cell O
infiltration O
of O
perivascular O
spaces O
, O
have O
been O
observed O
in O
dogs O
treated O
with O
other O
members O
of O
this O
class O
. O

Ketamine B-drug
is O
clinically O
compatible O
with O
the O
commonly O
used O
general O
and O
local O
anesthetic B-group
agents I-group
when O
an O
adequate O
respiratory O
exchange O
is O
maintained O
. O

Erythromycin B-drug

increased O
plasminogen O
antigen O
and O
activity O
. O

Although O
there O
was O
no O
clinical O
evidence O
in O
the O
vehicle-controlled O
studies O
of O
drug O
interactions O
with O
systemic O
antiretroviral B-group
agents I-group
, O
including O
protease B-group
inhibitors I-group
, O
macrolide B-group
antibiotics I-group
, O
and O
azole B-group
antifungals I-group
, O
the O
effect O
of O
Panretin B-brand
gel O
on O
the O
steady-state O
concentrations O
of O
these O
drugs O
is O
not O
known O
. O

In O
contrast O
, O
acute O
toxicity O
tests O
showed O
that O
oral O
CCNU B-drug
was O
1.45 O
times O
less O
toxic O
to O
normal O
tissue O
, O
although O
the O
dose-limiting O
organ O
may O
be O
different O
for O
the O
two O
routes O
. O

Levodopa B-drug
and O
Amantadine B-drug
: O
Limited O
clinical O
data O
suggest O
a O
higher O
incidence O
of O
adverse O
experiences O
in O
patients O
receiving O
bupropion B-drug
concurrently O
with O
either O
levodopa B-drug
or O
amantadine B-drug
. O

In O
patients O
receiving O
another O
serotonin B-group
reuptake I-group
inhibitor I-group
drug I-group
in O
combination O
with O
monoamine B-group
oxidase I-group
inhibitors I-group
( O
MAOI B-group
) O
, O
there O
have O
been O
reports O
of O
serious O
, O
sometimes O
fatal O
, O
reactions O
including O
hyperthermia O
, O
rigidity O
, O
myoclonus O
, O
autonomic O
instability O
with O
possible O
rapid O
fluctuations O
of O
vital O
signs O
, O
and O
mental O
status O
changes O
that O
include O
extreme O
agitation O
progressing O
to O
delirium O
and O
coma O
. O

In O
addition O
, O
several O
AED B-group
s O
that O
are O
cytochrome O
P450 O
inducers O
can O
decrease O
plasma O
concentrations O
of O
oxcarbazepine B-drug
and O
MHD B-drug_n
. O

Administer O
LEVSIN B-brand
before O
meals O
; O

No O
studies O
have O
been O
conducted O
at O
intermediate O
doses O
of O
cimetidine B-drug
. O

Inhibition O
of O
metabolism O
may O
produce O
significant O
increases O
in O
circulating O
phenytoin B-drug
concentrations O
and O
enhance O
the O
risk O
of O
drug O
toxicity O
. O

The O
mechanism O
for O
this O
interaction O
is O
not O
known O
. O

In O
ewes O
given O
40 O
mg O
of O
phenobarbital B-drug
sodium/kg O
for O
5 O
days O
intraperitoneally O
( O
IP O
) O
, O
the O
anticholinesterase O
effect O
of O
4 O
mg O
of O
coumaphos/kg B-drug_n
was O
significantly O
reduced O
and O
signs O
of O
toxicity O
were O
not O
present O
. O

There O
also O
was O
no O
effect O
on O
exposure O
to O
and O
the O
excretion O
of O
the O
primary O
metabolite O
, O
ucb O
L057 O
. O

Chlorthalidone B-drug
may O
add O
to O
or O
potentiate O
the O
action O
of O
other O
antihypertensive B-group
drugs I-group
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
conducted O
. O

OBJECTIVE O
: O
Our O
objective O
was O
to O
characterize O
the O
steady-state O
pharmacokinetics O
of O
everolimus B-drug
and O
cyclosporine B-drug
( O
INN O
, O
ciclosporin B-drug
) O
when O
coadministered O
in O
de O
novo O
kidney O
allograft O
recipients O
during O
the O
first O
year O
after O
transplantation O
. O

Adrenocorticoids O
: O
Metabolic O
clearance O
of O
adrenocorticoids O
is O
decreased O
in O
hypothyroid O
patients O
and O
increased O
in O
hyperthyroid O
patients O
, O
and O
may O
therefore O
change O
with O
changing O
thyroid O
status O
. O

The O
physician O
should O
be O
notified O
immediately O
if O
any O
of O
the O
following O
situations O
occur O
, O
which O
may O
be O
a O
sign O
of O
seriously O
worsening O
asthma O
: O
Decreased O
effectiveness O
of O
short-acting B-group
, I-group
inhaled I-group
beta2-agonists I-group
; O

cimetidine B-drug
) O
and O
many O
that O
are O
substrates O
for O
P450 O
2D6 O
( O
many O
other O
antidepressants B-group
, O
phenothiazines B-group
, O
and O
the O
Type B-group
1C I-group
antiarrhythmics I-group
propafenone B-drug
and O
flecainide B-drug
) O
. O

The O
steady-state O
Cmin O
concentration O
increased O
to O
17.8 O
micrograms/mL O
when O
2400 O
mg/day O
of O
felbamate B-drug
was O
coadministered O
for O
one O
week O
. O

Lithium B-drug
- O
Coadministration O
of O
racemic O
citalopram B-drug
( O
40 O
mg/day O
for O
10 O
days O
) O
and O
lithium B-drug
( O
30 O
mmol/day O
for O
5 O
days O
) O
had O
no O
significant O
effect O
on O
the O
pharmacokinetics O
of O
citalopram B-drug
or O
lithium B-drug
. O

Avoid O
the O
use O
of O
preparations O
such O
as O
decongestants B-group
and O
local O
anesthetics B-group
which O
contain O
any O
sympathomimetic B-group
amine I-group
( O
e.g. O
, O
epinephrine B-drug
, O
norepinephrine B-drug
) O
, O
since O
it O
has O
been O
reported O
that O
tricyclic B-group
antidepressants I-group
can O
potentiate O
the O
effects O
of O
catecholamines O
. O

The O
para-aminobenzoic O
acid O
metabolite O
of O
chloroprocaine O
inhibits O
the O
action O
of O
sulfonamides B-group
. O

Lithium B-drug
: O
Increased O
serum O
lithium B-drug
levels O
and O
symptoms O
of O
lithium B-drug
toxicity O
have O
been O
reported O
in O
patients O
receiving O
ACE B-group
inhibitors I-group
during O
therapy O
with O
lithium B-drug
. O

Use O
with O
caution O
and O
be O
prepared O
to O
treat O
hypertension O
, O
if O
necessary O
. O

Gastrointestinal O
agents O
( O
e.g. O
, O
antacids B-group
) O
. O

- O
Daunorubicin B-drug
( O
e.g. O
, O
Cerubidine B-brand
) O
or O

Pediatric O
Use O
The O
safety O
and O
effectiveness O
of O
PEGASYS B-brand
, O
alone O
or O
in O
combination O
with O
COPEGUS B-brand
in O
patients O
below O
the O
age O
of O
18 O
years O
have O
not O
been O
established O
. O

Prolonged O
menstrual O
cycles O
and/or O
amenorrhea O
were O
observed O
in O
female O
cynomolgus O
monkeys O
given O
sc O
injections O
of O
600 O
m O
g/kg/dose O
( O
7200 O
m O
g/m2/dose O
) O
of O
PEGASYS B-brand
every O
other O
day O
for O
one O
month O
, O
at O
approximately O
180 O
times O
the O
recommended O
weekly O
human O
dose O
for O
a O
60 O
kg O
person O
( O
based O
on O
body O
surface O
area O
) O
. O

Therefore O
, O
caution O
should O
be O
exercised O
when O
using O
these O
drugs O
together O
. O

Alternatives O
to O
rifampin B-drug
should O
be O
considered O
during O
the O
course O
of O
PCP O
treatment O
with O
MEPRON B-brand
. O

Component O
P2 O
, O
however O
, O
was O
increased O
in O
amplitude O
. O

In O
utero O
, O
serum O
levels O
of O
exposure O
in O
these O
monkeys O
were O
23 O
% O
of O
maternal O
serum O
levels O
. O

Patients O
on O
thyroid O
replacement O
therapy O
may O
require O
higher O
doses O
of O
thyroid B-group
hormone I-group
. O

Coadministration O
of O
LEXAPRO B-brand
and O
metoprolol B-drug
had O
no O
clinically O
significant O
effects O
on O
blood O
pressure O
or O
heart O
rate O
. O

NaCMC B-drug_n
at O
1 O
% O
( O
m/v O
) O
in O
the O
presence O
of O
free O
cysteine B-drug
had O
no O
significant O
effect O
on O
the O
R-value O
of O
NaFlu B-drug
compared O
to O
NaCMC B-drug_n
alone O
. O

It O
is O
recommended O
that O
these O
tests O
be O
performed O
prior O
to O
initiation O
of O
Soriatane B-brand
therapy O
, O
at O
1- O
to O
2-week O
intervals O
until O
stable O
and O
thereafter O
at O
intervals O
as O
clinically O
indicated O
. O

24.9 O
% O
( O
95 O
% O
CI O
, O
+/- O
4.5 O
) O
were O
PICR O
, O
detected O
in O
11.7 O
% O
( O
95 O
% O
CI O
, O
+/- O
2.5 O
) O
of O
the O
MAC O
. O

Data O
beyond O
10 O
days O
are O
not O
available O
. O

Each O
month O
of O
therapy O
, O
the O
patient O
must O
have O
a O
negative O
result O
from O
a O
urine O
or O
serum O
pregnancy O
test O
. O

When O
intravenous O
morphine B-drug
and O
BREVIBLOC B-brand
were O
concomitantly O
administered O
in O
normal O
subjects O
, O
no O
effect O
on O
morphine B-drug
blood O
levels O
was O
seen O
, O
but O
BREVIBLOC B-brand
steady-state O
blood O
levels O
were O
increased O
by O
46 O
% O
in O
the O
presence O
of O
morphine B-drug
. O

Because O
of O
the O
pronounced O
intersubject O
variability O
in O
the O
extent O
of O
the O
sirolimus-diltiazem B-drug
interaction O
, O
whole O
blood O
sirolimus B-drug
concentrations O
should O
be O
monitored O
closely O
in O
patients O
treated O
with O
the O
two O
drugs O
. O

Effect O

Therefore O
, O
patients O
receiving O
probenecid B-drug
will O
have O
erroneously O
low O
ERPF O
and O
Tm O
PAH B-drug
values O
. O

Drug-Drug O
Interactions O
: O
No O
clinically O
significant O
drug O
interactions O
have O
been O
found O
with O
theophylline B-drug
at O
a O
low O
dose O
, O
azithromycin B-drug
, O
pseudoephedrine B-drug
, O
ketoconazole B-drug
, O
or O
erythromycin B-drug
. O

Drug O
and O
Laboratory O
Test O
Interactions O
1 O
. O

Drug O
interactions O
with O
SUSTIVA B-brand
are O
summarized O
in O
Table O
5 O
. O

Since O
blood O
level O
of O
calcitriol/ergocalcitriol B-drug
will O
be O
reduced O
, O
higher O
doses O
of O
Rocaltrol B-brand
may O
be O
necessary O
if O
these O
drugs O
are O
administered O
simultaneously O
. O

Inhibitors O
of O
the O
CYP3A4 O
isoenzyme O
could O
increase O
systemic O
dofetilide B-drug
exposure O
. O

Furosemide B-drug
has O
a O
tendency O
to O
antagonize O
the O
skeletal O
muscle O
relaxing O
effect O
of O
tubocurarine B-drug
and O
may O
potentiate O
the O
action O
of O
succinylcholine B-drug
. O

The O
concomitant O
use O
of O
diflunisal B-drug
tablets O
and O
other O
NSAIDs B-group
is O
not O
recommended O
due O
to O
the O
increased O
possibility O
of O
gastrointestinal O
toxicity O
, O
with O
little O
or O
no O
increase O
in O
efficacy O
. O

Therefore O
, O
a O
slower O
onset O
can O
be O
anticipated O
if O
STADOL B-brand
NS I-brand
is O
administered O
concomitantly O
with O
, O
or O
immediately O
following O
, O
a O
nasal B-group
vasoconstrictor I-group
. O

Smokers O
have O
an O
increased O
clearance O
of O
benzodiazepines B-group
as O
compared O
to O
nonsmokers O
; O

In O
post-marketing O
experience O
there O
have O
been O
reports O
of O
increases O
in O
plasma O
lithium B-drug
levels O
. O

periodic O
monitoring O
of O
anticonvulsant B-group
plasma O
levels O
should O
be O
conducted O
. O

Patients O
receiving O
azathioprine B-drug
and O
allopurinol B-drug
concomitantly O
should O
have O
a O
dose O
reduction O
of O
azathioprine B-drug
, O
to O
approximately O
1/3 O
to O
1/4 O
the O
usual O
dose O
. O

These O
stimulants O
are O
commonly O
found O
in O
coffee O
and O
tea O
, O
respectively O
. O

The O
pharmacodynamic O
effects O
can O
be O
explained O
by O
a O
combination O
of O
the O
increase O
in O
dofetilide B-drug
exposure O
and O
the O
reductions O
in O
serum O
potassium O
. O

In O
about O
30 O
% O
of O
patients O
, O
the O
dose O
of O
cyclosporine B-drug
had O
to O
be O
reduced O
in O
order O
to O
maintain O
cyclosporine B-drug
concentrations O
within O
the O
therapeutic O
range O
, O
while O
in O
the O
remainder O
no O
adjustment O
was O
needed O
. O

The O
pharmacokinetics O
of O
fluvastatin B-drug
have O
also O
been O
assessed O
in O
various O
demographic O
groups O
. O

Potential O
drug O
interactions O
between O
Mentax B-brand
( O
butenafine B-drug
HCl I-drug
cream O
) O
Cream O
, O
1 O
% O
, O
and O
other O
drugs O
have O
not O
been O
systematically O
evaluated O
. O

( O
Thiazides B-group
may O
decrease O
arterial O
responsiveness O
to O
norepinephrine B-drug
. O

Nephrotoxicity O
has O
been O
reported O
following O
concomitant O
administration O
of O
cephalosporins B-group
with O
aminoglycoside B-group
antibiotics I-group
or O
potent O
diuretics B-group
such O
as O
furosemide B-drug
. O

. O

Lithium-A B-drug
drug O
interaction O
study O
of O
eplerenone B-drug
with O
lithium B-drug
has O
not O
been O
conducted O
. O

The O
acid-catalyzed O
ethanol-drug B-drug
reaction O
is O
a O
relatively O
unexplored O
area O
and O
may O
alter O
the O
pharmacological O
action O
of O
some O
drugs O
. O

Immunosuppressants B-group

Intestinal B-group
adsorbents I-group
( O
e. O
g. O
, O
charcoal B-drug
) O
and O
digestive B-group
enzyme I-group
preparations I-group
containing O
carbohydrate-splitting O
enzymes O
( O
e. O
g. O
, O
amylase B-drug
, O
pancreatin B-drug
) O
may O
reduce O
the O
effect O
of O
Acarbose B-drug
and O
should O
not O
be O
taken O
concomitantly O
. O

The O
augmentation O
persisted O
even O
after O
carbachol B-drug
was O
washed O
out O
and O
was O
resistant O
to O
chelated O
extracellular O
Ca O
( O
2+ O
) O
and O
to O
inhibitors O
of O
either O
protein O
kinase O
C O
or O
calmodulin O
kinase O
II O
. O

Much O
higher O
changes O
were O
observed O
in O
liver O
, O
increasing O
from O
a O
level O
of O
60 O
% O
at O
4 O
h O
up O
to O
nearly O
4 O
times O
the O
control O
at O
24 O
h O
for O
single O
dose O
. O

BACKGROUND O
: O
The O
effects O
of O
combined O
administration O
of O
bombesin B-drug_n
and O
verapamil B-drug
hydrochloride I-drug
( O
verapamil B-drug
) O
, O
a O
calcium B-group
channel I-group
blocker I-group
, O
on O
the O
incidence O
of O
peritoneal O
metastasis O
of O
intestinal O
adenocarcinomas O
induced O
by O
azoxymethane B-drug_n
( O
AOM B-drug_n
) O
and O
the O
labeling O
index O
of O
intestinal O
cancers O
were O
investigated O
in O
male O
Wistar O
rats O
. O

Exjade B-brand
tablets O
for O
oral O
suspension O
can O
be O
dispersed O
in O
water O
, O
orange O
juice O
, O
or O
apple O
juice O
. O

Since O
apraclonidine B-drug
may O
reduce O
pulse O
and O
blood O
pressure O
, O
caution O
in O
using O
drugs O
such O
as O
beta-blockers B-group
( O
ophthalmic O
and O
systemic O
) O
, O
antihypertensives B-group
, O
and O
cardiac B-group
glycosides I-group
is O
advised O
. O

The O
administration O
of O
lower O
doses O
of O
Vardenafil B-drug
with O
alpha-blockers B-group
has O
not O
been O
completely O
evaluated O
to O
determine O
if O
they O
can O
be O
safely O
administered O
together O
. O

Ascorbic B-drug
acid I-drug
: O
Doses O
of O
ascorbic B-drug
acid I-drug
( O
vitamin B-drug
C I-drug
) O
1 O
g/day O
have O
been O
reported O
to O
increase O
plasma O
concentration O
of O
synthetic B-group
estrogens I-group
by O
~47 O
% O
, O
possibly O
by O
inhibiting O
conjugation O
; O

In O
patients O
with O
impaired O
cardiac O
function O
, O
simultaneous O
use O
should O
be O
avoided O
altogether O
. O

Investigations O
into O
the O
effect O
of O
acitretin B-drug
on O
the O
protein O
binding O
of O
anticoagulants B-group
of I-group
the I-group
coumarin I-group
type I-group
( O
warfarin B-drug
) O
revealed O
no O
interaction O
. O

In O
order O
to O
avoid O
lithium B-drug
intoxication O
, O
lithium B-drug
plasma O
levels O
should O
be O
monitored O
closely O
. O

2 O
. O

THE O
DOSAGE O
OF O
THE O
ANTICOAGULANTS B-group
SHOULD O
BE O
REDUCED O
TO O
MAINTAIN O
THE O
PROTHROMBIN O
TIME/INR O
AT O
THE O
DESIRED O
LEVEL O
TO O
PREVENT O
BLEEDING O
COMPLICATIONS O
. O

The O
literature O
provides O
considerable O
evidence O
indicating O
that O
several O
, O
but O
not O
all O
antihistaminics B-group
, O
are O
indeed O
analgesic B-group
agents I-group
and O
some O
are O
analgesic B-group
adjuvants I-group
as O
well O
. O

Two O
of O
16 O
subjects O
dosed O
simultaneously O
with O
Vardenafil B-drug
10 O
mg O
and O
tamsulosin B-drug
0.4 O
mg O
experienced O
a O
standing O
systolic O
blood O
pressure O
below O
85 O
mm O
Hg O
. O

Thirty O
male O
rats O
of O
the O
Fischer-344 O
strain O
were O
divided O
into O
three O
equal O
groups O
and O
were O
given O
injections O
of O
trimethyl B-drug_n
lead I-drug_n
( O
TML B-drug_n
) O
( O
8.0 O
or O
17.0 O
mg/kg/ml O
SC O
) O
or O
the O
saline O
vehicle O
. O

Antacids B-group
and O
sucralfate B-drug
: O
Sucralfate B-drug
and O
antacids B-group
containing O
magnesium B-drug
or O
aluminum B-drug
, O
as O
well O
as O
formulations O
containing O
divalent O
and O
trivalent O
cations O
such O
as O
Videx B-brand
( O
didanosine B-drug
) O
, O
chewable/buffered O
tablets O
or O
the O
pediatric O
powder O
for O
oral O
solution O
can O
form O
chelation O
complexes O
with O
lomefloxacin B-drug
and O
interfere O
with O
its O
bioavailability O
. O

Flecainide B-drug
is O
not O
extensively O
bound O
to O
plasma O
proteins O
. O

In O
well-controlled O
patients O
undergoing O
concurrent O
therapy O
with O
cimetidine B-drug
, O
a O
decrease O
in O
the O
steady-state O
serum O
concentrations O
of O
tricyclic B-group
antidepressants I-group
may O
occur O
when O
cime-tidine O
therapy O
is O
discontinued O
. O

When O
such O
combined O
therapy O
is O
contemplated O
, O
the O
dose O
of O
one O
or O
both O
agents O
should O
be O
reduced O
. O

Other O
: O
Concomitant O
alcohol B-drug
or O
hot O
drinks O
may O
increase O
the O
side O
effects O
of O
flushing O
and O
pruritus O
and O
should O
be O
avoided O
at O
the O
time O
of O
drug O
ingestion O
. O

Furosemide B-drug
: O
TORADOL B-brand
IV/IM O
reduced O
the O
diuretic B-group
response O
to O
furosemide B-drug
in O
normovolemic O
healthy O
subjects O
by O
approximately O
20 O
% O
( O
mean O
sodium O
and O
urinary O
output O
decreased O
17 O
% O
) O
. O

After O
the O
coadministration O
of O
200 O
mg O
oral O
ketoconazole B-drug
twice O
daily O
and O
one O
20 O
mg O
dose O
of O
loratadine B-drug
to O
11 O
subjects O
, O
the O
AUC O
and O
Cmax O
of O
loratadine B-drug
averaged O
302 O
% O
( O
142 O
S.D O
. O
) O
and O
251 O
% O
( O
68 O
S.D O
. O
) O
, O
respectively O
, O
of O
those O
obtained O
after O
co-treatment O
with O
placebo O
. O

Warfarin B-drug
: O
Atorvastatin B-drug
had O
no O
clinically O
significant O
effect O
on O
prothrombin O
time O
when O
administered O
to O
patients O
receiving O
chronic O
warfarin B-drug
treatment O
. O

The O
combination O
is O
well O
tolerated O
. O

Acetazolamide B-drug
decreases O
urinary O
excretion O
of O
amphetamine B-drug
and O
may O
enhance O
the O
magnitude O
and O
duration O
of O
their O
effect O
. O

Theoretically O
, O
fenoprofen B-drug
could O
likewise O
be O
displaced O
. O

Oral O
Contraceptives B-group

It O
is O
concluded O
that O
ketamine B-drug
is O
not O
a O
short-acting O
drug O
and O
that O
concomitant O
use O
with O
halothane B-drug
would O
be O
expected O
to O
prolong O
further O
the O
duration O
of O
its O
action O
on O
the O
central O
nervous O
system O
. O

therefore O
it O
is O
not O
expected O
to O
affect O
the O
plasma O
concentrations O
of O
other O
drugs O
metabolized O
by O
CYP3A4 O
. O

However O
, O
since O
aspirin B-brand
, O
NSAIDs B-group
, O
and O
bisphosphonates B-group
are O
all O
associated O
with O
gastrointestinal O
irritation O
, O
caution O
should O
be O
exercised O
in O
the O
concomitant O
use O
of O
aspirin B-brand
or O
NSAIDs B-group
with O
Ibandronate B-drug
. O

Warfarin B-drug
: O
Quinolones B-group
have O
been O
reported O
to O
enhance O
the O
effects O
of O
the O
oral O
anticoagulant B-group
warfarin B-drug
or O
its O
derivatives O
. O

No O
clinically O
significant O
effect O
of O
famotidine B-drug
, O
valproate B-drug
, O
or O
lithium B-drug
was O
seen O
on O
the O
pharmacokinetics O
of O
aripiprazole B-drug
( O
see O
CLINICAL O
PHARMACOLOGY O
: O
Drug- O
Drug O
Interactions O
) O
. O

Carbamazepine B-drug
: O
Coadministration O
of O
carbamazepine B-drug
( O
200 O
mg O
BID O
) O
, O
a O
potent O
CYP3A4 O
inducer O
, O
with O
aripiprazole B-drug
( O
30 O
mg O
QD O
) O
resulted O
in O
an O
approximate O
70 O
% O
decrease O
in O
Cmax O
and O
AUC O
values O
of O
both O
aripiprazole B-drug
and O
its O
active O
metabolite O
, O
dehydro-aripiprazole B-drug_n
. O

Certain O
antibiotics B-group
, O
especially O
neomycin B-drug
, O
streptomycin B-drug
and O
kanamycin B-drug
, O
have O
a O
mild O
but O
definite O
nondepolarizing O
blocking O
action O
which O
may O
accentuate O
neuromuscular O
block O
. O

Loratadine B-drug
Descarboethoxyloratadine I-drug

. O

Drug/Laboratory O
Test O
Interactions O
There O
are O
no O
known O
interactions O
between O
APOKYN B-brand
and O
laboratory O
tests O
. O

as O
such O
it O
may O
impair O
intestinal O
absorption O
of O
any O
of O
vitamin B-group
D I-group
. O

In O
one O
study O
, O
following O
chronic O
administration O
of O
bupropion B-drug
, O
100 O
mg O
3 O
times O
daily O
to O
8 O
healthy O
male O
volunteers O
for O
14 O
days O
, O
there O
was O
no O
evidence O
of O
induction O
of O
its O
own O
metabolism O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
performed O
with O
Cetrotide B-brand
. O

Since O
hydroxyurea B-drug
may O
raise O
the O
serum O
uric O
acid O
level O
, O
dosage O
adjustment O
of O
uricosuric B-group
medication I-group
may O
be O
necessary O

Physiological O
changes O
resulting O
from O
smoking O
cessation O
, O
with O
or O
without O
nicotine B-drug
replacement O
, O
may O
alter O
the O
pharmacokinetics O
of O
certain O
concomitant O
medications O
, O
such O
as O
tricyclic B-group
antidepressants I-group
and O
theophylline B-drug
. O

The O
effect O
of O
administering O
different O
botulinum B-group
neurotoxin I-group
serotypes O
at O
the O
same O
time O
or O
within O
less O
than O
4 O
months O
of O
each O
other O
is O
unknown O
. O

Established O
Drug O
Interactions O

Non-nucleoside B-group
reverse I-group
transcriptase I-group
inhibitors I-group

Lithium B-drug
toxicity O
was O
usually O
reversible O
upon O
discontinuation O
of O
lithium B-drug
and O
the O
ACE B-group
inhibitor I-group
. O

The O
in O
vitro O
anti-cryptosporidial O
activity O
of O
buforin B-drug_n
II I-drug_n
alone O
and O
in O
combination O
with O
azithromycin B-drug
and O
minocycline B-drug
was O
investigated O
. O

Although O
this O
effect O
was O
noted O
even O
when O
cholestyramine B-drug
was O
given O
4 O
hours O
prior O
to O
fluvastatin B-drug
, O
this O
regimen O
did O
not O
result O
in O
diminished O
efficacy O
. O

Drug/Laboratory O
Test O
Interactions O
Cephalosporins B-group
are O
known O
to O
occasionally O
induce O
a O
positive O
direct O
Coombs O
test O
. O

Perioperative O
administration O
of O
drugs O
affecting O
hepatic O
blood O
flow O
or O
enzyme O
function O
may O
reduce O
plasma O
clearance O
and O
prolong O
recovery O
. O

CONCLUSIONS O
: O
Macrolide B-group
antibiotics I-group
inhibit O
the O
metabolism O
of O
HMG-CoA B-group
reductase I-group
inhibitors I-group
that O
are O
metabolized O
by O
CYP3A4 O
( O
i.e. O
, O
atorvastatin B-drug
, O
cerivastatin B-drug
, O
lovastatin B-drug
, O
simvastatin B-drug
) O
. O

CNS O
depression O
producing O
medications O
- O
concurrent O
use O
may O
potentiate O
the O
effects O
of O
either O
these O
medications O
or O
diphenidol B-drug
; O

Nicardipine B-drug
HCl I-drug
usually O
does O
not O
alter O
the O
plasma O
levels O
of O
digoxin B-drug
, O
however O
, O
serum O
digoxin B-drug
levels O
should O
be O
evaluated O
after O
concomitant O
therapy O
with O
nicardipine B-drug
HCl I-drug
is O
initiated O
. O

Sirolimus B-drug
works O
differently O
from O
the O
immunosuppressants B-group
currently O
available O
, O
and O
except O
for O
increased O
lipid O
levels O
, O
the O
adverse O
reaction O
profile O
of O
sirolimus B-drug
does O
not O
appear O
to O
overlap O
to O
any O
great O
extent O
with O
that O
associated O
with O
cyclosporine B-drug
or O
tacrolimus B-drug
. O

When O
carbamazepine B-drug
is O
withdrawn O
from O
the O
combination O
therapy O
, O
aripiprazole B-drug
dose O
should O
then O
be O
reduced O
. O

A O
common O
phenotypic O
subset O
of O
the O
serotype O
O11 O
strains O
from O
drug O
addicts O
was O
especially O
resistant O
to O
the O
inhibitory O
effects O
. O

Because O
there O
are O
no O
data O
on O
the O
compatibility O
of O
NovoLog B-brand
and O
crystalline O
zinc B-drug
insulin I-drug
preparations O
, O
NovoLog B-brand
should O
not O
be O
mixed O
with O
these O
preparations O
. O

In O
this O
paper O
lists O
of O
multiple O
exposure O
in O
which O
the O
doses O
of O
the O
substances O
, O
the O
types O
of O
interferences O
and O
the O
behaviour O
of O
the O
biological O
levels O
have O
been O
drawn O
up O
and O
proposed O
as O
a O
tool O
for O
easy O
consultation O
. O

Administration O
of O
WELLBUTRIN B-brand
Tablets O
to O
patients O
receiving O
either O
levodopa B-drug
or O
amantadine B-drug
concurrently O
should O
be O
undertaken O
with O
caution O
, O
using O
small O
initial O
doses O
and O
small O
gradual O
dose O
increases O
. O

consideration O
should O
be O
given O
to O
possible O
CNS O
and O
other O
effects O
of O
alcohol B-drug
. O

Agents O
Causing O
Renin O
Release O
: O
The O
antihypertensive O
effect O
of O
enalapril B-drug
and O
enalapril B-drug
IV O
is O
augmented O
by O
antihypertensive B-group
agents I-group
that O
cause O
renin O
release O
( O
e.g. O
, O
diuretics B-group
) O
. O

Serum O
lithium B-drug
levels O
should O
be O
monitored O
frequently O
if O
INSPRA B-brand
is O
administered O
concomitantly O
with O
lithium B-drug
. O

Increased O
hepatotoxicity O
of O
acetaminophen B-drug
by O
concomitant O
administration O
of O
caffeine B-drug
in O
the O
rat O
. O

Digoxin B-drug
: O
Supraventricular O
arrhythmias O
may O
mask O
the O
cardiotoxicity O
associated O
with O
excessive O
digoxin B-drug
levels O
. O

Since O
falsely O
elevated O
glucose O
levels O
have O
been O
observed O
with O
blood O
glucose O
monitoring O
devices O
and O
test O
strips O
that O
use O
glucose O
dehydrogenase O
pyrroloquinolinequinone O
( O
GDH O
PQQ O
) O
-based O
methods O
, O
GDH O
PQQ-based O
methods O
should O
not O
be O
used O
to O
measure O
glucose O
levels O
in O
patients O
administered O
EXTRANEAL.. B-brand

Both O
the O
magnitude O
and O
duration O
of O
central O
nervous O
system O
and O
cardiovascular O
effects O
may O
be O
enhanced O
when O
ALFENTA B-brand
is O
administered O
in O
combination O
with O
other O
CNS B-group
depressants I-group
such O
as O
barbiturates B-group
, O
tranquilizers B-group
, O
opioids B-group
, O
or O
inhalation O
general O
anesthetics B-group
. O

However O
, O
co O
administration O
of O
fexofenadine B-drug
hydrochloride I-drug
with O
either O
ketoconazole B-drug
or O
erythromycin B-drug
led O
to O
increased O
plasma O
concentrations O
of O
fexofenadine B-drug
. O

A O
single O
dose O
of O
pravastatin B-drug
had O
no O
clinically O
important O
effect O
on O
the O
pharmacokinetics O
of O
fenofibric B-drug_n
acid I-drug_n
. O

The O
drug O
interaction O
studies O
with O
valdecoxib B-drug
were O
performed O
both O
with O
valdecoxib B-drug
and O
a O
rapidly O
hydrolyzed O
intravenous O
prodrug O
form O
. O

Usually O
, O
severe O
abdominal O
symptoms O
appear O
before O
there O
is O
such O
a O
fall O
in O
the O
blood O
pressure O
. O

Determinations O
of O
serum O
digoxin B-drug
levels O
utilizing O
commercially O
available O
kits O
with O
an O
125I-labelled O
antigen O
were O
precise O
and O
not O
materially O
different O
from O
results O
obtained O
with O
a O
3H-labelled O
antigen O
. O

At O
least O
3 O
weeks O
should O
elapse O
between O
discontinuation O
of O
dexfenfluramine B-drug
and O
initiation O
of O
treatment O
with O
a O
MAO B-group
inhibitor I-group
. O

The O
lower O
rate O
of O
absorption O
in O
the O
groups O
receiving O
446 O
mg O
Fe B-drug
instead O
of O
48 O
mg O
of O
Fe B-drug
per O
kg O
diet O
resulted O
in O
a O
decreased O
renal O
excretion O
of O
cobalt B-drug
. O

Etofibrate B-drug
elicited O
62 O
% O
enhancement O
of O
post-heparin B-drug
lipolytic O
activity O
and O
100 O
% O
increase O
of O
3H-triglyceride O
fractional O
clearance O
rate O
compared O
with O
placebo O
treatment O
. O

Recovery O
from O
50 O
% O
twitch O
to O
75 O
% O
fade O
recovery O
took O
13.8 O
+/- O
0.8 O
min O
for O
atracurium B-drug
alone O
and O
13.7 O
+/- O
1.2 O
min O
for O
atracurium B-drug
plus O
gentamycin B-drug
. O

This O
increase O
is O
due O
to O
the O
inhibition O
of O
celecoxib B-drug
metabolism O
via O
P450 O
2C9 O
by O
fluconazole B-drug
( O
see O
CLINICAL O
PHARMACOLOGY O
- O
Pharmacokinetics O
: O
Metabolism O
) O
. O

Non-pegylated B-drug
interferon I-drug
alfa-2a I-drug
treatment O
of O
pregnant O
Rhesus O
monkeys O
at O
approximately O
20 O
to O
500 O
times O
the O
human O
weekly O
dose O
resulted O
in O
a O
statistically O
significant O
increase O
in O
abortions O
. O

In O
monkeys O
, O
the O
effects O
of O
( B-drug_n
- I-drug_n
) I-drug_n
-NANM I-drug_n
, O
but O
not O
( B-drug_n
+ I-drug_n
) I-drug_n
-NANM I-drug_n
or O
PCP B-drug_n
, O
were O
antagonized O
by O
naloxone B-drug
; O

In O
monkeys O
, O
( B-drug_n
- I-drug_n
) I-drug_n
-NANM I-drug_n
was O
about O
10 O
times O
more O
potent O
than O
( B-drug_n
+ I-drug_n
) I-drug_n
-NANM I-drug_n
in O
decreasing O
responding O
, O
whereas O
in O
pigeons O
( B-drug_n
- I-drug_n
) I-drug_n
-NANM I-drug_n
was O
about O
equipotent O
with O
( B-drug_n
+ I-drug_n
) I-drug_n
-NANM I-drug_n
. O

Increased O
toxicity O
( O
CNS O
depression O
) O
: O
CNS B-group
depressants I-group
, O
MAO B-group
inhibitors I-group
, O
tricyclic B-group
antidepressants I-group
, O
phenothiazines B-group
. O

Transient O
delirium O
has O
been O
reported O
in O
patients O
who O
were O
treated O
with O
one O
gram O
of O
ethchlorvynol B-drug
and O
75 O
- O
150 O
mg O
of O
amitriptyline B-drug
HCl I-drug
. O

In O
such O
patients O
, O
the O
mean O
area O
under O
the O
felodipine B-drug
plasma O
concentration-time O
curve O
was O
also O
reduced O
to O
approximately O
6 O
% O
of O
that O
observed O
in O
healthy O
volunteers O
. O

Several O
clinically O
important O
interactions O
have O
previously O
been O
reported O
for O
other O
immunosuppressive B-group
drugs I-group
that O
are O
metabolized O
by O
the O
same O
enzyme O
and O
for O
calcium B-group
antagonists I-group
. O

Clarithromycin B-drug

Alteration O
of O
pH O
may O
affect O
absorption O
of O
certain O
drugs O
( O
e.g. O
, O
ketoconazole B-drug
) O
. O

Both O
the O
toxicity O
of O
filipin B-drug_n
and O
the O
therapeutic O
value O
of O
amphotericin B-drug
B I-drug
can O
be O
rationalized O
at O
the O
cellular O
and O
molecular O
level O
by O
the O
following O
observations O
: O
( O
i O
) O
these O
polyene B-group
antibiotics I-group
showed O
differential O
effects O
on O
cells O
; O

Multivitamins B-group
, O
or O
other O
products O
containing O
iron B-drug
or O
zinc B-drug
, O
antacids B-group
or O
sucralfate B-drug
should O
not O
be O
administered O
concomitantly O
with O
, O
or O
within O
2 O
hours O
of O
, O
the O
administration O
of O
norfloxacin B-drug
, O
because O
they O
may O
interfere O
with O
absorption O
resulting O
in O
lower O
serum O
and O
urine O
levels O
of O
norfloxacin B-drug
. O

In O
addition O
, O
under O
the O
influence O
of O
sympatholytic O
medicinal O
products O
such O
as O
beta-blockers B-group
, O
clonidine B-drug
, O
guanethidine B-drug
, O
and O
reserpine B-drug
, O
the O
signs O
of O
hypoglycemia O
may O
be O
reduced O
or O
absent O
. O

Valproic B-drug
acid I-drug

May O
lead O
to O
loss O
of O
virologic O
response O
and O
possible O
resistance O
to O
CRIXIVAN B-brand
or O
to O
the O
class O
of O
protease B-group
inhibitors I-group
or O
other O
coadministered O
antiretroviral B-group
agents I-group
. O

The O
risk O
of O
myopathy O
during O
treatment O
with O
drugs O
of O
this O
class O
is O
increased O
with O
concurrent O
administration O
of O
cyclosporine B-drug
, O
fibric B-group
acid I-group
derivatives I-group
, O
niacin B-drug
( O
nicotinic B-drug
acid I-drug
) O
, O
erythromycin B-drug
, O
azole B-group
antifungals I-group
. O

In O
this O
formal O
interaction O
study O
, O
TAMBOCOR B-brand
and O
propranolol B-drug
were O
each O
found O
to O
have O
negative O
inotropic O
effects O
; O

This O
slowing O
potentiates O
amphetamines B-group
, O
increasing O
their O
effect O
on O
the O
release O
of O
norepinephrine O
and O
other O
monoamines O
from O
adrenergic O
nerve O
endings O
; O

Physiological O
oral O
magnesium B-drug
supplementation O
( O
5 O
mg/kg/day O
) O
is O
easy O
and O
can O
be O
carried O
out O
in O
the O
diet O
or O
with O
magnesium B-drug
salts O
, O
with O
practically O
only O
one O
contra-indication O
: O
overt O
renal O
failure O
. O

Rifampin B-drug

Influence O
of O
AED B-group
On O
MHD B-drug_n
Concentration O
( O
Mean O
change O
, O
90 O
% O
Confidence O
Interval O
) O

- O
Drugs O
with O
nephrotoxic O
potential O
: O
There O
has O
been O
no O
experience O
on O
the O
concurrent O
use O
of O
bumetanide B-drug
with O
drugs O
known O
to O
have O
a O
nephrotoxic O
potential O
. O

In O
this O
setting O
, O
cardioselective B-group
beta-blockers I-group
could O
be O
considered O
, O
although O
they O
should O
be O
administered O
with O
caution O
. O

Before O
taking O
glimepiride B-drug
, O
tell O
your O
doctor O
if O
you O
are O
taking O
any O
of O
the O
following O
medicines O
: O
- O
aspirin B-brand
or O
another O
salicylate B-group
such O
as O
magnesium/choline B-drug
salicylate I-drug
( O
Trilisate B-brand
) O
, O
salsalate B-drug
( O
Disalcid B-brand
, O
others O
) O
, O
choline B-drug
salicylate I-drug
( O
Arthropan B-drug
) O
, O
magnesium B-drug
salicylate I-drug
( O
Magan B-brand
) O
, O
or O
bismuth B-drug
subsalicylate I-drug
( O
Pepto-Bismol B-brand
) O
; O

It O
is O
postulated O
that O
some O
of O
the O
observed O
training-induced O
neurobiological O
alterations O
might O
reflect O
the O
interaction O
between O
two O
( O
or O
more O
) O
competing O
memory O
systems O
at O
the O
hippocampal O
level O
. O

These O
effects O
have O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
by O
the O
NSAID B-group
. O

Many O
people O
use O
both O
alcohol B-drug
and O
nicotine B-drug
( O
i.e. O
, O
cigarettes O
and O
other O
tobacco O
products O
) O
. O

In O
addition O
, O
reduced O
kidney O
and O
liver O
function O
secondary O
to O
PROLEUKIN B-brand
treatment O
may O
delay O
elimination O
of O
concomitant O
medications O
and O
increase O
the O
risk O
of O
adverse O
events O
from O
those O
drugs O
. O

Drugs O
That O
Induce O
CYP3A4 O
Rifampin B-drug
: O
CYP3A4 O
is O
ordinarily O
a O
minor O
metabolizing O
enzyme O
of O
zaleplon B-drug
. O

Atovaquone B-drug
is O
highly O
bound O
to O
plasma O
protein O
( O
99.9 O
% O
) O
. O

and O
Videx B-brand
, O
( O
Didanosine B-drug
) O
, O
chewable/buffered O
tablets O
or O
the O
pediatric O
powder O
for O
oral O
solution O
may O
substantially O
interfere O
with O
the O
absorption O
of O
quinolones B-group
, O
resulting O
in O
systemic O
levels O
considerably O
lower O
than O
desired O
. O

No O
specific O
pharmacokinetic O
or O
other O
formal O
drug O
interaction O
studies O
were O
conducted O
. O

Methylprednisolone B-drug

Vaccines B-group
neurological O
complications O
and O
lack O
of O
antibody O
response O
. O

Because O
of O
reports O
of O
prolongation O
of O
the O
prothrombin O
time O
beyond O
the O
therapeutic O
range O
in O
patients O
taking O
concurrent O
levamisole B-drug
and O
warfarin B-drug
sodium I-drug
, O
it O
is O
suggested O
that O
the O
prothrombin O
time O
be O
monitored O
carefully O
, O
and O
the O
dose O
of O
warfarin B-drug
sodium I-drug
or O
other O
coumarin-like B-group
drugs O
should O
be O
adjusted O
accordingly O
, O
in O
patients O
taking O
both O
drugs O
. O

Therefore O
, O
it O
can O
prolong O
bleeding O
time O
by O
approximately O
3 O
to O
4 O
minutes O
from O
baseline O
values O
. O

Time O
to O
reach O
Cmax O
is O
also O
prolonged O
by O
1 O
hour O
. O

There O
may O
remain O
some O
indications O
of O
the O
laxative O
and O
antacid O
properties O
of O
non O
soluble O
magnesium B-drug
, O
particularly O
during O
intermittent O
haemodialysis O
. O

Increased O
plasma O
levels O
of O
diazepam B-drug
were O
observed O
12 O
hours O
after O
dosing O
and O
onwards O
. O

Because O
of O
possible O
clinical O
significance O
, O
these O
two O
drugs O
should O
not O
be O
administered O
concurrently O
. O

increased O
thyroid O
binding O
globulin O
( O
TBG O
) O
leading O
to O
increased O
circulating O
total O
thyroid O
hormone O
, O
as O
measured O
by O
PBI O
, O
T4 O
by O
column O
, O
or O
T4 O
by O
radioimmunoassay O
. O

Whether O
an O
alteration O
in O
norepinephrine B-drug
uptake-1 O
occurs O
is O
still O
unresolved O
. O

The O
possibility O
of O
altered O
safety O
and O
efficacy O
should O
be O
considered O
when O
Ponstel B-brand
is O
used O
concomitantly O
with O
these O
drugs O
. O

Interactions O
for O
vitamin B-group
D I-group
analogues I-group
( O
Vitamin B-drug
D2 I-drug
, O
Vitamin B-drug
D3 I-drug
, O
Calcitriol B-drug
, O
and O
Calcidiol B-drug
) O
: O
Cholestyramine B-drug
: O
Cholestyramine B-drug
has O
been O
reported O
to O
reduce O
intestinal O
absorption O
of O
fat B-group
soluble I-group
vitamins I-group
; O

Reported O
examples O
of O
this O
interaction O
include O
the O
following O
: O
Immunosuppressives B-drug
: O
Cyclosporine B-drug
( O
CYP3A4 B-drug
substrate O
) O
administered O
in O
combination O
with O
oral O
amiodarone B-drug
has O
been O
reported O
to O
produce O
persistently O
elevated O
plasma O
concentrations O
of O
cyclosporine B-drug
resulting O
in O
elevated O
creatinine O
, O
despite O
reduction O
in O
dose O
of O
cyclosporine B-drug
. O

In O
addition O
, O
results O
from O
regression O
analyses O
of O
patient O
pharmacokinetic O
data O
suggest O
that O
co-administration O
of O
other O
inducers O
of O
drug O
clearance O
( O
efavirenz B-drug
, O
nevirapine B-drug
, O
phenytoin B-drug
, O
dexamethasone B-drug
, O
or O
carbamazepine B-drug
) O
with O
CANCIDAS B-brand
may O
result O
in O
clinically O
meaningful O
reductions O
in O
caspofungin B-drug
concentrations O
. O

Concomitant O
administration O
of O
drugs O
known O
to O
inhibit O
the O
activity O
of O
cytochrome O
P450 O
isozymes O
may O
increase O
the O
plasma O
levels O
of O
clozapine B-drug
. O

Insulin O
parameters O
were O
not O
affected O
. O

Specific O
and O
aspecific O
treatments O
of O
magnesium B-drug
depletion O
are O
tricky O
using O
for O
example O
magnesium B-group
sparing I-group
diuretics I-group
, O
pharmacological O
doses O
of O
vitamin B-drug
B6 I-drug
, O
physiological O
doses O
of O
vitamin B-group
D I-group
and O
of O
selenium B-drug
. O

Therefore O
, O
precaution O
should O
be O
taken O
when O
coadministration O
is O
necessary O
. O

The O
effects O
of O
Mefloquineuine O
on O
the O
compromised O
cardiovascular O
system O
have O
not O
been O
evaluated O
. O

The O
clinical O
relevance O
of O
this O
difference O
is O
unknown O
. O

Caution O
is O
therefore O
advised O
in O
the O
coadministration O
of O
ATROVENT B-brand
Inhalation O
Aerosol O
with O
other O
anticholinergic-containing B-group
drugs O
. O

Amphotericin B-drug
B I-drug
injection O
and O
potassium-depleting O
agents O
: O
When O
corticosteroids B-group
are O
administered O
concomitantly O
with O
potassium-depleting O
agents O
( O
e.g. O
, O
amphotericin B-drug
B I-drug
, O
diuretics B-group
) O
, O
patients O
should O
be O
observed O
closely O
for O
development O
of O
hypokalemia O
. O

No O
clinically O
relevant O
pharmacokinetic O
interactions O
between O
anagrelide B-drug
and O
acetylsalicylic B-drug
acid I-drug
were O
observed O
. O

SETTING O
: O
Rural O
primary O
care O
centre O
. O

Cyclosporine B-drug
: O
Elevated O
serum O
levels O
of O
cyclosporine B-drug
have O
been O
reported O
with O
concomitant O
use O
of O
cyclosporine B-drug
with O
other O
members O
of O
the O
quinolone B-group
class I-group
. O

Wait O
2 O
weeks O
after O
stopping O
an O
MAO B-group
inhibitor I-group
before O
starting O
escitalopram B-drug
. O

Tolbutamide B-drug
: O
Aprepitant B-drug
, O
when O
given O
as O
125 O
mg O
on O
Day O
1 O
and O
80 O
mg/day O
on O
Days O
2 O
and O
3 O
, O
decreased O
the O
AUC O
of O
tolbutamide B-drug
( O
a O
CYP2C9 O
substrate O
) O
by O
23 O
% O
on O
Day O
4 O
, O
28 O
% O
on O
Day O
8 O
, O
and O
15 O
% O
on O
Day O
15 O
, O
when O
a O
single O
dose O
of O
tolbutamide B-drug
500 O
mg O
was O
admini O
, O
stered O
orally O
prior O
to O
the O
administration O
of O
the O
3-day O
regimen O
of O
Aprepitant B-drug
and O
on O
Days O
4,8 O
, O
and O
15 O
. O

increased O
factors O
II O
, O
VII O
antigen O
, O
VIII O
antigen O
, O
VIII O
coagulant O
activity O
, O
IX O
, O
X O
, O
XII O
, O
VII-X O
complex O
, O
II-VII-X O
complex O
, O
and O
beta-thromboglobulin O
; O

There O
is O
one O
report O
of O
cardiopulmonary O
arrest O
, O
with O
full O
recovery O
, O
in O
a O
patient O
who O
was O
taking O
a O
beta B-group
blocker I-group
( O
propranolol B-drug
) O
. O

Such O
agents O
must O
be O
discontinued O
at O
least O
seven O
days O
prior O
to O
starting O
therapy O
with O
VISTIDE B-brand
. O

Ephedrine B-drug
: O
Ephedrine B-drug
may O
enhance O
the O
metabolic O
clearance O
of O
corticosteroids B-group
, O
resulting O
in O
decreased O
blood O
levels O
and O
lessened O
physiologic O
activity O
, O
thus O
requiring O
an O
increase O
in O
corticosteroid B-group
dosage O
. O

- O
Anabolic B-group
steroids I-group
( O
nandrolone B-drug
[ O
e.g. O
, O
Anabolin B-brand
] O
, O
oxandrolone B-drug
[ O
e.g. O
, O
Anavar B-brand
] O
, O
oxymetholone B-drug
[ O
e.g. O
, O
Anadrol B-brand
] O
, O
stanozolol B-drug
[ O
e.g. O
, O
Winstrol B-brand
] O
) O
or O

When O
given O
concomitantly O
with O
felodipine B-drug
, O
the O
tacrolimus B-drug
blood O
concentration O
should O
be O
followed O
and O
the O
tacrolimus O
dose O
may O
need O
to O
be O
adjusted O
. O

Increased O
anticoagulation O
effects O
due O
to O
a O
drug O
interaction O
with O
erythromycin B-drug
may O
be O
more O
pronounced O
in O
the O
elderly O
. O

A O
specific O
treatment O
for O
extravasation O
reactions O
is O
unknown O
at O
this O
time O
. O

An O
interval O
of O
at O
least O
two O
hours O
between O
intake O
of O
this O
agent O
and O
chloroquine B-drug
should O
be O
observed O
. O

Amphetamines B-group
may O
decrease O
the O
hypotensive O
effect O
of O
antihypertensives B-group
. O

Although O
one O
study O
tentatively O
supports O
the O
hypothesis O
that O
such O
doses O
of O
ascorbic B-drug
acid I-drug
may O
be O
efficacious O
, O
a O
second O
study O
by O
the O
same O
group O
did O
not O
confirm O
the O
significant O
findings O
, O
and O
no O
clear O
, O
reproducible O
pattern O
of O
efficacy O
has O
emerged O
from O
the O
review O
of O
all O
the O
evidence O
. O

This O
has O
been O
observed O
with O
Benedict O
s O
and O
Fehling O
s O
solutions O
and O
also O
with O
Clinitest O
tablets O
. O

Therefore O
, O
dose O
adjustments O
of O
concomitant O
medications O
that O
are O
predominantly O
metabolized O
by O
CYP2D6 O
and O
have O
a O
narrow O
therapeutic O
index O
( O
e.g. O
, O
flecainide B-drug
, O
vinblastine B-drug
, O
thioridazine B-drug
and O
most O
tricyclic B-group
antidepressants I-group
) O
may O
be O
required O
. O

Plasma O
concentrations O
of O
quinolone B-group
antibiotics I-group
are O
decreased O
when O
administered O
with O
antacids B-group
containing O
magnesium B-drug
, O
calcium B-drug
, O
or O
aluminum B-drug
. O

However O
, O
patients O
receiving O
infusions O
of O
FLOLAN B-brand
in O
clinical O
trials O
were O
maintained O
on O
anticoagulants B-group
without O
evidence O
of O
increased O
bleeding O
. O

Monitoring O
of O
cyclosporine B-drug
levels O
and O
possible O
adjustment O
of O
cyclosporine B-drug
dosage O
should O
be O
considered O
when O
these O
drugs O
are O
co-administered O
. O

Since O
amiodarone B-drug
is O
a O
substrate O
for O
CYP3A4 B-drug
, O
there O
is O
the O
potential O
that O
the O
use O
of O
St. O
John O
s O
Wort O
in O
patients O
receiving O
amiodarone B-drug
could O
result O
in O
reduced O
amiodarone B-drug
levels O
. O

However O
, O
decreases O
in O
exposure O
were O
as O
much O
as O
56 O
% O
and O
66 O
% O
, O
respectively O
, O
in O
individual O
subjects O
. O

Drug O
Class O

High O
concentrations O
of O
cefoxitin B-drug
in O
the O
urine O
may O
interfere O
with O
measurement O
of O
urinary O
17-hydroxy-corticosteroids O
by O
the O
Porter-Silber O
reaction O
, O
and O
produce O
false O
increases O
of O
modest O
degree O
in O
the O
levels O
reported O
. O

Based O
on O
total O
ertapenem B-drug
concentrations O
, O
probenecid B-drug
increased O
the O
AUC O
by O
25 O
% O
and O
reduced O
the O
plasma O
and O
renal O
clearances O
by O
20 O
% O
and O
35 O
% O
, O
respectively O
. O

CASE O
SUMMARY O
: O
A O
64-year-old O
African-American O
man O
was O
admitted O
to O
the O
hospital O
for O
worsening O
renal O
failure O
, O
elevated O
creatine O
phosphokinase O
, O
diffuse O
muscle O
pain O
, O
and O
severe O
muscle O
weakness O
. O

Allopurinol B-drug
: O
Increased O
possibility O
of O
skin O
rash O
, O
particularly O
in O
hyperuricemic O
patients O
may O
occur O
. O

Effects O
of O
xanthine B-group
derivatives I-group
in O
a O
light/dark O
test O
in O
mice O
and O
the O
contribution O
of O
adenosine O
receptors O
. O

Therefore O
, O
patients O
on O
propranolol B-drug
should O
be O
observed O
when O
COLESTID B-brand
Tablets O
are O
either O
added O
or O
deleted O
from O
a O
therapeutic O
regimen O
. O

Phenothiazines B-group
and O
butyrophenones B-group
may O
reduce O
or O
reverse O
the O
pressor O
effect O
of O
epinephrine B-drug
. O

There O
were O
no O
reports O
of O
skeletal O
myopathy O
in O
a O
placebo-controlled O
Phase O
I O
trial O
in O
which O
10 O
healthy O
subjects O
on O
stable O
simvastatin B-drug
therapy O
were O
treated O
concurrently O
with O
daptomycin B-drug
( O
4 O
mg/kg O
once O
every O
24 O
hours O
) O
for O
14 O
days O
. O

METHODS O
: O
We O
carried O
out O
two O
different O
3-way O
crossover O
studies O
in O
healthy O
subjects O
( O
each O
, O
n O
= O
9 O
) O
. O

In O
addition O
, O
under O
the O
influence O
of O
sympatholytic O
medicinal O
products O
such O
as O
beta-blockers B-group
, O
clonidine B-drug
, O
guanethidine B-drug
, O
and O
reserpine B-drug
, O
the O
signs O
of O
hypoglycemia O
may O
be O
reduced O
or O
absent O
. O

Since O
barbiturates B-group
are O
potentiated O
by O
the O
anticholinesterases B-group
, O
they O
should O
be O
used O
cautiously O
in O
the O
treatment O
of O
convulsions O
. O

Patients O
receiving O
medications O
that O
interfere O
with O
platelet O
function O
or O
coagulation O
should O
have O
more O
frequent O
laboratory O
monitoring O
for O
thrombocytopenia O
. O

Pre-treatment O
with O
the O
CYP3A4 O
inducer O
rifampicin B-drug
decreased O
erlotinib B-drug
AUC O
by O
about O
2/3 O
. O

These O
doses O
are O
lower O
than O
the O
therapeutic O
doses O
for O
both O
drugs O
. O

Should O
not O
be O
used O
as O
sole O
protease B-group
inhibitor I-group
in O
combination O
with O
SUSTIVA B-brand
. O

In O
vitro O
studies O
: O
Studies O
in O
human O
liver O
microsomes O
showed O
that O
vardenafil B-drug
is O
metabolized O
primarily O
by O
cytochrome O
P450 O
( O
CYP O
) O
isoforms O
3A4/5 O
, O
and O
to O
a O
lesser O
degree O
by O
CYP2C9 O
. O

Careful O
observation O
is O
required O
when O
amantadine B-drug
is O
administered O
concurrently O
with O
central B-group
nervous I-group
system I-group
stimulants I-group
. O

Accutane B-brand
use O
is O
associated O
with O
depression O
in O
some O
patients O
. O

Antiretroviral B-group
regimens O
consisted O
of O
two O
reverse B-group
transcriptase I-group
inhibitors I-group
and O
one O
protease B-group
inhibitor I-group
. O

If O
concomitant O
treatment O
with O
AXERT B-brand
and O
an O
SSRI B-group
is O
clinically O
warranted O
, O
appropriate O
observation O
of O
the O
patient O
is O
advised O
. O

Fenbufen B-drug
is O
not O
approved O
in O
the O
United O
States O
at O
this O
time O
. O

weaker O
inhibitors O
( O
erythromycin B-drug
, O
grapefruit O
juice O
) O
have O
not O
been O
studied O
. O

The O
risk O
of O
using O
loxapine B-drug
in O
combination O
with O
CNS-active O
drugs O
has O
not O
been O
systematically O
evaluated O
. O

In O
practice O
, O
the O
greatest O
value O
of O
the O
thioether O
assay O
appears O
to O
lie O
in O
its O
signal O
function O
. O

Renal O
clearance O
of O
ucb O
L057 O
in O
the O
presence O
of O
probenecid B-drug
decreased O
60 O
% O
, O
probably O
related O
to O
competitive O
inhibition O
of O
tubular O
secretion O
of O
ucb O
L057 O
. O

Fat O
redistribution O
: O
Redistribution/accumulation O
of O
body O
fat O
including O
central O
obesity O
, O
dorsocervical O
fat O
enlargement O
( O
buffalo O
hump O
) O
, O
peripheral O
wasting O
, O
facial O
wasting O
, O
breast O
enlargement O
, O
and O
cushingoid O
appearance O
have O
been O
observed O
in O
patients O
receiving O
antiretroviral B-group
therapy O
. O

In O
patients O
with O
chronic O
hepatitis O
C O
treated O
with O
PEGASYS B-brand
in O
combination O
with O
COPEGUS B-brand
, O
PEGASYS B-brand
treatment O
did O
not O
affect O
ribavirin B-drug
distribution O
or O
clearance O
. O

In O
addition O
, O
several O
cardiovascular O
drugs O
directly O
affect O
renal O
function O
and O
the O
management O
of O
patients O
with O
renal O
disease O
. O

FREQUENT O
PROTHROMBIN O
TIME/INR O
DETERMINATIONS O
ARE O
ADVISABLE O
UNTIL O
IT O
HAS O
BEEN O
DEFINITELY O
DETERMINED O
THAT O
THE O
PROTHROMBIN O
TIME/INR O
HAS O
STABILIZED O
. O

PEGASYS B-brand
and O
COPEGUS B-brand
are O
excreted O
by O
the O
kidney O
, O
and O
the O
risk O
of O
toxic O
reactions O
to O
this O
therapy O
may O
be O
greater O
in O
patients O
with O
impaired O
renal O
function O
. O

Volatile O
Anesthetic B-drug
Agents O
: O
. O

Lansoprazole B-drug
is O
metabolized O
through O
the O
cytochrome O
P450 O
system O
, O
specifically O
through O
the O
CYP3A O
and O
CYP2C19 O
isozymes O
. O

Cholinergic O
role O
in O
alcohol B-drug
's O
effects O
on O
evoked O
potentials O
in O
visual O
cortex O
of O
the O
albino O
rat O
. O

alopecia O

Use O
in O
Ambulatory O
Patients O
The O
effects O
of O
ROMAZICON B-brand
may O
wear O
off O
before O
a O
long-acting B-group
benzodiazepine I-group
is O
completely O
cleared O
from O
the O
body O
. O

Therefore O
, O
it O
is O
critically O
important O
for O
women O
of O
childbearing O
potential O
to O
select O
and O
commit O
to O
use O
2 O
forms O
of O
effective O
contraception O
simultaneously O
, O
at O
least O
1 O
of O
which O
must O
be O
a O
primary O
form O
, O
unless O
absolute O
abstinence O
is O
the O
chosen O
method O
, O
or O
the O
patient O
has O
undergone O
a O
hysterectomy O

Pharmacokinetics O
were O
assessed O
in O
two O
of O
these O
trials O
. O

increased O
serum O
digoxin B-drug
concentrations O
may O
result O
. O

monoamine B-group
oxidase I-group
inhibitors I-group
; O

There O
does O
not O
appear O
to O
be O
an O
increase O
in O
adverse O
events O
in O
subjects O
who O
received O
oral O
contraceptives B-group
and O
loratadine B-drug
. O

However O
, O
numerous O
potentiation O
effects O
have O
frequently O
been O
reported O
for O
combined O
exposure O
to O
substances O
of O
widespread O
use O
. O

Because O
of O
its O
lack O
of O
platelet O
effects O
, O
VIOXX B-brand
is O
not O
a O
substitute O
for O
aspirin B-brand
for O
cardiovascular O
prophylaxis O
. O

Monoamine B-drug
Oxidase I-drug
Inhibitors I-drug
: O
Guanethidine B-drug
or O
similarly O
acting O
compounds O
; O

Since O
blood O
level O
of O
calcitriol/ergocalcitriol B-drug
will O
be O
reduced O
, O
higher O
doses O
of O
Rocaltrol B-brand
may O
be O
necessary O
if O
these O
drugs O
are O
administered O
simultaneously O
. O

Furosemide B-drug
: O
Clinical O
studies O
, O
as O
well O
as O
post-marketing O
observations O
, O
have O
shown O
that O
NSAIDs B-group
can O
reduce O
the O
natriuretic O
effect O
of O
furosemide B-drug
and O
thiazides B-group
in O
some O
patients O
. O

Caution O
should O
be O
exercised O
when O
taking O
this O
medicine O
certain O
antibiotics B-group
, O
such O
as O
erythromycin B-drug
, O
clarithromycin B-drug
, O
or O
azithromycin B-drug
. O

Drugs O
Metabolized O
by O
Cytochrome O
P450IID6 O
( O
CYP2D6 O
) O
: O
Many O
drugs O
, O
including O
most O
antidepressants B-group
( O
SSRIs O
, O
many O
tricyclics B-group
) O
, O
beta-blockers B-group
, O
antiarrhythmics B-drug
, O
and O
antipsychotics B-group
are O
metabolized O
by O
the O
CYP2D6 O
isoenzyme O
. O

Moreover O
, O
each O
task O
induced O
significant O
alterations O
in O
hippocampal O
adenylate O
cyclase O
activity O
but O
in O
opposite O
directions O
. O

Registered O
trademark O
of O
Ames O
Company O
, O
Division O
of O
Miles O
Laboratories O
, O
Inc O
. O

Twenty O
four O
male O
Wistar O
rats O
were O
divided O
into O
four O
groups O
. O

Quinidine B-drug
: O
Immediate O
Release O
Capsules O
: O
There O
have O
been O
rare O
reports O
of O
an O
interaction O
between O
quinidine B-drug
and O
nifedipine B-drug
( O
with O
a O
decreased O
plasma O
level O
of O
quinidine B-drug
) O
. O

There O
is O
no O
known O
drug O
interference O
with O
standard O
clinical O
laboratory O
tests O
. O

The O
absorption O
of O
oral O
gemifloxacin B-drug
is O
significantly O
reduced O
by O
the O
concomitant O
administration O
of O
an O
antacid B-group
containing O
aluminum B-drug
and O
magnesium B-drug
. O

- O
Phenytoin B-drug
( O
e.g. O
, O
Dilantin B-brand
) O
Use O
of O
phenytoin B-drug
with O
sulfapyridine B-drug
may O
increase O
the O
chance O
of O
side O
effects O
affecting O
the O
liver O
and/or O
the O
side O
effects O
of O
phenytoin B-drug

Multivalent O
Cation-Containing O
Products O
: O
Concurrent O
administration O
of O
a O
quinolone B-group
, O
including O
ciprofloxacin B-drug
, O
with O
multivalent O
cation-containing O
products O
such O
as O
magnesium B-drug
or O
aluminum B-drug
antacids B-group
, O
sucralfate B-drug
, O
VIDEX B-brand
chewable/buffered O
tablets O
or O
pediatric O
powder O
, O
or O
products O
containing O
calcium B-drug
, O
iron B-drug
, O
or O
zinc B-drug
may O
substantially O
decrease O
the O
absorption O
of O
ciprofloxacin B-drug
, O
resulting O
in O
serum O
and O
urine O
levels O
considerably O
lower O
than O
desired O
. O

Compounds O
that O
have O
been O
tested O
in O
man O
include O
antipyrine B-drug
, O
digoxin B-drug
, O
propranolol B-drug
, O
theophylline B-drug
, O
and O
warfarin B-drug
and O
no O
clinically O
meaningful O
interactions O
were O
found O
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
of O
PEGASYS B-brand
in O
pregnant O
women O
. O

cholestyramine B-drug
; O

cases O
of O
rhabdomyolysis O
have O
been O
reported O
in O
seriously O
ill O
patients O
. O

There O
have O
been O
reports O
of O
theophylline-related B-drug
side O
effects O
in O
patients O
on O
concomitant O
therapy O
with O
quinolones B-group
and O
theophylline B-drug
. O

. O

Use O
with O
Other O
Agents O
Affecting O
Myelopoesis O
: O
Drugs O
which O
may O
affect O
leukocyte O
production O
, O
including O
co-trimoxazole B-brand
, O
may O
lead O
to O
exaggerated O
leukopenia O
, O
especially O
in O
renal O
transplant O
recipients O
. O

Together O
with O
previous O
findings O
, O
these O
results O
suggest O
that O
the O
hippocampus O
is O
involved O
in O
both O
the O
so-called O
" O
hippocampal-dependent O
" O

A O
clinical O
interaction O
study O
was O
also O
conducted O
with O
alosetron B-drug
and O
the O
CYP3A4 O
substrate O
cisapride B-drug
. O

In O
addition O
, O
drugs O
that O
are O
actively O
secreted O
via O
this O
route O
( O
e.g. O
, O
triamterene B-drug
, O
metformin B-drug
and O
amiloride B-drug
) O
should O
be O
co-administered O
with O
care O
as O
they O
might O
increase O
dofetilide B-drug
levels O
. O

Endothelium-intact O
aortic O
rings O
from O
high-estradiol B-drug
rats O
were O
supersensitive O
to O
noradrenaline B-drug
when O
compared O
to O
vehicle- O
, O
progesterone- B-drug
and O
progesterone B-drug
+ O
high-estradiol-treated O
rats O
( O
pD2 O
values O
= O
7.77+/-0.12 O
, O
7.21+/-0.13 O
, O
6.93+/-0.04 O
and O
7.22+/-0.18 O
, O
respectively O
) O
. O

A O
potential O
interaction O
between O
oral O
miconazole B-drug
and O
oral O
hypoglycemic B-group
agents I-group
leading O
to O
severe O
hypoglycemia O
has O
been O
reported O
. O

as O
such O
it O
may O
impair O
intestinal O
absorption O
of O
any O
of O
vitamin B-group
D I-group
. O

Elevated O
plasma O
levels O
of O
theophylline B-drug
have O
been O
reported O
with O
concomitant O
use O
of O
some O
quinolones B-group
. O

The O
drug O
interaction O
data O
described O
in O
this O
section O
were O
obtained O
from O
controlled O
clinical O
trials O
and O
studies O
involving O
otherwise O
healthy O
adults O
with O
epilepsy O
. O

decreased O
antithrombin B-drug
3 I-drug
; O

The O
hypoglycemic O
action O
of O
sulfonylureas B-group
may O
be O
potentiated O
by O
certain O
drugs O
including O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
and O
other O
drugs O
that O
are O
highly O
protein O
bound O
, O
salicylates B-group
, O
sulfonamides B-group
, O
chloramphenicol B-drug
, O
probenecid B-drug
, O
coumarins B-group
, O
monoamine B-group
oxidase I-group
inhibitors I-group
, O
and O
beta B-group
adrenergic I-group
blocking I-group
agents I-group
. O

The O
AUC O
and O
Cmax O
of O
both O
the O
( O
R O
) O
and O
( O
S O
) O
isomers O
of O
warfarin B-drug
were O
unaffected O
by O
concurrent O
dosing O
of O
0.3 O
mg O
cerivastatin B-drug
sodium I-drug
. O

Clinical O
studies O
with O
celecoxib B-drug
have O
identified O
potentially O
significant O
interactions O
with O
fluconazole B-drug
and O
lithium B-drug
. O

Rifabutin B-drug

Digitalis B-group

Coadministration O
of O
digoxin B-drug
did O
not O
influence O
the O
pharmacokinetics O
of O
levetiracetam B-drug
. O

The O
mechanism O
and O
long-term O
consequences O
of O
these O
events O
are O
currently O
unknown O
. O

- O
Estrogens B-group
( O
female O
hormones O
) O
or O

Administration O
of O
phenytoin B-drug
to O
patients O
receiving O
dopamine B-drug
HCl I-drug
has O
been O
reported O
to O
lead O
to O
hypotension O
and O
bradycardia O
. O

As O
immediate-early O
genes O
( O
IEGs O
) O
are O
thought O
to O
play O
a O
critical O
role O
in O
mediating O
stimulus-induced O
neural O
plasticity O
, O
IEG O
response O
induced O
by O
methamphetamine B-drug
( O
METH B-drug
) O
has O
been O
characterized O
to O
define O
the O
changes O
in O
gene O
expression O
that O
may O
underlie O
its O
long-lasting O
behavioral O
effects O
. O

In O
seven O
experiments O
reactions O
to O
norepinephrine B-drug
and O
oxytocin B-drug
were O
PGF2alpha B-drug
. O

Both O
itraconazole B-drug
and O
its O
major O
metabolite O
, O
hydroxyitraconazole B-drug_n
, O
are O
inhibitors O
of O
the O
cytochrome O
P450 O
3A4 O
enzyme O
system O
. O

Prothrombin O
times O
were O
measured O
four O
times O
weekly O
during O
five O
long-term O
experiments O
. O

Caution O
should O
be O
used O
when O
alosetron B-drug
and O
ketoconazole B-drug
are O
administered O
concomitantly O
. O

Caution O
is O
therefore O
advised O
when O
administering O
PEGANONE B-brand
to O
patients O
receiving O
coumarin B-group
anticoagulants I-group
. O

In O
vitro O
studies O
indicate O
CYP3A4 O
isoform O
and O
CYP1A2 O
isoform O
mediate O
the O
metabolism O
of O
levobupivacaine B-drug
to O
desbutyl B-drug_n
levobupivacaine I-drug_n
and O
3-hydroxy B-drug_n
levobupivacaine I-drug_n
, O
respectively O
. O

3 O
. O

Venlafaxine B-drug
: O
Coadministration O
of O
a O
single O
dose O
of O
zaleplon B-drug
10 O
mg O
and O
multiple O
doses O
of O
venlafaxine B-drug
ER O
( O
extended O
release O
) O
150 O
mg O
did O
not O
result O
in O
any O
significant O
changes O
in O
the O
pharmacokinetics O
of O
either O
zaleplon B-drug
or O
venlafaxine B-drug
. O

Amprenavir B-drug
does O
not O
inhibit O
CYP2D6 O
, O
CYP1A2 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2E1 O
, O
or O
uridine O
glucuronosyltransferase O
( O
UDPGT O
) O
. O

Co-administration O
of O
single O
25-mg O
dose O
warfarin B-drug
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
total O
lenalidomide B-drug
. O

Advantages O
offered O
by O
this O
class O
of O
antibiotics B-group
include O
optimal O
pharmacokinetics O
, O
effectiveness O
against O
multidrug-resistant O
organisms O
, O
and O
oral O
administration O
even O
when O
parenteral O
antibiotics B-drug
are O
generally O
used O
. O

- O
Amiodarone B-drug
( O
e.g. O
, O
Cordarone B-brand
) O
or O

Coadministration O
of O
Itraconazole B-drug
with O
oral O
midazolam B-drug
or O
triazolam B-drug
has O
resulted O
in O
elevated O
plasma O
concentrations O
of O
the O
latter O
two O
drugs O
. O

Ritonavir B-drug
( O
600 O
mg O
b.i.d O
. O
) O
co-administered O
with O
Vardenafil B-drug
5 O
mg O
resulted O
in O
a O
49-fold O
increase O
in O
vardenafil B-drug
AUC O
and O
a O
13-fold O
increase O
in O
vardenafil B-drug
Cmax O
. O

Drug/Laboratory O
Test O
Interactions O
The O
administration O
of O
ceftazidime B-drug
may O
result O
in O
a O
false-positive O
reaction O
for O
glucose O
in O
the O
urine O
when O
using O
CLINITEST O
tablets O
, O
Benedicts O
solution O
, O
or O
Fehlings O
solution O
. O

In O
addition O
, O
olanzapine B-drug
is O
not O
associated O
with O
a O
risk O
of O
agranulocytosis O
as O
seen O
with O
clozapine B-drug
or O
clinically O
significant O
hyperprolactinaemia O
as O
seen O
with O
risperidone B-drug
or O
prolongation O
of O
the O
QT O
interval O
. O

Ethinyl I-drug
estradiol I-drug
Norethindrone I-drug

Clinical O
trials O
have O
indicated O
that O
Pulmozyme B-brand
can O
be O
effectively O
and O
safely O
used O
in O
conjunction O
with O
standard O
cystic O
fibrosis O
therapies O
including O
oral O
, O
inhaled O
and/or O
parenteral O
antibiotics B-group
, O
bronchodilators B-group
, O
enzyme O
supplements O
, O
vitamins B-group
, O
oral O
or O
inhaled O
corticosteroids B-group
, O
and O
analgesics B-group
. O

Drug/Laboratory O
Test O
Interaction O
Captopril B-drug
may O
cause O
a O
false-positive O
urine O
test O
for O
acetone O
. O

Tolbutamide B-drug
: O
In O
in O
vitro O
studies O
, O
M1 O
was O
shown O
to O
cause O
increases O
ranging O
from O
13 O
- O
50 O
% O
in O
the O
free O
fraction O
of O
tolbutamide B-drug
at O
concentrations O
in O
the O
clinical O
range O
. O

Interactions O
between O
COPAXONE B-brand
and O
other O
drugs O
have O
not O
been O
fully O
evaluated O
. O

Therefore O
, O
patients O
without O
a O
functioning O
thyroid B-group
gland O
who O
are O
on O
thyroid O
replacement O
therapy O
may O
need O
to O
increase O
their O
thyroid O
dose O
if O
estrogens B-group
or O
estrogen-containing B-group
oral O
contraceptives B-group
are O
given O
. O

These O
drugs O
should O
be O
coadministered O
with O
caution O
, O
and O
frequent O
monitoring O
of O
serum O
lithium B-drug
levels O
is O
recommended O
. O

Serum O
samples O
from O
patients O
treated O
with O
cefoxitin B-drug
should O
not O
be O
analyzed O
for O
creatinine O
if O
withdrawn O
within O
2 O
hours O
of O
drug O
administration O
. O

- O
Gold B-drug
salts O
( O
medicine O
for O
arthritis O
) O
or O

Calcium B-group
channel I-group
blockers I-group
may O
also O
have O
an O
additive O
effect O
when O
given O
with O
TENORMIN B-brand
. O

Fluvoxamine B-drug
has O
also O
been O
shown O
to O
inhibit O
P450 O
1A2 O
, O
an O
isoform O
also O
involved O
in O
TCAmetabolism B-group
. O

Coadminstration O
with O
agents O
that O
induce O
3A4 O
activity O
may O
reduce O
the O
efficacy O
of O
DURAGESIC B-brand
. O

1 O
. O

Antiarrhythmics B-group
: O
amiodarone B-drug

Digitalis B-group
: O
Vitamin B-group
D I-group
dosage O
must O
be O
determined O
with O
care O
in O
patients O
undergoing O
treatment O
with O
digitalis B-group
, O
as O
hypercalcemia O
in O
such O
patients O
may O
precipitate O
cardiac O
arrhythmias O
. O

Administration O
of O
0.1-mg/kg O
( O
2 O
x O
ED95 O
) O
NIMBEX B-brand
at O
10 O
% O
or O
95 O
% O
recovery O
following O
an O
intubating O
dose O
of O
succinylcholine B-drug
( O
1 O
mg/kg O
) O
produced O
95 O
% O
neuromuscular O
block O
. O

There O
have O
been O
reports O
of O
interactions O
of O
erythromycin B-drug
with O
carbamazepine B-drug
, O
cyclosporine B-drug
, O
tacrolimus B-drug
, O
hexobarbital B-drug
, O
phenytoin B-drug
, O
alfentanil B-drug
, O
cisapride B-drug
, O
disopyramide B-drug
, O
lovastatin B-drug
, O
bromocriptine B-drug
, O
valproate B-drug
, O
terfenadine B-drug
, O
and O
astemizole B-drug
. O

( O
SGOT O
) O
, O
ALT O
( O
SGPT O
) O

However O
, O
10 O
patients O
who O
switched O
from O
therapy O
with O
Interferon B-drug
beta I-drug
to O
COPAXONE B-brand
did O
not O
report O
any O
serious O
and O
unexpected O
adverse O
reactions O
thought O
to O
be O
related O
to O
treatment O
. O

Therefore O
, O
esomeprazole B-drug
may O
interfere O
with O
the O
absorption O
of O
drugs O
where O
gastric O
pH O
is O
an O
important O
determinant O
of O
bioavailability O
( O
eg O
, O
ketoconazole B-drug
, O
iron B-drug
salts O
and O
digoxin B-drug
) O
. O

In O
a O
similar O
study O
, O
attempting O
to O
replicate O
this O
finding O
, O
no O
interactive O
effect O
on O
hepatic O
transaminases O
was O
identified O
. O

inhalation O
anesthetics B-group
; O

Because O
of O
its O
lack O
of O
platelet O
effects O
, O
CELEBREX B-brand
is O
not O
a O
substitute O
for O
aspirin B-brand
for O
cardiovascular O
prophylaxis O
. O

Paroxetine B-drug
( O
20 O
mg O
QD O
) O
increased O
the O
concentration O
of O
duloxetine B-drug
( O
40 O
mg O
QD O
) O
by O
about O
60 O
% O
, O
and O
greater O
degrees O
of O
inhibition O
are O
expected O
with O
higher O
doses O
of O
paroxetine B-drug
. O

Thus O
, O
when O
NSAIDs B-group
and O
lithium B-drug
are O
administered O
concurrently O
, O
subjects O
should O
be O
observed O
carefully O
for O
signs O
of O
lithium B-drug
toxicity O
. O

These O
findings O
suggest O
that O
intracellular O
Ca O
( O
2+ O
) O
release O
by O
cholinergic O
stimulation O
is O
critical O
for O
determining O
synergism O
with O
cAMP O
in O
parietal O
cell O
activation O
and O
that O
functional O
coupling O
between O
the O
Ca O
( O
2+ O
) O
store O
and O
the O
receptor O
is O
maintained O
by O
actin O
microfilaments O
. O

Dose O
adjustments O
of O
either O
class O
of O
agents O
may O
be O
necessary O
. O

Serum O
concentration O
of O
digoxin B-drug
and O
digitoxin B-drug
may O
increase O
when O
patients O
take O
antithyroid B-group
agents I-group
. O

The O
administration O
of O
naratriptan B-drug
with O
other O
5-HT1 B-group
agonists I-group
has O
not O
been O
evaluated O
in O
migraine O
patients O
. O

Molecular O
basis O
for O
the O
selective O
toxicity O
of O
amphotericin B-drug
B I-drug
for O
yeast O
and O
filipin B-drug_n
for O
animal O
cells O
. O

Estazolam B-drug
: O
Interaction O
with O
Other O
Drugs O
that O
are O
Metabolized O
by O
Cytochrome O
P450 O
( O
CYP O
) O
: O
At O
clinically O
relevant O
concentrations O
, O
in O
vitro O
studies O
indicate O
that O
estazolam B-drug
( O
0.6 O
M O
) O
was O
not O
inhibitory O
towards O
the O
major O
cytochrome O
P450 O
isoforms O
CYP1A2 O
, O
CYP2A6 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2D6 O
, O
CYP2E1 O
, O
and O
CYP3A O
. O

However O
, O
when O
the O
thioether O
concentration O
ranges O
within O
the O
limits O
of O
the O
normal O
value O
, O
one O
must O
not O
conclude O
that O
there O
is O
no O
, O
or O
negligible O
, O
exposure O
. O

- O
Naltrexone B-drug
( O
e.g. O
, O
Trexan B-brand
) O
( O
with O
long-term O
, O
high-dose O
use O
) O
or O

Drugs O
that O
reportedly O
may O
increase O
oral O
anticoagulant B-group
response O
, O
ie O
, O
increased O
prothrombin O
response O
, O
in O
man O
include O
: O
alcohol* B-drug
; O

Again O
, O
sertraline B-drug
neutralized O
the O
increase O
in O
glycemia O
after O
glucose B-drug
overload O
both O
in O
diabetic O
and O
non-diabetic O
rats O
. O

Coadministration O
of O
phenytoin B-drug
with O
40 O
mg O
SULAR B-brand
tablets O
in O
epileptic O
patients O
lowered O
the O
nisoldipine B-drug
plasma O
concentrations O
to O
undetectable O
levels O
. O

The O
effects O
of O
coadministration O
of O
BARACLUDE B-brand
with O
other O
drugs O
that O
are O
renally O
eliminated O
or O
are O
known O
to O
affect O
renal O
function O
have O
not O
been O
evaluated O
, O
and O
patients O
should O
be O
monitored O
closely O
for O
adverse O
events O
when O
BARACLUDE B-brand
is O
coadministered O
with O
such O
drugs O
. O

Garlic O
Capsules O
Garlic O
capsules O
should O
not O
be O
used O
while O
taking O
saquinavir B-drug
( O
FORTOVASE B-brand
) O
as O
the O
sole O
protease B-group
inhibitor I-group
due O
to O
the O
risk O
of O
decreased O
saquinavir B-drug
plasma O
concentrations O
. O

In O
addition O
, O
certain O
drugs O
inhibit O
the O
activity O
of O
this O
isozyme O
and O
make O
normal O
metabolizers O
resemble O
poor O
metabolizers O
. O

Mylotarg B-brand
is O
not O
known O
to O
interfere O
with O
any O
routine O
diagnostic O
tests O
. O

pyrazolones B-group
; O

. O

Oral O
Hypoglycemics B-group
: O
Bepridil B-drug
has O
been O
safely O
used O
in O
diabetic O
patients O
without O
significantly O
lowering O
their O
blood O
glucose O
levels O
or O
altering O
their O
need O
for O
insulin B-drug
or O
oral O
hypoglycemic B-group
agents I-group
. O

however O
, O
patients O
with O
moderate O
to O
severe O
cardiovascular O
disease O
or O
those O
taking O
nitrate B-group
therapy O
are O
at O
increased O
risk O
for O
potentially O
serious O
cardiovascular O
adverse O
effects O
with O
sildenafil B-drug
therapy O
. O

A O
dose O
increase O
of O
lopinavir/ritonavir B-drug
to O
533/133 O
mg O
( O
4 O
capsules O
or O
6.5 O
mL O
) O
twice O
daily O
taken O
with O
food O
is O
recommended O
when O
used O
in O
combination O
with O
SUSTIVA B-brand
. O

Systemic O
antibiotic B-group
agents I-group
. O

Currently O
, O
it O
is O
conceived O
that O
a O
number O
of O
events O
, O
or O
hits O
, O
are O
required O
for O
the O
induction O
of O
tumors O
by O
chemical O
agents O
. O

In O
contrast O
, O
in O
Ontario O
alone O
, O
in O
1972 O
and O
1973 O
there O
were O
26 O
deaths O
in O
amphetamine B-drug
users O
, O
of O
which O
16 O
were O
due O
to O
accident O
suicide O
or O
homicide O
. O

These O
effects O
have O
been O
observed O
with O
co-administration O
of O
itraconazole B-drug
( O
a O
potent O
CYP3A4 B-drug
inhibitor O
) O
. O

Thus O
patients O
receiving O
oral O
anticoagulants B-group
and O
Fluvoxamine B-drug
Tablets O
should O
have O
their O
prothrombin O
time O
monitored O
and O
their O
anticoagulant B-group
dose O
adjusted O
accordingly O
. O

We O
compared O
indinavir B-drug
pharmacokinetics O
and O
gastric O
pH O
in O
12 O
human O
immunodeficiency O
virus-positive O
patients O
by O
use O
of O
800 O
mg O
of O
indinavir B-drug
alone O
versus O
800 O
mg O
of O
indinavir B-drug
administered O
1 O
h O
after O
didanosine B-drug
administration O
. O

3 O
. O

The O
possible O
adverse O
effects O
of O
ZINECARD B-brand
on O
the O
fertility O
of O
humans O
and O
experimental O
animals O
, O
male O
or O
female O
, O
have O
not O
been O
adequately O
studied O
. O

Terfenadine B-drug
, O
astemizole B-drug
and O
cisapride B-drug
are O
all O
metabolized O
by O
the O
cytochrome O
P450IIIA4 O
isozyme O
, O
and O
it O
has O
been O
demonstrated O
that O
ketoconazole B-drug
, O
a O
potent O
inhibitor O
of O
IIIA4 O
, O
blocks O
the O
metabolism O
of O
these O
drugs O
, O
resulting O
in O
increased O
plasma O
concentrations O
of O
parent O
drug O
. O

Loperamide B-drug
and O
morphine B-drug
( O
0.1 O
and O
1.0 O
mg/kg O
, O
s.c. O
) O
inhibited O
the O
dmPGE2 B-drug_n
( O
0.3 O
mg/kg O
, O
p.o O
. O
) O
-induced O
diarrhea O
in O
cecectomized O
rats O
. O

In O
geriatric O
subjects O
( O
n=7 O
) O
there O
was O
a O
reduction O
in O
the O
rate O
but O
not O
the O
extent O
of O
flurbiprofen B-drug
absorption O
. O

Influence O
of O
coadministration O
of O
fluoxetine B-drug
on O
cisapride B-drug
pharmacokinetics O
and O
QTc O
intervals O
in O
healthy O
volunteers O
. O

Coadministration O
of O
esomeprazole B-drug
30 O
mg O
and O
diazepam B-drug
, O
a O
CYP2C19 O
substrate O
, O
resulted O
in O
a O
45 O
% O
decrease O
in O
clearance O
of O
diazepam B-drug
. O

. O

SIDE O
EFFECTS O
( O
KEMSTRO B-brand
) O
The O
most O
common O
adverse O
reaction O
during O
treatment O
with O
baclofen B-drug
is O
transient O
drowsiness O
( O
10-63 O
% O
) O
. O

Coadministration O
of O
CRIXIVAN B-brand
and O
drugs O
primarily O
metabolized O
by O
CYP3A4 O
may O
result O
in O
increased O
plasma O
concentrations O
of O
the O
other O
drug O
, O
which O
could O
increase O
or O
prolong O
its O
therapeutic O
and O
adverse O
effects O
. O

The O
relevance O
of O
this O
finding O
to O
humans O
is O
not O
known O
at O
this O
time O
. O

Effect O
of O
Sensipar B-brand
on O
other O
drugs O
: O
Drugs O
metabolized O
by O
cytochrome O
P450 O
2D6 O
( O
CYP2D6 O
) O
: O
Sensipar B-brand
is O
a O
strong O
in O
vitro O
inhibitor O
of O
CYP2D6 O
. O

This O
study O
was O
designed O
to O
evaluate O
the O
pharmacokinetic O
basis O
of O
this O
interaction O
in O
10 O
normal O
subjects O
. O

In O
uninfected O
volunteers O
, O
46 O
% O
developed O
rash O
while O
receiving O
SUSTIVA B-brand
and O
clarithromycin B-drug
. O

Interactions O
for O
Vitamin B-drug
B3 I-drug
( O
Niacin B-drug
) O
: O
Antihypertensive B-group
Therapy O
: O
Nicotinic B-drug
acid I-drug
may O
potentiate O
the O
effects O
of O
ganglionic B-group
blocking I-group
agents I-group
and O
vasoactive O
drugs O
resulting O
in O
postural O
hypotension O
. O

Of O
particular O
importance O
, O
sufficient O
time O
must O
elapse O
before O
initiating O
TCA O
treatment O
in O
a O
patient O
being O
withdrawn O
from O
fluoxetine B-drug
, O
given O
the O
long O
half-life O
of O
the O
parent O
and O
active O
metabolite O
( O
at O
least O
5 O
weeks O
may O
be O
necessary O
) O
. O

Following O
oral O
administration O
of O
two O
150-mg O
sustained-release O
tablets O
with O
and O
without O
800 O
mg O
of O
cimetidine B-drug
, O
the O
pharmacokinetics O
of O
bupropion B-drug
and O
hydroxybupropion B-drug_n
were O
unaffected O
. O

In O
addition O
, O
most O
macrolides B-group
are O
contraindicated O
in O
patients O
receiving O
terfenadine B-drug
therapy O
who O
have O
pre-existing O
cardiac O
abnormalities O
( O
arrhythmia O
, O
bradycardia O
, O
QT O
c O
interval O
prolongation O
, O
ischemic O
heart O
disease O
, O
congestive O
heart O
failure O
, O
etc O
. O
) O
or O
electrolyte O
disturbances O
. O

OBJECTIVE O
: O
This O
paper O
reviews O
recent O
studies O
of O
the O
efficacy O
of O
sildenafil B-drug
, O
its O
adverse O
effects O
and O
drug O
interactions O
, O
and O
socioeconomic O
factors O
involved O
in O
its O
use O
, O
with O
a O
focus O
on O
specific O
patient O
populations O
( O
prostate O
cancer O
, O
diabetes O
mellitus O
, O
ischemic O
heart O
disease O
, O
spinal O
cord O
injuries O
, O
neurologic O
disorders O
) O
. O

Drug/Laboratory O
Test O
Interactions O
: O
Measurement O
of O
serum O
creatinine O
levels O
should O
be O
determined O
by O
the O
Jaffe O
reaction O
, O
since O
Ancobon B-brand
does O
not O
interfere O
with O
the O
determination O
of O
creatinine O
values O
by O
this O
method O
. O

Other O
strong O
selective O
CYP3A4 O
inhibitors O
such O
as O
ketoconazole B-drug
can O
also O
be O
expected O
to O
increase O
the O
exposure O
of O
zaleplon B-drug
. O

Phenobarbital B-drug
: O
Amphetamines B-group
may O
delay O
intestinal O
absorption O
of O
phenobarbital B-drug
; O

In O
two O
combined O
12-week O
placebo O
controlled O
trials O
that O
included O
BROVANA B-brand
doses O
of O
15 O
mcg O
twice O
daily O
, O
25 O
mcg O
twice O
daily O
, O
and O
50 O
mcg O
once O
daily O
, O
54 O
of O
873 O
BROVANA B-brand
-treated O
subjects O
received O
concomitant O
theophylline B-drug
at O
study O
entry O
. O

Limited O
comparative O
data O
in O
patients O
with O
high O
viral O
loads O
treated O
with O
nevirapine- B-drug
or O
delavirdine-based B-drug
regimens O
currently O
exist O
. O

Norepinephrine B-drug
: O
Amphetamines B-group
enhance O
the O
adrenergic O
effect O
of O
norepinephrine B-drug
. O

Ketoconazole B-drug
: O
Ketoconazole B-drug
400 O
mg O
daily O
did O
not O
have O
any O
clinically O
important O
effect O
on O
the O
pharmacokinetics O
of O
rofecoxib B-drug
. O

) O

paraldehyde B-drug
; O

*Not O
administered O
, O
but O
an O
active O
metabolite O
of O
carbamazepine B-drug
. O

Clinical O
studies O
have O
shown O
increased O
sedation O
with O
concurrent O
hypnotic B-group
medications I-group
. O

The O
digoxin B-drug
median O
tmax O
was O
0.5 O
hours O
for O
both O
treatments O
. O

No O
pharmacokinetic O
interactions O
between O
dexmedetomidine B-drug
and O
isoflurane B-drug
, O
propofol B-drug
, O
alfentanil B-drug
, O
and O
midazolam B-drug
have O
been O
demonstrated O
. O

Close O
supervision O
and O
careful O
adjustment O
of O
the O
dosage O
are O
required O
when O
nortriptyline B-drug
hydrochloride I-drug
is O
used O
with O
other O
anticholinergic B-group
drugs I-group
or O
sympathomimetic B-group
drugs I-group
. O

Also O
flucytosine B-drug
. O

An O
individual O
who O
is O
stable O
on O
a O
given O
dose O
of O
TCA B-group
may O
become O
abruptly O
toxic O
when O
given O
one O
of O
these O
inhibiting O
drugs O
as O
concomitant O
therapy O
. O

Theophylline B-drug
serum O
levels O
should O
be O
monitored O
and O
appropriate O
dose O
adjustments O
considered O
for O
patients O
given O
both O
theophylline B-drug
and O
PEGASYS B-brand
. O

AXERT B-brand
is O
not O
known O
to O
interfere O
with O
commonly O
employed O
clinical O
laboratory O
tests O
. O

Bosentan B-drug
is O
also O
expected O
to O
reduce O
plasma O
concentrations O
of O
other O
statins B-group
that O
have O
significant O
metabolism O
by O
CYP3A4 O
, O
such O
as O
lovastatin B-drug
and O
atorvastatin B-drug
. O

No O
clinically O
relevant O
interactions O
with O
drugs O
metabolized O
by O
these O
CYP O
enzymes O
would O
be O
expected O
. O

therefore O
, O
nitroglycerin B-drug
or O
other O
nitrates B-group
( O
as O
used O
for O
management O
of O
angina O
) O
or O
other O
drugs O
having O
vasodilator O
activity O
should O
, O
if O
possible O
, O
be O
discontinued O
before O
starting O
captopril B-drug
. O

( O
Thiazide B-group
drugs I-group
may O
increase O
the O
responsiveness O
to O
tubocurarine B-drug
. O
) O

DISULFIRAM B-drug
SHOULD O
BE O
USED O
WITH O
CAUTION O
IN O
THOSE O
PATIENTS O
REVEIVING O
PHENYTOIN B-drug
AND O
ITS O
CONGENERS O
. O

These O
increased O
exposures O
of O
norethindrone B-drug
and O
ethinyl B-drug
estradiol I-drug
should O
be O
taken O
into O
consideration O
when O
selecting O
an O
oral O
contraceptive B-group
for O
women O
taking O
valdecoxib B-drug
. O

Patients O
receiving O
narrow O
therapeutic O
ratio O
drugs O
or O
other O
drugs O
that O
require O
careful O
titration O
should O
be O
followed O
closely O
; O

Evidence O
supporting O
the O
conclusion O
that O
it O
is O
inadvisable O
to O
co-administer O
fluvoxamine B-drug
and O
diazepam B-drug
is O
derived O
from O
a O
study O
in O
which O
healthy O
volunteers O
taking O
150 O
mg/day O
of O
fluvoxamine B-drug
were O
administered O
a O
single O
oral O
dose O
of O
10 O
mg O
of O
diazepam B-drug
. O

Inhibition O
of O
these O
isoenzymes O
may O
increase O
the O
plasma O
concentration O
of O
bosentan B-drug
. O

These O
results O
are O
consistent O
with O
the O
in O
vitro O
finding O
that O
neither O
isotretinoin B-drug
nor O
its O
metabolites O
induce O
or O
inhibit O
the O
activity O
of O
the O
CYP O
2C9 O
human O
hepatic O
P450 O
enzyme O
. O

Although O
clinical O
studies O
have O
not O
been O
conducted O
, O
in O
vitro O
studies O
of O
iloprost B-drug
indicate O
that O
no O
relevant O
inhibition O
of O
cytochrome O
P450 O
drug O
metabolism O
would O
be O
expected O
. O

Quinolone B-group
Antibiotics O
: O
VIDEX B-brand
should O
be O
administered O
at O
least O
2 O
hours O
after O
or O
6 O
hours O
before O
dosing O
with O
ciprofloxacin B-drug
because O
plasma O
concentrations O
of O
ciprofloxacin B-drug
are O
decreased O
when O
administered O
with O
antacids B-group
containing O
magnesium B-drug
, O
calcium B-drug
, O
or O
aluminum B-drug
. O

Thyroid B-group
administration O
to O
a O
digitalized O
, O
hypothyroid O
patient O
may O
increase O
the O
dose O
requirement O
of O
digoxin B-drug
. O

Similarly O
, O
diazepam B-drug
decreased O
the O
antinociceptive O
effect O
of O
metamizol B-drug
( O
only O
in O
the O
tail-flick O
test O
) O
and O
indomethacin B-drug
. O

The O
following O
are O
examples O
of O
substances O
that O
may O
increase O
the O
blood-glucose-lowering O
effect O
and O
susceptibility O
to O
hypoglycemia O
: O
oral O
antidiabetes O
products O
, O
ACE B-group
inhibitors I-group
, O
disopyramide B-drug
, O
fibrates B-group
, O
fluoxetine B-drug
, O
MAO B-group
inhibitors I-group
, O
propoxyphene B-drug
, O
salicylates B-group
, O
somatostatin B-group
analog I-group
( O
e.g. O
, O
octreotide B-drug
) O
, O
sulfonamide B-group
antibiotics I-group
. O

Patients O
should O
be O
monitored O
for O
signs O
of O
withdrawal O
and O
their O
methadone B-drug
dose O
increased O
as O
required O
to O
alleviate O
withdrawal O
symptoms O
. O

Therefore O
, O
positive O
test O
results O
in O
patients O
receiving O
piperacillin B-drug
should O
be O
interpreted O
cautiously O
and O
confirmed O
by O
other O
diagnostic O
methods O
. O

Concomitant O
use O
of O
cimetidine B-drug
should O
be O
avoided O
. O

Antacids B-group
: O
Concomitant O
administration O
of O
antacids B-group
may O
reduce O
plasma O
levels O
of O
diflunisal B-drug
. O

In O
patients O
who O
have O
been O
reported O
to O
be O
well O
controlled O
on O
tricyclic B-group
antidepressants I-group
receiving O
concurrent O
cimetidine B-drug
therapy O
, O
discontinuation O
of O
cimetidine B-drug
has O
been O
reported O
to O
decrease O
established O
steady-state O
serum O
tricyclic B-group
antidepressant I-group
levels O
and O
compromise O
their O
therapeutic O
effects O
. O

Insulin B-drug
requirements O
in O
diabetic O
patients O
may O
be O
increased O
, O
decreased O
, O
or O
unchanged O
. O

at O
high O
doses O
, O
( B-drug_n
- I-drug_n
) I-drug_n
-NANM I-drug_n
decreased O
FI O
and O
FR O
responding O
. O

The O
pharmacokinetics O
of O
terfenadine B-drug
and O
its O
acid O
metabolite O
and O
the O
electrocardiographic O
QT O
c O
interval O
were O
measured O
during O
both O
periods O
: O
with O
terfenadine B-drug
alone O
, O
and O
with O
terfenadine B-drug
plus O
dirithromycin B-drug
. O

Thus O
, O
if O
such O
treatment O
is O
essential O
, O
the O
possibility O
of O
increased O
risk O
relative O
to O
benefits O
should O
be O
considered O
. O

In O
10 O
otherwise O
healthy O
subjects O
with O
epilepsy O
ingesting O
phenytoin B-drug
, O
the O
steadystate O
trough O
( O
Cmin O
) O
phenytoin B-drug
plasma O
concentration O
was O
17 O
5 O
micrograms/mL O
. O

Antiretroviral B-group
Agents I-group
: O
No O
drug O
interactions O
with O
other O
antiretroviral B-group
medications I-group
have O
been O
identified O
that O
would O
warrant O
alteration O
of O
either O
the O
enfuvirtide B-drug
dose O
or O
the O
dose O
of O
the O
other O
antiretroviral B-group
medication I-group
. O

Toxicology O
studies O
of O
heroin-related B-drug_n
deaths O
reveal O
frequent O
involvement O
of O
other O
central B-group
nervous I-group
system I-group
depressants I-group
, O
including O
alcohol B-drug
, O
benzodiazepines B-group
such O
as O
diazepam B-drug
( O
Valium B-brand
) O
, O
and O
, O
to O
a O
rising O
degree O
, O
methadone B-drug
. O

Aprepitant B-drug
has O
been O
shown O
to O
induce O
the O
metabolism O
of O
S B-drug
( I-drug
- I-drug
) I-drug
warfarin I-drug
and O
tolbutamide B-drug
, O
which O
are O
metabolized O
through O
CYP2C9 O
. O

5 O
. O

Although O
increased O
plasma O
concentrations O
( O
C O
max O
and O
AUC O
0-24 O
hrs O
) O
of O
desloratadine B-drug
and O
3-hydroxydesloratadine B-drug_n
were O
observed O
, O
there O
were O
no O
clinically O
relevant O
changes O
in O
the O
safety O
profile O
of O
desloratadine B-drug
, O
as O
assessed O
by O
electrocardiographic O
parameters O
( O
including O
the O
corrected O
QT O
interval O
) O
, O
clinical O
laboratory O
tests O
, O
vital O
signs O
, O
and O
adverse O
events O
. O

Plasma O
exposure O
of O
diazepam B-drug
( O
10 O
mg O
BID O
) O
was O
increased O
by O
28 O
% O
following O
administration O
of O
valdecoxib B-drug
( O
40 O
mg O
BID O
) O
for O
12 O
days O
, O
while O
plasma O
exposure O
of O
valdecoxib B-drug
( O
40 O
mg O
BID O
) O
was O
not O
substantially O
increased O
following O
administration O
of O
diazepam B-drug
( O
10 O
mg O
BID O
) O
for O
12 O
days O
. O

When O
administered O
concurrently O
, O
the O
following O
drugs O
may O
interact O
with O
ampicillin B-drug
. O

Concomitant O
treatment O
with O
methylxanthines B-group
( O
aminophylline B-drug
, O
theophylline B-drug
) O
, O
steroids B-group
, O
or O
diuretics B-group
may O
potentiate O
any O
hypokalemic O
effect O
of O
adrenergic B-group
agonists I-group
. O

When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
glipizide B-drug
, O
the O
patient O
should O
be O
observed O
closely O
for O
hypoglycemia O
. O

Drug/LaboratoryTest O
Interactions O
Dactinomycin B-drug
may O
interfere O
with O
bioassay O
procedures O
for O
the O
determination O
of O
antibacterial B-group
drug I-group
levels O
. O

In O
addition O
, O
certain O
drugs O
inhibit O
the O
activity O
of O
this O
isozyme O
and O
make O
normal O
metabolizers O
resemble O
p.o O
. O

Intravenous O
Adenocard B-brand
( O
adenosine B-drug
) O
has O
been O
effectively O
administered O
in O
the O
presence O
of O
other O
cardioactive O
drugs O
, O
such O
as O
quinidine B-drug
, O
beta-adrenergic B-group
blocking I-group
agents I-group
, O
calcium B-group
channel I-group
blocking I-group
agents I-group
, O
and O
angiotensin B-group
converting I-group
enzyme I-group
inhibitors I-group
, O
without O
any O
change O
in O
the O
adverse O
reaction O
profile O
. O

8 O
. O

At O
24 O
hours O
postdose O
, O
a O
similar O
proportion O
of O
patients O
treated O
with O
methotrexate B-drug
alone O
( O
94 O
% O
) O
and O
subsequently O
treated O
with O
methotrexate B-drug
co-administered O
with O
75 O
mg O
of O
rofecoxib B-drug
( O
88 O
% O
) O
had O
methotrexate B-drug
plasma O
concentrations O
below O
the O
measurable O
limit O
( O
5 O
ng/mL O
) O
. O

In O
a O
p53 O
( O
+/- O
) O
mouse O
carcinogenicity O
study O
at O
doses O
up O
to O
the O
maximum O
tolerated O
dose O
of O
100 O
mg/kg/day O
ribavirin B-drug
was O
not O
oncogenic O
. O

Results O
of O
studies O
in O
multiple O
sclerosis O
patients O
taking O
TYSABRI B-brand
and O
concomitant O
interferon B-drug
beta-1a I-drug
( O
AVONEX B-brand
30 O
mcg O
IM O
once O
weekly O
) O
or O
glatiramer B-drug
acetate I-drug
were O
inconclusive O
with O
regard O
to O
the O
need O
for O
dose O
adjustment O
of O
the O
beta-interferon B-drug
or O
glatiramer B-drug
acetate I-drug
. O

Laboratory O
Test O
Interactions O

Drugs O
Metabolized O
by O
P450 O
2D6 O
: O
The O
biochemical O
activity O
of O
the O
drug O
metabolizing O
isozyme O
cytochrome O
P450 O
2D6 O
( O
debrisoquin O
hydroxylase O
) O
is O
reduced O
in O
a O
subset O
of O
the O
Caucasian O
population O
( O
about O
7-10 O
% O
of O
Caucasians O
are O
so-called O
poor O
metabolizers O
) O
; O

Concomitant O
use O
of O
tricyclic B-group
antidepressants I-group
with O
other O
drugs O
metabolized O
by O
cytochrome O
P450IID6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
the O
tricyclic B-group
antidepressant I-group
or O
the O
other O
drug O
. O

In O
general O
, O
any O
added O
antiarrhythmic B-drug
drug I-drug
should O
be O
initiated O
at O
a O
lower O
than O
usual O
dose O
with O
careful O
monitoring O
. O

There O
have O
been O
rare O
postmarketing O
reports O
of O
rhabdomyolysis O
, O
some O
associated O
with O
strenuous O
physical O
activity O
. O

The O
effects O
of O
concomitant O
administration O
of O
TAMBOCOR B-brand
and O
propranolol B-drug
on O
the O
PR O
interval O
were O
less O
than O
additive O
. O

Influence O
of O
calcium-channel B-group
blockers I-group
on O
platelet O
function O
and O
arachidonic O
acid O
metabolism O
. O

Amphetamines B-group
may O
interfere O
with O
urinary O
steroid O
determinations O
. O

Studies O
have O
shown O
that O
lansoprazole B-drug
does O
not O
have O
clinically O
significant O
interactions O
with O
other O
drugs O
metabolized O
by O
the O
cytochrome O
P450 O
system O
, O
such O
as O
warfarin B-drug
, O
antipyrine B-drug
, O
indomethacin B-drug
, O
ibuprofen B-drug
, O
phenytoin B-drug
, O
propranolol B-drug
, O
prednisone B-drug
, O
diazepam B-drug
, O
clarithromycin B-drug
, O
or O
terfenadine B-drug
in O
healthy O
subjects O
. O

We O
report O
the O
case O
of O
an O
adolescent O
with O
altered O
consciousness O
caused O
by O
carbamazepine B-drug
overdose O
with O
a O
positive O
tricyclic B-group
antidepressant I-group
level O
to O
alert O
clinicians O
to O
the O
cross-reactivity O
of O
carbamazepine B-drug
with O
a O
toxicology O
screen O
for O
tricyclic B-group
antidepressants I-group
. O

nc1 O
18 O
% O
decrease O
[ O
CI O
: O
13 O
% O
decrease O
, O
40 O
% O
decrease O
] O

Trough O
plasma O
enoxacin B-drug
levels O
were O
also O
20 O
% O
higher O
when O
caffeine B-drug
and O
enoxacin B-drug
were O
administered O
concomitantly O
. O

In O
contrast O
, O
preliminary O
results O
from O
an O
8-week O
controlled O
study O
suggested O
risperidone B-drug
2 O
to O
6 O
mg/day O
was O
superior O
to O
olanzapine B-drug
5 O
to O
20 O
mg/day O
against O
positive O
and O
anxiety/depressive O
symptoms O
( O
p O
< O
0.05 O
) O
, O
although O
consistent O
with O
the O
first O
study O
, O
both O
agents O
demonstrated O
similar O
efficacy O
on O
measures O
of O
overall O
psychopathology O
. O

The O
goal O
of O
this O
review O
was O
to O
cite O
primary O
sources O
for O
virtually O
all O
research O
specific O
to O
POPs O
since O
1975 O
. O

Then O
, O
the O
effects O
of O
metabotropic O
glutamate O
receptor O
( O
mGluR O
) O
agonists O
, O
DCG-IV B-drug_n
and O
L-CCG-1 B-drug_n
, O
on O
the O
above O
behavioral O
changes O
induced O
by O
PCP B-drug_n
were O
found O
. O

It O
is O
desirable O
to O
monitor O
TCA B-group
plasma O
levels O
whenever O
a O
TCA B-group
is O
going O
to O
be O
co-administered O
with O
another O
drug O
known O
to O
be O
an O
inhibitor O
of O
P450 O
2D6 O
. O

Patients O
treated O
with O
proton B-group
pump I-group
inhibitors I-group
and O
warfarin B-drug
concomitantly O
may O
need O
to O
be O
monitored O
for O
increases O
in O
INR O
and O
prothrombin O
time O
. O

Both O
hypo- O
and O
hyperglycemic O
effects O
have O
been O
reported O
. O

There O
were O
no O
clinically O
significant O
changes O
in O
corrected O
QT O
intervals O
during O
administration O
of O
cisapride B-drug
alone O
or O
with O
fluoxetine B-drug
. O

A O
rare O
, O
but O
serious O
, O
constellation O
of O
symptoms O
, O
termed O
serotonin O
syndrome O
, O
has O
been O
reported O
with O
the O
concomitant O
use O
of O
selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
( O
SSRIs B-group
) O
and O
agents O
for O
migraine O
therapy O
, O
such O
as O
Imitrex B-brand
( O
sumatriptan B-drug
succinate I-drug
) O
and O
dihydroergotamine B-drug
. O

Concomitant O
cyclophosphamide B-drug
, O
doxorubicin B-drug
, O
vincristine B-drug
, O
and O
prednisone B-drug
chemotherapy O
plus O
highly B-group
active I-group
antiretroviral I-group
therapy O
in O
patients O
with O
human O
immunodeficiency O
virus-related O
, O
non-Hodgkin O
lymphoma O
. O

Most O
automated O
equipment O
for O
measurement O
of O
creatinine O
makes O
use O
of O
the O
Jaffe O
reaction O
. O

Some O
quinolones B-group
have O
also O
been O
shown O
to O
interfere O
with O
the O
metabolism O
of O
caffeine B-drug
. O

vii O
. O

No O
inhibition O
of O
deferasirox B-drug
metabolism O
by O
hydroxyurea B-drug
is O
expected O
based O
on O
the O
results O
of O
an O
in O
vitro O
study O
. O

Since O
aminotransferase O
determinations O
are O
important O
in O
the O
differential O
diagnosis O
of O
myocardial O
infarction O
, O
liver O
disease O
and O
pulmonary O
emboli O
, O
rises O
that O
might O
be O
caused O
by O
drugs O
( O
heparin B-drug
sodium I-drug
) O
should O
be O
interpreted O
with O
caution O
. O

This O
product O
can O
affect O
the O
results O
of O
certain O
lab O
tests O
. O

The O
mean O
QT O
c O
interval O
( O
msec O
) O
was O
369 O
with O
terfenadine B-drug
alone O
and O
367 O
with O
terfenadine B-drug
plus O
dirithromycin B-drug
. O

Therefore O
you O
may O
need O
to O
take O
a O
vitamin B-drug
B12 I-drug
supplement O
while O
taking O
aminosalicylic B-drug
acid I-drug
. O

Beta B-group
Blockers I-group

Atorvastatin B-drug
: O
Atorvastatin B-drug
increases O
the O
AUC O
for O
norethindrone B-drug
and O
ethinyl B-drug
estradiol I-drug
. O

Combinations O
of O
clindamycin B-drug
and O
gentamicin B-drug
were O
indifferent O
for O
29 O
strains O
and O
synergistic O
for O
33 O
strains O
. O

Agents O
Causing O
Renin O
Release O
Captopril B-drug
's O
effect O
will O
be O
augmented O
by O
antihypertensive B-group
agents I-group
that O
cause O
renin O
release O
. O

Amprenavir B-drug
inhibits O
the O
ERMBT O
, O
and O
rifampin B-drug
and O
rifabutin B-drug
are O
equipotent O
inducers O
of O
the O
ERMBT O
. O

Concomitant O
use O
of O
zalcitabine B-drug
and O
lamivudine B-drug
is O
not O
recommended O
. O

Although O
activation O
of O
several O
transcription O
factor O
IEGs O
has O
been O
described O
, O
little O
is O
known O
about O
effector O
IEGs O
. O

Clostridium B-drug_n
difficile I-drug_n
toxin I-drug_n
A I-drug_n
displays O
both O
cytotoxic O
and O
enterotoxic O
activities O
. O

It O
is O
likely O
that O
experience O
significantly O
underestimates O
the O
degree O
of O
accumulation O
that O
might O
occur O
with O
repealed O
diazepam B-drug
administration O
. O

The O
use O
of O
dexfenfluramine B-drug
with O
other O
CNS-active O
drugs O
has O
not O
been O
systematically O
evaluated O
; O

NSAIDs B-group
may O
decrease O
the O
hemodynamic O
effects O
of O
hydralazine B-drug
; O

therefore O
, O
close O
monitoring O
of O
prothrombin O
time O
is O
recommended O
, O
and O
adjustment O
of O
the O
anticoagulant B-group
dose O
may O
be O
necessary O
when O
Tagamet B-brand
is O
administered O
concomitantly O
. O

Genetic O
variation O
also O
occurs O
in O
proteins O
interacting O
with O
drugs O
, O
which O
may O
change O
the O
effect O
of O
e.g O
. O

Before O
using O
this O
medication O
, O
tell O
your O
doctor O
or O
pharmacist O
of O
all O
prescription O
and O
nonprescription O
products O
you O
may O
use O
, O
especially O
of O
: O
aminoglycosides B-group
( O
e.g. O
, O
gentamicin B-drug
, O
amikacin B-drug
) O
, O
amphotericin B-drug
B I-drug
, O
cyclosporine B-drug
, O
non-steroidal B-group
anti-inflammatory I-group
drugs O
( O
e.g. O
, O
ibuprofen B-drug
) O
, O
tacrolimus B-drug
, O
vancomycin B-drug
. O

- O
a O
diuretic B-group
( O
water O
pill O
) O
such O
as O
hydrochlorothiazide B-drug
( O
HCTZ B-drug
, O
Hydrodiuril B-brand
) O
, O
chlorothiazide B-drug
( O
Diuril B-brand
) O
, O
and O
others O
; O

Diuretics B-group
: O
Etodolac O
has O
no O
apparent O
pharmacokinetic O
interaction O
when O
administered O
with O
furosemide B-drug
or O
hydrochlorothiazide B-drug
. O

Interaction O
studies O
have O
been O
performed O
with O
fluvastatin B-drug
and O
several O
drugs O
with O
which O
it O
might O
be O
coadministered O
. O

As O
with O
other O
antihypertensive B-group
agents I-group
, O
the O
antihypertensive O
effect O
of O
losartan B-drug
may O
be O
blunted O
by O
the O
non-steroidal B-group
anti-inflammatory I-group
drug I-group
indomethacin B-drug

Erythromycin O
Co-administration O
of O
felodipine B-drug
( O
PLENDIL B-drug
) O
with O
erythromycin B-drug
resulted O
in O
approximately O
2.5- O
fold O
increase O
in O
the O
AUC O
and O
Cmax O
, O
and O
about O
2- O
fold O
prolongation O
in O
the O
half- O
life O
of O
felodipine B-drug
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
conducted O
with O
VELCADE B-brand
. O

If O
SPRYCEL B-brand
must O
be O
administered O
with O
a O
CYP3A4 O
inducer O
, O
a O
dose O
increase O
in O
SPRYCEL B-brand
should O
be O
considered O
. O

In O
a O
multiple-dose O
study O
, O
enoxacin B-drug
caused O
a O
dose-related O
increase O
in O
the O
mean O
elimination O
half-life O
of O
caffeine B-drug
, O
thereby O
decreasing O
the O
clearance O
of O
caffeine B-drug
by O
up O
to O
80 O
% O
and O
leading O
to O
a O
five-fold O
increase O
in O
the O
AUC O
and O
the O
half-life O
of O
caffeine B-drug
. O

Interaction O
between O
exogenous O
and O
endogenous O
oxytocin B-drug
and O
vasopressin O
was O
found O
to O
affect O
the O
mechanism O
of O
milk O
ejection O
by O
the O
alveoli O
of O
the O
mammary O
gland O
in O
lactating O
rats O
. O

Administration O
of O
ELLENCE B-brand
after O
previous O
radiation O
therapy O
may O
induce O
an O
inflammatory O
recall O
reaction O
at O
the O
site O
of O
the O
irradiation O
. O

[ O
The O
effect O
of O
cimetidine B-drug
on O
the O
renal O
excretion O
of O
verografin B-drug
and O
iodamide B-drug
in O
dogs O
] O
The O
intravenous O
injection O
of O
cimetidine B-drug
in O
a O
dose O
of O
20 O
mg/kg O
enhanced O
verografine B-drug
and O
iodamide B-drug
excretion O
in O
chronic O
canine O
experiments O
. O

An O
adjustment O
in O
the O
diltiazem B-drug
dose O
may O
be O
warranted O
. O

The O
concomitant O
use O
of O
heparin B-drug
or O
aspirin B-brand
during O
the O
first O
24 O
hours O
following O
symptom O
onset O
were O
prohibited O
in O
The O
NINDS O
t-PA O
Stroke O
Trial O
. O

The O
effects O
of O
concomitant O
administration O
of O
cimetidine B-drug
on O
the O
pharmacokinetics O
of O
bupropion B-drug
and O
its O
active O
metabolites O
were O
studied O
in O
24 O
healthy O
young O
male O
volunteers O
. O

Gleevec B-brand
will O
increase O
plasmaconcentration O
of O
other O
CYP3A4 O
metabolized O
drugs O
( O
e.g. O
, O
triazolo-benzodiazepines B-group
, O
dihydropyridine B-group
calcium I-group
channel I-group
blockers I-group
, O
certain O
HMG-CoA B-group
reductase I-group
inhibitors I-group
, O
etc O
. O
) O
. O

Pharmacokinetics O
of O
levetiracetam B-drug
were O
also O
not O
affected O
by O
phenytoin B-drug
. O

Fulvestrant B-drug
is O
metabolized O
by O
CYP O
3A4 O
in O
vitro O
. O

The O
results O
of O
assays O
using O
red O
cells O
from O
healthy O
subjects O
to O
determine O
whether O
ceftibuten B-drug
would O
cause O
direct O
Coombs O
reactions O
in O
vitro O
showed O
no O
positive O
reaction O
at O
ceftibuten B-drug
concentrations O
as O
high O
as O
40 O
g/mL O
. O

Theophylline B-drug
: O
Enoxacin B-drug
is O
a O
potent O
inhibitor O
of O
the O
cytochrome O
P-450 O
isozymes O
responsible O
for O
the O
metabolism O
of O
methylxanthines B-group
. O

Lithium B-drug
Reversible O
increases O
in O
serum O
lithium B-drug
concentrations O
and O
toxicity O
have O
been O
reported O
during O
concomitant O
administration O
of O
lithium B-drug
with O
ACE B-group
inhibitors I-group
, O
and O
with O
some O
angiotensin B-group
II I-group
receptor I-group
antagonists I-group
. O

Adjustment O
of O
adenosine B-drug
dosage O
may O
be O
necessary O
. O

The O
proposed O
mechanisms O
of O
analgesic O
action O
of O
antihistaminics B-group
are O
reviewed O
and O
discussed O
. O

PGF2alpha B-drug
produced O
significantly O
increased O
vasoconstriction O
after O
a O
single O
administration O
of O
oxytocin B-drug
. O

For O
these O
reasons O
, O
it O
is O
felt O
that O
, O
in O
most O
subjects O
who O
have O
had O
an O
unsatisfactory O
lipid O
response O
to O
either O
drug O
alone O
, O
the O
possible O
benefits O
of O
combined O
therapy O
with O
lovastatin B-drug
and O
a O
fibrate B-group
do O
not O
outweigh O
the O
risks O
of O
severe O
myopathy O
, O
rhabdomyolysis O
, O
and O
acute O
renal O
failure O
. O

The O
risk O
of O
hypoglycemia O
secondary O
to O
this O
mechanism O
may O
be O
increased O
if O
allopurinol B-drug
and O
chlorpropamide B-drug
are O
given O
concomitantly O
in O
the O
presence O
of O
renal O
insufficiency O
. O

When O
combined O
therapy O
is O
contemplated O
, O
the O
dose O
of O
one O
or O
both O
agents O
should O
be O
reduced O
. O

As O
noted O
below O
, O
a O
sub- O
for O
fluvoxamine B-drug
in O
combination O
with O
alprazolam B-drug
, O
a O
drug O
that O
is O
known O
to O
be O
metabolized O
by O
the O
IIIA4 O
isozyme O
. O

In O
a O
clinical O
pharmacology O
study O
, O
indomethacin B-drug
or O
sulindac B-drug
was O
administered O
to O
hypertensive O
patients O
receiving O
VASOTEC B-brand
. O

Concomitant O
administration O
of O
alosetron B-drug
and O
moderate O
CYP1A2 O
inhibitors O
, O
including O
quinolone B-group
antibiotics I-group
and O
cimetidine B-drug
, O
has O
not O
been O
evaluated O
, O
but O
should O
be O
avoided O
unless O
clinically O
necessary O
because O
of O
similar O
potential O
drug O
interactions O
. O

This O
effect O
may O
be O
mediated O
by O
the O
ability O
of O
rifampin B-drug
to O
induce O
microsomal O
enzymes O
and O
, O
thus O
, O
the O
catabolism O
of O
warfarin B-drug
. O

NSAIDs B-group
should O
be O
used O
with O
caution O
in O
patients O
taking O
cyclosporine B-drug
, O
and O
renal O
function O
should O
be O
carefully O
monitored O
. O

The O
reddish O
color O
is O
due O
to O
the O
formation O
of O
a O
nonabsorbable O
complex O
between O
cefdinir B-drug
or O
its O
breakdown O
products O
and O
iron B-drug
in O
the O
gastrointestinal O
tract O
. O

On O
administration O
of O
oral O
amiodarone B-drug
, O
the O
need O
for O
digitalis B-group
therapy O
should O
be O
reviewed O
and O
the O
dose O
reduced O
by O
approximately O
50 O
% O
or O
discontinued O
. O

Anagrelide B-drug
demonstrates O
some O
limited O
inhibitory O
activity O
towards O
CYP1A2 O
which O
may O
present O
a O
theoretical O
potential O
for O
interaction O
with O
other O
coadministered O
medicinal O
products O
sharing O
that O
clearance O
mechanism O
e.g O
. O

In O
vitro O
studies O
indicate O
that O
celecoxib B-drug
is O
not O
an O
inhibitor O
of O
cytochrome O
P450 O
2C9 O
, O
2C19 O
or O
3A4 O
. O

The O
metabolism O
of O
TAXOL B-brand
is O
catalyzed O
by O
cytochrome O
P450 O
isoen-zymes O
CYP2C8 O
and O
CYP3A4 O
. O

In O
order O
to O
maintain O
phenytoin B-drug
levels O
, O
limit O
adverse O
experiences O
, O
and O
achieve O
the O
felbamate B-drug
dose O
of O
3600 O
mg/day O
, O
a O
phenytoin B-drug
dose O
reduction O
of O
approximately O
40 O
% O
was O
necessary O
for O
eight O
of O
these O
10 O
subjects O
. O

Rare O
cases O
of O
a O
disulfiram-like O
reaction O
to O
alcohol B-drug
have O
been O
reported O
. O

Because O
elderly O
patients O
are O
more O
likely O
to O
have O
decreased O
renal O
function O
, O
care O
should O
be O
taken O
in O
dose O
selection O
and O
it O
may O
be O
useful O
to O
monitor O
renal O
function O
. O

diet O
high O
in O
vitamin B-group
K I-group
; O

Oral O
Contraceptives B-group
: O
Valdecoxib B-drug
( O
40 O
mg O
BID O
) O
did O
not O
induce O
the O
metabolism O
of O
the O
combination O
oral O
contraceptive B-group
norethindrone/ethinyl B-drug
estradiol I-drug
( O
1 O
mg O
/35 O
mcg O
combination O
, O
Ortho-Novum B-brand
1/35 O
) O
. O

Ketoconazole B-drug

In O
vitro O
studies O
: O
Vardenafil B-drug
and O
its O
metabolites O
had O
no O
effect O
on O
CYP1A2 O
, O
2A6 O
, O
and O
2E1 O
( O
Ki O
100uM O
) O
. O

MAO B-group
inhibitors I-group
MAOI I-group
antidepressants I-group
, O
as O
well O
as O
a O
metabolite O
of O
furazolidone B-drug
, O
slow O
amphetamine B-drug
metabolism O
. O

Occasionally O
TAXOL B-brand
infusions O
must O
be O
interrupted O
or O
discontinued O
because O
of O
initial O
or O
recurrent O
hypertension O
. O

Because O
their O
vasospastic O
effects O
may O
be O
additive O
, O
coadministration O
of O
naratriptan B-drug
and O
other O
5-HT1 B-group
agonists I-group
within O
24 O
hours O
of O
each O
other O
is O
not O
recommended O
. O

Drugs O
that O
are O
contraindicated O
specifically O
due O
to O
the O
expected O
magnitude O
of O
interaction O
and O
potential O
for O
serious O
adverse O
events O
are O
listed O
CONTRAINDICATIONS O
. O

It O
has O
not O
been O
as O
effective O
in O
women O
with O
sexual O
dysfunction O
, O
with O
the O
exception O
of O
SSRI-associated B-group
sexual O
dysfunction O
. O

Corticosteroids B-group
. O

Ethopropazine B-drug
can O
interact O
with O
chlorpromazine B-drug
, O
increasing O
the O
metabolism O
of O
chlorpromazine B-drug
. O

In O
1992 O
and O
1993 O
, O
two O
outbreaks O
of O
arsenical O
reactive O
encephalopathy O
( O
ARE O
) O
occurred O
in O
the O
sleeping O
sickness O
center O
of O
Adjumani O
. O

Herbal O
products O
: O
St. O
John O
s O
wort O
( O
Hypericum O
perforatum O
) O

Selegiline B-drug
: O
Combination B-group
hormonal I-group
contraceptives I-group
may O
increase O
the O
serum O
concentration O
of O
selegiline B-drug
. O

This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
BEXTRA B-brand
concomitantly O
with O
ACE-inhibitors B-group
. O

Ventricular O
tachycardia O
induced O
by O
ouabain B-drug
was O
generally O
converted O
to O
sinus O
rhythm O
following O
administration O
of O
Innovar B-brand
, O
ketamine B-drug
, O
or O
droperidol B-drug
but O
not O
after O
administration O
of O
fentayl B-drug
alone O
or O
after O
pentobarbital B-drug
. O

The O
most O
common O
adverse O
effects O
reported O
with O
olanzapine B-drug
are O
bodyweight O
gain O
, O
somnolence O
, O
dizziness O
, O
anticholinergic O
effects O
( O
constipation O
and O
dry O
mouth O
) O
and O
transient O
asymptomatic O
liver O
enzyme O
elevations O
. O

Lymphocytopenia O
has O
been O
reported O
in O
patients O
receiving O
CAMPTOSAR B-brand
, O
and O
it O
is O
possible O
that O
the O
administration O
of O
dexamethasone B-drug
as O
antiemetic O
prophylaxis O
may O
have O
enhanced O
the O
likelihood O
of O
this O
effect O
. O

Because O
alosetron B-drug
is O
metabolized O
by O
a O
variety O
of O
hepatic O
CYP O
drug-metabolizing O
enzymes O
, O
inducers O
or O
inhibitors O
of O
these O
enzymes O
may O
change O
the O
clearance O
of O
alosetron B-drug
. O

Dual O
effect O
of O
ouabain B-drug
on O
the O
palytoxin-induced B-drug_n
contraction O
and O
norepinephrine O
release O
in O
the O
guinea-pig O
vas O
deferens O
. O

Aspirin B-brand
should O
be O
used O
cautiously O
in O
conjunction O
with O
corticosteroids B-group
in O
hypoprothrombinemia O
. O

Antacids B-group
: O
Concomitant O
administration O
of O
magnesium B-drug
hydroxide I-drug
and O
aluminum B-drug
hydroxide I-drug
does O
not O
interfere O
with O
the O
rate O
or O
extent O
of O
the O
absorption O
of O
ketoprofen B-drug
administered O
as O
Orudis B-brand
. O

Clinically O
significant O
effects O
have O
been O
reported O
with O
the O
tricyclic B-drug
antidepressants I-drug
when O
used O
concomitantly O
with O
cimetidine B-drug
. O

Sildenafil B-drug
citrate I-drug
: O
a O
therapeutic O
update O
. O

Oral O
doses O
of O
Antizol B-brand
( O
10-20 O
mg/kg O
) O
, O
via O
alcohol O
dehydrogenase O
inhibition O
, O
significantly O
reduced O
the O
rate O
of O
elimination O
of O
ethanol B-drug
( O
by O
approximately O
40 O
% O
) O
given O
to O
healthy O
volunteers O
in O
moderate O
doses O
. O

Monitor O
salicylate B-group
levels O
or O
the O
therapeutic O
effect O
for O
which O
aspirin B-brand
is O
given O
; O

The O
interaction O
was O
pharmacodynamic O
with O
no O
alteration O
of O
the O
pharmacokinetics O
of O
either O
drug O
. O

Cyclosporine O
, O
Digoxin O
, O
Methotrexate O
Lodine B-brand
, O
like O
other O
NSAIDs B-group
, O
through O
effects O
on O
renal O
prostaglandins O
, O
may O
cause O
changes O
in O
the O
elimination O
of O
these O
drugs O
leading O
to O
elevated O
serum O
levels O
of O
cyclosporine B-drug
, O
digoxin B-drug
, O
methotrexate B-drug
, O
and O
increased O
toxicity O
. O

Caution O
should O
be O
used O
when O
NSAIDs B-group
are O
administered O
concomitantly O
with O
methotrexate B-drug
. O

If O
the O
dose O
of O
lovastatin B-drug
is O
changed O
, O
the O
same O
procedure O
should O
be O
repeated O
. O

Although O
no O
clinical O
studies O
have O
been O
conducted O
, O
it O
is O
likely O
that O
the O
metabolism O
of O
levobupivacaine B-drug
may O
be O
affected O
by O
the O
known O
CYP3A4 O
inducers O
( O
such O
as O
phenytoin B-drug
, O
phenobarbital B-drug
, O
rifampin B-drug
) O
, O
CYP3A4 O
inhibitors O
( O
azole O
antimycotics O
e.g. O
, O
ketoconazole B-drug
; O

Salicylic B-drug
acid I-drug
: O
Combination O
hormonal B-group
contraceptives I-group
may O
increase O
the O
clearance O
of O
salicylic B-drug
acid I-drug
. O

When O
such O
drugs O
are O
withdrawn O
from O
patients O
receiving O
Acarbose B-drug
in O
combination O
with O
sulfonylureas B-group
or O
insulin B-drug
, O
patients O
should O
be O
observed O
closely O
for O
any O
evidence O
of O
hypoglycemia O
. O

Only O
with O
knowledge O
of O
the O
interaction O
can O
the O
therapeutic O
regimen O
be O
altered O
so O
as O
to O
provide O
therapeutic O
levels O
of O
necessary O
drugs O
while O
avoiding O
toxicity O
. O

Reduced O
efficacy O
and O
increased O
incidence O
of O
breakthrough O
bleeding O
and O
menstrual O
irregularities O
have O
been O
associated O
with O
concomitant O
use O
of O
rifampin B-drug
. O

Additionally O
, O
anti-malarial B-group
drugs I-group
, O
such O
as O
chloroquine B-drug
and O
mefloquine B-drug
, O
may O
antagonize O
the O
activity O
of O
carbamazepine B-drug
. O

Whether O
this O
interaction O
also O
occurs O
with O
the O
intravenous O
, O
topical O
, O
or O
vaginal O
preparations O
of O
miconazole B-drug
is O
not O
known O
. O

. O

Agents O
Increasing O
Serum O
Potassium O
Since O
captopril B-drug
decreases O
aldosterone O
production O
, O
elevation O
of O
serum O
potassium O
may O
occur O
. O

In O
the O
first O
double-blind O
comparative O
study O
( O
28-week O
) O
of O
olanzapine B-drug
and O
risperidone B-drug
, O
olanzapine B-drug
10 O
to O
20 O
mg/day O
proved O
to O
be O
significantly O
more O
effective O
than O
risperidone B-drug
4 O
to O
12 O
mg/day O
in O
the O
treatment O
of O
negative O
and O
depressive O
symptoms O
but O
not O
on O
overall O
psychopathology O
symptoms O
. O

Secondary O
prevention O
of O
atherosclerotic O
risk O
factors O
is O
also O
important O
: O
regulation O
of O
blood O
pressure O
and O
blood O
sugar O
level O
, O
hyperlipidaemia O
and O
obesity O
, O
as O
well O
as O
a O
change O
of O
lifestyle O
( O
giving O
up O
smoking O
, O
adapting O
of O
diet O
and O
more O
physical O
exertion O
) O
. O

Drug/Laboratory O
Test O
Interactions O
FROVA B-brand
is O
not O
known O
to O
interfere O
with O
commonly O
employed O
clinical O
laboratory O
tests O
. O

By O
decreasing O
the O
gastrointestinal O
absorption O
of O
primidone B-drug
, O
DIAMOX B-brand
may O
decrease O
serum O
concentrations O
of O
primidone B-drug
and O
its O
metabolites O
, O
with O
a O
consequent O
possible O
decrease O
in O
anticonvulsant O
effect O
. O

Other O
plasma O
proteins O
may O
be O
increased O
( O
angiotensinogen/renin O
substrate O
, O
alpha-1-antitrypsin O
, O
ceruloplasmin O
) O
. O

These O
models O
are O
typically O
nonlinear O
in O
the O
parameters O
, O
and O
as O
such O
, O
a O
nonlinear O
weighted O
least O
squares O
approach O
can O
be O
employed O
for O
the O
purpose O
of O
designing O
experiments O
. O

Fluvoxamine B-drug
inhibits O
the O
CYP2C9 O
catalyzed O
biotransformation O
of O
tolbutamide B-drug
. O

Norepinephrine B-drug

Oral O
anticoagulants B-group
decreased O
prothrombin O
time O
response O
. O

No O
adjustment O
of O
dosage O
is O
recommended O
in O
such O
patients O
. O

In O
a O
placebo-controlled O
trial O
in O
normal O
volunteers O
, O
the O
administration O
of O
a O
single O
1 O
mg O
dose O
of O
doxazosin B-drug
on O
day O
1 O
of O
a O
four-day O
regimen O
of O
oral O
cimetidine B-drug
( O
400 O
mg O
twice O
daily O
) O
resulted O
in O
a O
10 O
% O
increase O
in O
mean O
AUC O
of O
doxazosin B-drug
( O
p=0.006 O
) O
, O
and O
a O
slight O
but O
not O
statistically O
significant O
increase O
in O
mean O
Cmax O
and O
mean O
half-life O
of O
doxazosin B-drug
. O

RESULTS O
. O

Similar O
decreases O
in O
Cmax O
and O
AUC O
were O
seen O
after O
the O
first O
dose O
. O

No O
in O
vitro O
metabolism O
studies O
were O
performed O
. O

If O
concomitant O
treatment O
with O
naratriptan B-drug
and O
an O
SSRI B-group
is O
clinically O
warranted O
, O
appropriate O
observation O
of O
the O
patient O
is O
advised O
. O

- O
Other O
anti-infectives B-group
by O
mouth O
or O
by O
injection O
( O
medicine O
for O
infection O
) O
or O

[ O
Multiple O
occupational O
exposure O
to O
solvents O
] O
This O
article O
review O
papers O
published O
over O
the O
last O
20 O
years O
on O
multiple O
occupational O
exposure O
to O
solvents O
. O

Drug O
exposure O
in O
rodent O
pups O
from O
fulvestrant-treated B-drug
lactating O
dams O
was O
estimated O
as O
10 O
% O
of O
the O
administered O
dose O
. O

If O
rifampicin B-drug
therapy O
is O
required O
, O
isradipine B-drug
concentrations O
and O
therapeutic O
effects O
are O
likely O
to O
be O
markedly O
reduced O
or O
abolished O
as O
a O
consequence O
of O
increased O
metabolism O
and O
higher O
clearance O
of O
isradipine B-drug
. O

Use O
of O
a O
nonhormonal B-group
contraceptive I-group
product I-group
is O
recommended O
. O

Subsequent O
adjustment O
of O
doses O
of O
mercaptopurine B-drug
or O
azathioprine B-drug
should O
be O
made O
on O
the O
basis O
of O
therapeutic O
response O
and O
the O
appearance O
of O
toxic O
effects O
. O

All O
drugs O
were O
injected O
intraperitoneally O
. O

Glyburide B-drug
: O
Etodolac B-drug
has O
no O
apparent O
pharmacokinetic O
interaction O
when O
administered O
with O
glyburide B-drug
. O

Concomitant O
administration O
of O
fenofibrate B-drug
( O
equivalent O
to O
145 O
mg O
TRICOR B-brand
) O
with O
atorvastatin B-drug
( O
20 O
mg O
) O
once O
daily O
for O
10 O
days O
resulted O
in O
approximately O
17 O
% O
decrease O
( O
range O
from O
67 O
% O
decrease O
to O
44 O
% O
increase O
) O
in O
atorvastatin B-drug
AUC O
values O
in O
22 O
healthy O
males O
. O

Drug/Food O
Interactions O
The O
bioavailability O
( O
AUC O
) O
of O
deferasirox B-drug
was O
variably O
increased O
when O
taken O
with O
a O
meal O
. O

Pharmacokinetic O
data O
from O
these O
patients O
demonstrated O
a O
decrease O
in O
paclitaxel B-drug
clearance O
of O
approximately O
33 O
% O
when O
TAXOL B-brand
was O
administered O
following O
cisplatin B-drug
. O

In O
secretions O
such O
as O
colostrum O
, O
IgA O
is O
the O
only O
protein O
precipitated O
by O
jacalin B-drug_n
. O

Trecator B-brand
has O
been O
found O
to O
temporarily O
raise O
serum O
concentrations O
of O
isoniazid B-drug
. O

Therefore O
, O
when O
MIDAMOR B-brand
and O
non-steroidal B-group
anti-inflammatory I-group
agents I-group
are O
used O
concomitantly O
, O
the O
patient O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
of O
the O
diuretic B-group
is O
obtained O
. O

Omeprazole B-drug
: O
The O
rate O
and O
extent O
of O
absorption O
of O
ciprofloxacin B-drug
was O
bioequivalent O
when O
Proquin B-brand
XR I-brand
was O
given O
alone O
or O
when O
Proquin B-brand
XR I-brand
was O
given O
2 O
hours O
after O
omeprazole B-drug
at O
the O
dose O
that O
maximally O
suppresses O
gastric O
acid O
secretion O
. O

Chlorotrianisene B-drug
may O
interact O
with O
antidepressants B-group
, O
aspirin B-brand
, O
barbiturates B-group
, O
bromocriptine B-drug
, O
calcium B-drug
supplements O
, O
corticosteroids B-group
, O
corticotropin B-drug
, O
cyclosporine B-drug
, O
dantrolene B-drug
, O
nicotine B-drug
, O
somatropin B-drug
, O
tamoxifen B-drug
, O
and O
warfarin B-drug
. O

Therefore O
, O
co-administration O
of O
clozapine B-drug
with O
other O
drugs O
that O
are O
metabolized O
by O
this O
isozyme O
, O
including O
antidepressants B-group
, O
phenothiazines B-group
, O
carbamazepine B-drug
, O
and O
Type B-group
1C I-group
antiarrhythmics I-group
( O
e.g. O
, O
propafenone B-drug
, O
flecainide B-drug
and O
encainide B-drug
) O
, O
or O
that O
inhibit O
this O
enzyme O
( O
e.g. O
, O
quinidine B-drug
) O
, O
should O
be O
approached O
with O
caution O
. O

There O
is O
a O
significant O
increase O
in O
exposure O
to O
imatinib B-drug
when O
Gleevec B-brand
is O
coadministered O
with O
ketoconazole B-drug
( O
CYP3A4 O
inhibitor O
) O
. O

There O
is O
one O
report O
suggesting O
that O
the O
concomitant O
use O
of O
trazodone B-drug
hydrochloride I-drug
( O
Desyrel B-brand
) O
and O
buspirone B-drug
HCl I-drug
may O
have O
caused O
3- O
to O
6-fold O
elevations O
on O
SGPT O
( O
ALT O
) O
in O
a O
few O
patients O
. O

An O
alternative O
or O
additional O
method O
of O
contraception O
is O
recommended O
. O

- O
rifampin B-drug
( O
Rifadin B-brand
, O
Rifamate B-brand
) O
; O

ACE B-group
inhibitors I-group
: O
Reports O
suggest O
that O
NSAIDs B-group
may O
diminish O
the O
antihypertensive O
effect O
of O
Angiotensin B-group
Converting I-group
Enzyme I-group
( I-group
ACE I-group
) I-group
inhibitors I-group
. O

Cimetidine B-drug
: O
Atorvastatin B-drug
plasma O
concentrations O
and O
LDL-C O
reduction O
were O
not O
altered O
by O
coadministration O
of O
cimetidine B-drug
. O

In O
vivo O
studies O
: O
Nitrates B-group
: O
The O
blood O
pressure O
lowering O
effects O
of O
sublingual O
nitrates B-group
( O
0.4 O
mg O
) O
taken O
1 O
and O
4 O
hours O
after O
vardenafil B-drug
and O
increases O
in O
heart O
rate O
when O
taken O
at O
1 O
, O
4 O
and O
8 O
hours O
were O
potentiated O
by O
a O
20 O
mg O
dose O
of O
Vardenafil B-drug
in O
healthy O
middle-aged O
subjects O
. O

aeruginosa O
serotype O
O11 O
strains O
, O
but O
not O
S O
. O

Eprosartan B-drug
has O
been O
shown O
to O
have O
no O
effect O
on O
the O
pharmacokinetics O
of O
digoxin B-drug
and O
the O
pharmacodynamics O
of O
warfarin B-drug
and O
glyburide B-drug
. O

Neither O
subject O
demonstrated O
clinical O
evidence O
of O
allergic O
or O
anaphylactic O
reactions O
and O
repeat O
testing O
was O
not O
performed O
. O

No O
specific O
information O
available O

METHODS O
: O
Healthy O
subjects O
who O
were O
20 O
to O
43 O
years O
old O
participated O
in O
an O
open O
, O
three-period O
, O
randomized O
, O
crossover O
study O
of O
the O
pharmacokinetics O
of O
a O
single O
10-mg O
oral O
dose O
of O
sirolimus B-drug
, O
a O
single O
oral O
120-mg O
dose O
of O
diltiazem B-drug
, O
and O
the O
two O
drugs O
given O
together O
. O

These O
lines O
showed O
variable O
degrees O
of O
locomotor O
activities O
in O
response O
to O
cocaine B-drug
. O

An O
adequate O
period O
of O
observation O
must O
be O
provided O
for O
any O
patient O
in O
whom O
either O
long-acting B-group
benzodiazepines I-group
( O
such O
as O
diazepam B-drug
) O
or O
large O
doses O
of O
short-acting B-group
benzodiazepines I-group
( O
such O
as O
10 O
mg O
of O
midazolam B-drug
) O
have O
been O
used O
. O

The O
vasodilating O
effects O
of O
isosorbide B-drug
dinitrate I-drug
may O
be O
additive O
with O
those O
of O
other O
vasodilators B-group
. O

In O
the O
Duloxetine B-drug
clinical O
trials O
database O
, O
three O
Duloxetine-treated B-drug
patients O
had O
liver O
injury O
as O
manifested O
by O
ALT O
and O
total O
bilirubin O
elevations O
, O
with O
evidence O
of O
obstruction O
. O

Stavudine B-drug
and O
Zidovudine B-drug
Ribavirin I-drug
can O
antagonize O
the O
in O
vitro O
antiviral O
activity O
of O
stavudine B-drug
and O
zidovudine B-drug
against O
HIV O
. O

No O
reported O
interactions O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
low O
and O
high O
doses O
of O
estradiol B-drug
, O
and O
of O
progesterone B-drug
on O
the O
response O
to O
noradrenaline B-drug
in O
rat O
thoracic O
aorta O
. O

The O
similarity O
of O
the O
TYSABRI B-brand
-associated O
adverse O
event O
profile O
between O
Study O
1 O
( O
without O
co-administered O
AVONEX B-brand
) O
and O
Study O
2 O
( O
with O
co-administered O
AVONEX B-brand
) O
indicates O
that O
this O
alteration O
in O
clearance O
does O
not O
necessitate O
reduction O
of O
the O
TYSABRI B-brand
dose O
to O
maintain O
safety O
, O
General O
) O
. O

Haloperidol B-drug
: O
Haloperidol B-drug
blocks O
dopamine O
and O
norepinephrine O
reuptake O
, O
thus O
inhibiting O
the O
central O
stimulant O
effects O
of O
amphetamines B-group
. O

Patients O
on O
oral O
antidiabetic B-group
agents I-group
receiving O
VELCADE B-brand
treatment O
may O
require O
close O
monitoring O
of O
their O
blood O
glucose O
levels O
and O
adjustment O
of O
the O
dose O
of O
their O
antidiabetic B-group
medication I-group
. O

Concurrent O
administration O
of O
cimetidine B-drug
and O
tricyclic B-group
antidepressants I-group
can O
produce O
clinically O
significant O
increases O
in O
the O
plasma O
levels O
of O
the O
tricyclic B-group
antidepressants I-group
. O

Haemodynamic O
effects O
of O
glucose B-drug
and O
insulin B-drug
were O
additive O
when O
somatostatin B-drug
was O
co-administered O
but O
not O
under O
basal O
conditions O
. O

Inhibits O
CYP1A2 O
( O
weak O
) O
, O
2B6 O
( O
weak O
) O
, O
2C19 O
( O
weak O
) O
, O
3A4 O
( O
weak O
) O
. O

Subjects O
who O
do O
not O
metabolize O
losartan B-drug
to O
active O
metabolite O
have O
been O
shown O
to O
have O
a O
specific O
, O
rare O
defect O
in O
cytochrome O
P450 O
2C9 O
. O

This O
diminution O
is O
not O
sufficient O
to O
preclude O
effectiveness O
of O
the O
pressor O
agent O
for O
therapeutic O
use O
. O

Thus O
, O
probenecid B-drug
should O
not O
be O
administered O
concurrently O
with O
bumetanide B-drug
. O

A O
3-fold O
increase O
was O
seen O
in O
another O
5 O
patients O
. O

However O
, O
the O
systemic O
administration O
of O
some O
quinolones B-group
has O
been O
shown O
to O
elevate O
plasma O
concentrations O
of O
theophylline B-drug
, O
interfere O
with O
the O
metabolism O
of O
caffeine B-drug
, O
and O
enhance O
the O
effects O
of O
the O
oral O
anticoagulant B-group
warfarin B-drug
and O
its O
derivatives O
, O
and O
has O
been O
associated O
with O
transient O
elevations O
in O
serum O
creatinine O
in O
patients O
receiving O
systemic O
cyclosporine B-drug
concomitantly O
. O

Other O
Agents O

Coumarin B-group
Anticoagulants I-group
: O
There O
have O
been O
rare O
reports O
of O
increased O
prothrombin O
time O
in O
patients O
taking O
coumarin B-group
anticoagulants I-group
to O
whom O
nifedipine B-drug
was O
administered O
. O

In O
a O
pharmacokinetic O
study O
, O
40 O
healthy O
female O
subjects O
received O
fluvoxamine B-drug
in O
escalating O
doses O
from O
50 O
to O
200 O
mg O
per O
day O
for O
16 O
days O
, O
with O
coadministration O
of O
alosetron B-drug
1 O
mg O
on O
the O
last O
day O
. O

Anakinra B-drug
: O
Concurrent O
administration O
of O
anakinra B-drug
( O
an O
interleukin-1 B-group
antagonist I-group
) O
and O
another O
TNF-blocking B-group
agent I-group
has O
been O
associated O
with O
an O
increased O
risk O
of O
serious O
infections O
, O
an O
increased O
risk O
of O
neutropenia O
and O
no O
additional O
benefit O
compared O
to O
these O
medicinal O
products O
alone O
. O

Some O
of O
the O
CNS O
and O
genitourinary O
symptoms O
may O
be O
related O
to O
the O
underlying O
disease O
rather O
than O
to O
drug O
therapy O
. O

This O
has O
been O
observed O
with O
Benedict O
s O
and O
Fehling O
s O
solutions O
but O
not O
with O
the O
glucose O
enzymatic O
test O
. O

If O
co-administration O
is O
essential O
, O
conduct O
close O
clinical O
and O
laboratory O
monitoring O

Using O
this O
technique O
, O
it O
was O
possible O
to O
escalate O
the O
cisplatin B-drug
dose O
to O
225 O
mg/m2 O
before O
dose-limiting O
toxicities O
were O
encountered O
. O

Close O
observation O
of O
the O
patient O
is O
recommended O
when O
a O
beta-blocker B-group
is O
administered O
to O
patients O
receiving O
catecholamine-depleting O
drugs O
such O
as O
reserpine B-drug
, O
because O
of O
possible O
additive O
effects O
and O
the O
production O
of O
hypotension O
and/or O
marked O
bradycardia O
, O
which O
may O
produce O
vertigo O
, O
syncope O
or O
postural O
hypotension O
. O

primidone B-drug
; O

Physiological O
oral O
magnesium B-drug
load O
constitutes O
the O
best O
tool O
for O
diagnosis O
of O
magnesium B-drug
deficiency O
and O
the O
first O
step O
of O
its O
treatment O
. O

sildenafil I-drug
concentration O

Concomitant O
administration O
of O
Kerlone B-brand
with O
the O
oral O
anticoagulant B-group
warfarin B-drug
has O
been O
shown O
not O
to O
potentiate O
the O
anticoagulant O
effect O
of O
warfarin B-drug
. O

Free O
hormone O
concentrations O
may O
be O
decreased O
. O

2 O
. O

Diazepam B-drug
at O
doses O
of O
0.25 O
mg/kg O
and O
2.5 O
mg/kg O
injected O
with O
morphine B-drug
was O
found O
to O
decrease O
the O
antinociceptive O
effect O
of O
morphine B-drug
. O

Mutagenesis O
Impairment O
of O
Fertility O
PEGASYS B-brand
may O
impair O
fertility O
in O
women O
. O

Caution O
should O
be O
used O
if O
ibuprofen B-drug
is O
administered O
concomitantly O
with O
methotrexate B-drug
. O

However O
, O
antacids B-group
can O
decrease O
the O
peak O
concentration O
reached O
by O
15 O
% O
to O
20 O
% O
but O
have O
no O
detectable O
effect O
on O
the O
time-to-peak O
. O

The O
anesthesiologist O
should O
be O
informed O
when O
a O
patient O
is O
receiving O
labetalol B-drug
HCl I-drug
. O

Interactions O
with O
Other O
Antiretroviral B-group
Drugs I-group
: O
Significant O
decreases O
in O
the O
AUC O
of O
delavirdine B-drug
( O
20 O
% O
) O
and O
indinavir B-drug
( O
84 O
% O
) O
occurred O
following O
simultaneous O
administration O
of O
these O
agents O
with O
VIDEX B-brand
. O

Other O
Drugs O
: O
Drugs O
such O
as O
quinidine B-drug
, O
disopyramide B-drug
, O
procainamide B-drug
, O
phenothiazines B-group
, O
antihistamines B-group
, O
and O
tricyclic B-group
antidepressants I-group
may O
be O
associated O
with O
QT-interval O
prolongation O
and O
an O
increased O
risk O
of O
ventricular O
arrhythmia O
. O

Cyclophosphamide B-drug
treatment O
, O
which O
causes O
a O
marked O
and O
persistent O
inhibition O
of O
cholinesterase O
activity O
, O
potentiates O
the O
effect O
of O
succinylcholine B-drug
chloride I-drug
. O

Chloral B-drug
hydrate I-drug
may O
cause O
an O
increased O
prothrombin O
response O
by O
displacing O
the O
anticoagulant B-group
from O
protein O
binding O
sites O
or O
a O
diminished O
prothrombin O
response O
through O
increased O
metabolism O
of O
the O
unbound O
drug O
by O
hepatic O
enzyme O
induction O
, O
thus O
leading O
to O
inter-patient O
variation O
in O
ultimate O
prothrombin O
effect O
. O

The O
plasma O
concentration O
of O
imipramine B-drug
may O
increase O
when O
the O
drug O
is O
given O
concomitantly O
with O
hepatic O
enzyme O
inhibitors O
( O
e.g. O
, O
cimetidine B-drug
, O
fluoxetine B-drug
) O
and O
decrease O
by O
concomitant O
administration O
of O
hepatic O
enzyme O
inducers O
( O
e.g. O
, O
barbiturates B-group
, O
phenytoin B-drug
) O
, O
and O
adjustment O
of O
the O
dosage O
of O
imipramine B-drug
may O
therefore O
be O
necessary O
. O

Lomefloxacin B-drug
is O
unlikely O
to O
have O
a O
significant O
effect O
on O
phenytoin B-drug
metabolism O
. O

Hemodynamic O
and O
electrophysiologic O
interactions O
have O
also O
been O
observed O
after O
concomitant O
administration O
with O
propranolol B-drug
, O
diltiazem B-drug
, O
and O
verapamil B-drug
. O

Therefore O
, O
appropriate O
dose O
adjustments O
may O
be O
necessary O
for O
these O
drugs O
. O

- O
Perhexiline B-drug
hydrogen I-drug
maleate I-drug
or O
MAO-inhibitors B-group
( O
with O
hepatotoxic O
potential O
) O
must O
not O
be O
administered O
together O
with O
Bezalip B-brand
or O
Bezalip B-brand
retard I-brand
. O

These O
data O
suggest O
that O
the O
conversion O
of O
losartan B-drug
to O
its O
active O
metabolite O
is O
mediated O
primarily O
by O
P450 O
2C9 O
and O
not O
P450 O
3A4 O
. O

Analgesia O
and O
pupil O
constriction O
were O
measured O
. O

Effects O
on O
in O
vitro O
excystment O
rates O
over O
a O
2 O
h O
period O
demonstrated O
widespread O
effects O
for O
cercariae-exposed O
P O
. O

In O
a O
single O
subject O
given O
one O
dose O
of O
ciprofloxacin B-drug
2 O
hours O
after O
a O
dose O
of O
didanosine-placebo B-drug
tablets O
, O
a O
greater O
than O
50 O
% O
reduction O
in O
the O
AUC O
of O
ciprofloxacin B-drug
was O
observed O
. O

If O
you O
are O
also O
using O
a O
steroid B-group
inhaler O
, O
take O
bitolterol B-drug
first O
and O
then O
wait O
about O
15 O
minutes O
before O
using O
the O
steroid B-group
inhaler O
. O

Urinary O
acidifying O
agents O
These O
agents O
( O
ammonium B-drug
chloride I-drug
, O
sodium B-drug
acid I-drug
phosphate I-drug
, O
etc O
. O
) O
increase O
the O
concentration O
of O
the O
ionized O
species O
of O
the O
amphetamine B-drug
molecule O
, O
thereby O
increasing O
urinary O
excretion O
. O

6 O
. O

In O
vitro O
, O
nilutamide B-drug
has O
been O
shown O
to O
inhibit O
the O
activity O
of O
liver O
cytochrome O
P-450 O
isoenzymes O
and O
therefore O
, O
may O
reduce O
the O
metabolism O
of O
compounds O
requiring O
these O
systems O
. O

Both O
of O
these O
effects O
were O
endothelium-dependent O
. O

Although O
clinical O
studies O
have O
not O
established O
a O
cause O
and O
effect O
relationship O
, O
physicians O
should O
be O
aware O
that O
variable O
effects O
an O
blood O
coagulation O
have O
been O
reported O
very O
rarely O
in O
patients O
receiving O
oral O
anticoagulants B-group
and O
chlordiazepoxide B-drug
. O

There O
was O
no O
evidence O
in O
clinical O
trials O
of O
drug O
interactions O
with O
concurrent O
medications O
. O

Erythromycin B-drug
use O
in O
patients O
who O
are O
receiving O
high O
doses O
of O
theophylline B-drug
may O
be O
associated O
with O
an O
increase O
in O
serum O
theophylline B-drug
levels O
and O
potential O
theophylline B-drug
toxicity O
. O

If O
concomitant O
use O
can O
not O
be O
avoided O
, O
serum O
levels O
of O
theophylline B-drug
should O
be O
monitored O
and O
dosage O
adjustments O
made O
as O
appropriate O
. O

In O
a O
study O
in O
normal O
volunteers O
, O
it O
was O
found O
that O
chronic O
concurrent O
administration O
of O
3.6 O
g O
of O
aspirin B-brand
per O
day O
decreases O
indomethacin B-drug
blood O
levels O
approximately O
20 O
% O
. O

The O
safety O
and O
efficacy O
of O
concomitant O
use O
of O
REVIA B-brand
and O
disulfiram B-drug
is O
unknown O
, O
and O
the O
concomitant O
use O
of O
two O
potentially O
hepatotoxic O
medications O
is O
not O
ordinarily O
recommended O
unless O
the O
probable O
benefits O
outweigh O
the O
known O
risks O
. O

Propranolol B-drug
increases O
hydralazines B-drug
serum O
concentrations O
. O

Uricosuric B-group
Agents I-group
: O
Since O
the O
excretion O
of O
oxipurinol B-drug
is O
similar O
to O
that O
of O
urate O
, O
uricosuric B-group
agents I-group
, O
which O
increase O
the O
excretion O
of O
urate O
, O
are O
also O
likely O
to O
increase O
the O
excretion O
of O
oxipurinol B-drug
and O
thus O
lower O
the O
degree O
of O
inhibition O
of O
xanthine O
oxidase O
. O

No O
data O
for O
delavirdine B-drug
; O

All O
elevations O
resolved O
, O
2 O
with O
continuation O
of O
both O
drugs O
and O
3 O
after O
discontinuation O
of O
leflunomide B-drug
. O

Reports O
of O
fatal O
hepatic O
failure O
, O
as O
well O
as O
peripheral O
neuropathy O
, O
pancreatitis O
, O
and O
symptomatic O
hyperlactatemia/lactic O
acidosis O
have O
been O
reported O
in O
clinical O
trials O
. O

There O
is O
thus O
an O
enhancement O
effect O

Systemic O
exposure O
to O
substrates O
of O
CYP2D6 O
is O
expected O
to O
be O
increased O
when O
coadministered O
with O
Gleevec O
. O

If O
chlorprothixene B-drug
is O
given O
concomitantly O
with O
opioids B-group
, O
the O
opioid B-group
dose O
should O
be O
reduced O
( O
by O
approx O
. O
50 O
% O
) O
, O
because O
chlorprothixene B-drug
amplifies O
the O
therapeutic O
actions O
and O
side-effects O
of O
opioids B-group
massively O
. O

Close O
supervision O
and O
careful O
adjustment O
of O
dosage O
is O
required O
when O
this O
drug O
is O
administered O
concomitantly O
with O
anticholinergic B-group
drugs I-group
. O

Sucralfate B-drug
and O
antacids B-group
: O
Quinolones B-group
form O
chelates O
with O
metal O
cations O
. O

These O
doses O
correspond O
to O
approximately O
1- O
, O
3- O
, O
and O
5-fold O
( O
in O
females O
) O
and O
1.3- O
, O
1.3- O
, O
and O
1.6-fold O
( O
in O
males O
) O
the O
systemic O
exposure O
[ O
AUC0-30 O
days O
] O
] O
achieved O
in O
women O
receiving O
the O
recommended O
dose O
of O
250 O
mg/month O
. O

Antibiotics B-group
: O
Macrolide B-group
antibiotics I-group
have O
been O
reported O
to O
cause O
a O
significant O
decrease O
in O
corticosteroid B-group
clearance O
. O

Digoxin O
When O
given O
concomitantly O
with O
PLENDIL B-drug
the O
pharmacokinetics O
of O
digoxin B-drug
in O
patients O
with O
heart O
failure O
were O
not O
significantly O
altered O
. O

It O
is O
recommended O
that O
glucose O
tests O
based O
on O
enzymatic O
glucose O
oxidase O
reactions O
( O
such O
as O
Clinistix O
or O
Tes-Tape O
) O
be O
used O
. O

Potassium-sparing B-group
diuretics I-group
( O
spironolactone B-drug
, O
amiloride B-drug
, O
triamterene B-drug
, O
and O
others O
) O
or O
potassium B-drug
supplements O
can O
increase O
the O
risk O
of O
hyperkalemia O
. O

Valproate B-drug
: O
Available O
data O
suggest O
that O
there O
is O
no O
significant O
effect O
of O
valproate B-drug
on O
the O
clearance O
of O
Felbatol B-brand
at O
steady O
state O
, O
Therefore O
, O
the O
addition O
of O
valproate B-drug
is O
not O
expected O
to O
cause O
a O
clinically O
important O
effect O
on O
Felbatol B-brand
( O
felbamate B-drug
) O
plasma O
concentrations O
. O

Ascorbic B-drug
acid I-drug
and O
the O
common O
cold O
. O

CYP3A4 O
Interactions O

Methotrexate B-drug
: O
Ketoprofen B-drug
, O
like O
other O
NSAIDs B-group
, O
may O
cause O
changes O
in O
the O
elimination O
of O
methotrexate B-drug
leading O
to O
elevated O
serum O
levels O
of O
the O
drug O
and O
increased O
toxicity O
. O

The O
clinical O
significance O
of O
these O
observations O
is O
unknown O
. O

Antacids B-group
containing O
magnesium B-drug
, O
aluminum B-drug
, O
or O
calcium B-drug
; O

Tinnitus O
and O
decreased O
hearing O
have O
been O
reported O
in O
patients O
concomitantly O
receiving O
Itraconazole B-drug
and O
quinidine B-drug
. O

No O
significant O
effects O
were O
noted O
with O
other O
drug O
combinations O
or O
with O
the O
addition O
of O
ethanol B-drug
. O

Drug/Laboratory O
Tests O
Interactions O
There O
are O
no O
known O
clinically O
significant O
interactions O
of O
CLOLAR B-brand
with O
other O
medications O
or O
laboratory O
tests O
. O

Dicumarol B-drug
and O
warfarin B-drug
may O
decrease O
hypoprothrombinemic O
effect O
. O

apomorphine B-drug
- O
prior O
ingestion O
of O
diphenidol B-drug
may O
decrease O
the O
emetic B-group
response O
to O
apomorphine B-drug
in O
the O
treatment O
of O
poisoning O
. O

Dosing O
recommendations O
for O
SUSTIVA B-brand
and O
atazanavir B-drug
in O
treatment-experienced O
patients O
have O
not O
been O
established O
. O

Toxicity O
associated O
with O
concomitant O
use O
of O
aerosolized O
pentamidine B-drug
has O
not O
been O
reported O
. O

Lithium B-drug
carbonate I-drug
: O
The O
stimulatory O
effects O
of O
amphetamines B-group
may O
be O
inhibited O
by O
lithium B-drug
carbonate I-drug
. O

The O
treatment O
of O
depression O
in O
diabetic O
patients O
must O
take O
into O
account O
variations O
of O
glycemic O
levels O
at O
different O
times O
and O
a O
comparison O
of O
the O
available O
antidepressant B-group
agents I-group
is O
important O
. O

Caution O
should O
be O
exercised O
when O
administering O
ETOPOPHOS B-brand
with O
drugs O
that O
are O
known O
to O
inhibit O
phosphatase O
activities O
( O
e.g. O
, O
levamisole B-drug
hydrochloride I-drug
) O
. O

Because O
there O
is O
a O
theoretical O
basis O
that O
these O
effects O
may O
be O
additive O
, O
use O
of O
ergotamine-containing B-drug
or O
ergot-type B-group
medications I-group
( O
like O
dihydroergotamine B-drug
or O
methysergide B-drug
) O
and O
naratriptan B-drug
within O
24 O
hours O
is O
contraindicated O
. O

This O
suggests O
that O
interactions O
between O
the O
two O
elements O
only O
take O
place O
at O
the O
site O
of O
absorption O
. O

Aminoglycosides B-group
: O
The O
mixing O
of O
piperacillin B-drug
with O
an O
aminoglycoside B-group
in O
vitro O
can O
result O
in O
substantial O
inactivation O
of O
the O
aminoglycoside B-group
. O

A O
dose O
adjustment O
is O
not O
needed O
when O
zidovudine B-drug
is O
administered O
with O
VIRACEPT B-brand
. O

HIV B-group
Protease I-group
Inhibitors I-group
: O
Indinavir B-drug
( O
800 O
mg O
t.i.d O
. O
) O
co-administered O
with O
Vardenafil B-drug
10 O
mg O
resulted O
in O
a O
16-fold O
increase O
in O
vardenafil B-drug
AUC O
, O
a O
7-fold O
increase O
in O
vardenafil B-drug
Cmax O
and O
a O
2-fold O
increase O
in O
vardenafil B-drug
half-life O
. O

AED B-group
Co-administered O

Antiarrhythmic B-drug
agents I-drug
, I-drug
class I-drug
I I-drug
( O
such O
as O
flecainide B-drug
, O
lidocaine B-drug
, O
or O
quinidine B-drug
) O
: O
concurrent O
use O
with O
arbutamine B-drug
may O
have O
a O
proarrhythmic O
effect O
. O

Antitubercular O
drugs O
: O
Serum O
concentrations O
of O
isoniazid B-drug
may O
be O
decreased O
. O

No O
information O
available O
. O

Other O
Potentially O
Important O
Drug O
Interactions O
: O
Benzodiazepines B-group
: O
Benzodiazepines B-group
metabolized O
by O
hepatic O
oxidation O
( O
e.g. O
, O
alprazolam B-drug
, O
midazolam B-drug
, O
triazolam B-drug
elc O
. O
) O
should O
be O
used O
with O
caution O
because O
the O
clearance O
of O
these O
drugs O
is O
likely O
to O
be O
reduced O
by O
fluvoxamine B-drug
. O

Fluoxetine B-drug
does O
not O
affect O
the O
pharmacokinetics O
of O
clonazepam B-drug
. O

In O
a O
drug O
interaction O
study O
, O
co-administration O
of O
orally O
inhaled O
ciclesonide B-drug
and O
oral O
erythromycin B-drug
, O
an O
inhibitor O
of O
cytochrome O
P450 O
3A4 O
, O
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
either O
des-ciclesonide B-drug
or O
erythromycin B-drug
. O

In O
vitro O
data O
in O
human O
plasma O
indicate O
that O
doxazosin B-drug
mesylate I-drug
has O
no O
effect O
on O
protein O
binding O
of O
digoxin B-drug
, O
warfarin B-drug
, O
phenytoin B-drug
or O
indomethacin B-drug
. O

Herbal O
Products O
: O
St. O
John O
s O
wort O
( O
hypericum O
perforatum O
) O
WARNING O
coadministration O
may O
lead O
to O
loss O
of O
virologic O
response O
and O
possible O
resistance O
to O
INVIRASE B-brand
or O
to O
the O
class O
of O
protease O
inhibitors O
. O

The O
action O
of O
nondepolarizing O
relaxants O
is O
augmented O
by O
Enflurane B-drug
. O

Theophylline B-drug
VIOXX B-brand
12.5 O
, O
25 O
, O
and O
50 O
mg O
administered O
once O
daily O
for O
7 O
days O
increased O
plasma O
theophylline B-drug
concentrations O
( O
AUC O
( O
0- O
) O
) O
by O
38 O
to O
60 O
% O
in O
healthy O
subjects O
administered O
a O
single O
300-mg O
dose O
of O
theophylline B-drug
. O

If O
bupropion B-drug
is O
added O
to O
the O
treatment O
regimen O
of O
a O
patient O
already O
receiving O
a O
drug O
metabolized O
by O
CYP2D6 O
, O
the O
need O
to O
decrease O
the O
dose O
of O
the O
original O
medication O
should O
be O
considered O
, O
particularly O
for O
those O
concomitant O
medications O
with O
a O
narrow O
therapeutic O
index O
. O

Consequently O
, O
TRACLEER B-brand
is O
not O
expected O
to O
increase O
the O
plasma O
concentrations O
of O
drugs O
metabolized O
by O
these O
enzymes O
. O

Each O
subject O
received O
an O
individualized O
fixed O
daily O
dose O
of O
warfarin B-drug
and O
served O
as O
his O
own O
pre- O
and O
postsedative O
treatment O
control O
. O

Warfarin B-drug
: O
Multiple O
oral O
doses O
of O
Sonata B-brand
( O
20 O
mg O
q24h O
for O
13 O
days O
) O
did O
not O
affect O
the O
pharmacokinetics O
of O
warfarin B-drug
( O
R+ O
) O
- O
or O
( O
S- O
) O
-enantiomers O
or O
the O
pharmacodynamics O
( O
prothrombin O
time O
) O
following O
a O
single O
25-mg O
oral O
dose O
of O
warfarin B-drug
. O

The O
hypoglycemic O
action O
of O
sulfonylurea B-group
may O
be O
potentiated O
by O
certain O
drugs O
including O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
and O
other O
drugs O
that O
are O
highly O
protein O
bound O
, O
salicylates B-group
, O
sulfonamides B-group
, O
chloramphenicol B-drug
, O
probenecid B-drug
, O
coumarins B-group
, O
monoamine B-group
oxidase I-group
inhibitors I-group
, O
and O
beta B-group
adrenergic I-group
blocking I-group
agents I-group
. O

Rates O
of O
patients O
with O
maximum O
potassium O
levels O
5.5 O
mEq/L O
were O
similar O
regardless O
of O
the O
use O
of O
ACEI/ARB B-group
. O

SUBSEQUENT O
TO O
INITIATION O
OF O
DISULFIRAM B-drug
THERAPY O
. O

Lithium B-drug
: O
Increased O
serum O
lithium B-drug
levels O
and O
symptoms O
of O
lithium B-drug
toxicity O
have O
been O
reported O
in O
patients O
receiving O
ACE B-group
inhibitors I-group
during O
therapy O
with O
lithium B-drug
. O

Phenytoin B-drug
is O
known O
to O
cause O
osteomalacia O
. O

The O
beneficial O
effects O
on O
arterial O
thrombus O
formation O
from O
combined O
therapy O
with O
antiplatelet O
and O
anticoagulant B-group
medication I-group
must O
be O
weighed O
against O
an O
increased O
risk O
of O
inducing O
hemorrhage O
. O

Sulfacetamide B-drug
preparations O
are O
incompatible O
with O
silver B-drug
preparations O
. O

antibody O

Cimetidine B-drug
: O
Albendazole B-drug
sulfoxide I-drug
concentrations O
in O
bile O
and O
cystic O
fluid O
were O
increased O
( O
about O
2-fold O
) O
in O
hydatid O
cyst O
patients O
treated O
with O
cimetidine B-drug
( O
10 O
mg/kg/day O
) O
( O
n=7 O
) O
compared O
with O
albendazole B-drug
( O
20 O
mg/kg/day O
) O
alone O
( O
n=12 O
) O
. O

Omeprazole B-drug
: O
Omeprazole B-drug
is O
a O
CYP O
3A4 O
substrate O
and O
CYP O
2C19 O
substrate O
and O
inhibitor O
. O

It O
was O
observed O
that O
MPTP B-drug_n
induced O
long O
lasting O
depletions O
of O
striatal O
dopamine O
concentrations O
and O
this O
neurotoxic O
effect O
could O
be O
prevented O
by O
pargyline B-drug
pretreatment O
. O

Patients O
treated O
concurrently O
with O
BREVIBLOC B-brand
( O
esmolol B-drug
HCl I-drug
) O
and O
a O
catecholamine O
depletor O
should O
therefore O
be O
closely O
observed O
for O
evidence O
of O
hypotension O
or O
marked O
bradycardia O
, O
which O
may O
result O
in O
vertigo O
, O
syncope O
, O
or O
postural O
hypotension O
. O

Other O
Concomitant O
Therapy O
In O
healthy O
subjects O
there O
were O
no O
clinically O
significant O
interactions O
when O
felodipine B-drug
was O
given O
concomitantly O
with O
indomethacin B-drug
or O
spironolactone B-drug
. O

vasopressors B-group
, O
such O
as O
dopamine B-drug
and O
isoproterenol B-drug
; O

Decreasing O
the O
concentration O
of O
CMC-Cys B-drug_n
, O
exhibiting O
7.3 O
% O
( O
m/m O
) O
of O
immobilised O
cysteine B-drug
( O
CMC-Cys7.3 O
) O
from O
1 O
% O
( O
m/v O
) O
to O
0.5 O
% O
( O
m/v O
) O
decreased O
the O
R-value O
of O
NaFlu B-drug
from O
1.8 O
to O
1.2 O
. O

Antidepressants B-group
, O
tricyclic B-group
Amphetamines I-group
may O
enhance O
the O
activity O
of O
tricyclic B-drug
antidepressants I-drug
or O
sympathomimetic B-group
agents I-group
; O

. O

However O
, O
modification O
abolished O
the O
'cold O
' O
binding O
of O
toxin O
to O
bovine O
thyroglobulin O
in O
an O
ELISA O
and O
reduced O
ligand O
binding O
activity O
in O
a O
rabbit O
erythrocyte O
haemagglutination O
assay O
. O

However O
, O
at O
that O
time O
, O
the O
plasma O
levels O
of O
diazepam B-drug
were O
below O
the O
therapeutic O
interval O
, O
and O
thus O
this O
interaction O
is O
unlikely O
to O
be O
of O
clinical O
relevance O
. O

In O
simultaneous O
treatment O
with O
imidazole B-group
drugs I-group
and O
coumarin B-group
drugs I-group
, O
the O
anticoagulant O
effect O
should O
be O
carefully O
titrated O
and O
monitored O
. O

There O
was O
no O
evidence O
of O
drug O
interactions O
in O
clinical O
studies O
in O
which O
dobutamine B-drug
was O
administered O
concurrently O
with O
other O
drugs O
, O
including O
digitalis B-group
preparations I-group
, O
furosemide B-drug
, O
spironolactone B-drug
, O
lidocaine B-drug
, O
glyceryl B-drug
trinitrate I-drug
, O
isosorbide B-drug
dinitrate I-drug
, O
morphine B-drug
, O
atropine B-drug
, O
heparin B-drug
, O
protamine B-drug
, O
potassium B-drug
chloride I-drug
, O
folic B-drug
acid I-drug
, O
and O
acetaminophen B-drug
. O

halothane B-drug
; O

Olanzapine B-drug
: O
an O
updated O
review O
of O
its O
use O
in O
the O
management O
of O
schizophrenia O
. O

We O
assessed O
the O
ability O
of O
gene O
transfer O
to O
reverse O
vancomycin B-drug
resistance O
in O
class O
A O
( O
VanA O
) O
glycopeptide-resistant O
Enterococcus O
faecalis O
. O

Laboratory O
Test O
Interactions O
There O
are O
no O
reported O
laboratory O
test O
interactions O
. O

Cell O
permeable O
caspase-3 O
inhibitor O
added O
in O
the O
medium O
blocked O
the O
decrease O
of O
nucleophosmin/B23 O
and O
apoptosis O
induced O
by O
serum O
deprivation O
in O
NIH-3T3 O
cells O
. O

Therefore O
, O
co-administration O
of O
Duloxetine B-drug
with O
other O
drugs O
that O
are O
extensively O
metabolized O
by O
this O
isozyme O
and O
which O
have O
a O
narrow O
therapeutic O
index O
, O
including O
certain O
antidepressants B-group
( O
tricyclic B-group
antidepressants I-group
[ O
TCAs B-group
] O
, O
such O
as O
nortriptyline B-drug
, O
amitriptyline B-drug
, O
and O
imipramine B-drug
) O
, O
phenothiazines B-group
and O
Type B-group
1C I-group
antiarrhythmics I-group
( O
e.g. O
, O
propafenone B-drug
, O
flecainide B-drug
) O
, O
should O
be O
approached O
with O
caution O
. O

aureus O
to O
P O
. O

gestational O
trophoblastic O
disease O
; O

While O
only O
a O
limited O
number O
of O
in O
vivo O
drug-drug O
interactions O
with O
amiodarone B-drug
have O
been O
reported O
, O
chiefly O
with O
the O
oral O
formulation O
, O
the O
potential O
for O
other O
interactions O
should O
be O
anticipated O
. O

Discontinuing O
colestipol B-drug
hydrochloride I-drug
could O
pose O
a O
hazard O
to O
health O
if O
a O
potentially O
toxic O
drug O
that O
is O
significantly O
bound O
to O
the O
resin B-group
has O
been O
titrated O
to O
a O
maintenance O
level O
while O
the O
patient O
was O
taking O
colestipol B-drug
hydrochloride I-drug
. O

DEA O
concentrations O
were O
not O
affected O
. O

thrombocytopenia O

Since O
there O
is O
a O
high O
degree O
of O
variability O
in O
the O
bioavailability O
of O
verapamil B-drug
, O
the O
clinical O
significance O
of O
this O
finding O
is O
unclear O
. O

Nevirapine B-drug

Therefore O
, O
caffeine B-drug
has O
the O
potential O
to O
interact O
with O
drugs O
that O
are O
substrates O
for O
CYP1A2 O
, O
inhibit O
CYP1A2 O
, O
or O
induce O
CYP1A2 O
. O

Conversely O
, O
decreases O
in O
plasma O
levels O
of O
the O
tricyclic B-group
antidepressants I-group
have O
been O
reported O
upon O
discontinuation O
of O
cimetidine B-drug
which O
may O
result O
in O
the O
loss O
of O
the O
therapeutic O
efficacy O
of O
the O
tricyclic B-group
antidepressant I-group
6 O
. O

Prothrombin O
time O
was O
increased O
by O
5 O
% O
, O
the O
clinical O
significance O
of O
which O
is O
unknown O
. O

Iron B-drug
salts O
may O
reduce O
the O
bioavailability O
of O
carbidopa B-drug
and O
levodopa B-drug
. O

Monoamine O
Oxidase O
Inhibition O
: O
Linezolid B-drug
is O
a O
reversible O
, O
nonselective O
inhibitor O
of O
monoamine O
oxidase O
. O

Patients O
in O
clinical O
studies O
were O
prohibited O
from O
receiving O
growth O
factor O
treatment O
for O
2 O
weeks O
prior O
to O
the O
ZEVALIN B-brand
therapeutic O
regimen O
as O
well O
as O
for O
2 O
weeks O
following O
completion O
of O
the O
regimen O
. O

It O
is O
believed O
that O
the O
toxicity O
may O
have O
resulted O
from O
a O
previously O
unrecognized O
interaction O
between O
isoniazid B-drug
and O
acetaminophen B-drug
and O
a O
molecular O
basis O
for O
this O
interaction O
has O
been O
proposed O
. O

Vesselinovitch O
et O
al O
. O

Patients O
taking O
these O
drugs O
with O
LODOSYN B-brand
and O
levodopa B-drug
or O
carbidopa-levodopa B-drug
combination O
products O
should O
be O
carefully O
observed O
for O
loss O
of O
therapeutic O
response O
. O

In O
addition O
, O
certain O
drugs O
inhibit O
the O
activity O
of O
this O
isozyme O
and O
make O
normal O
metabolizers O
resemble O
p.o O
. O

Therefore O
, O
precaution O
should O
be O
taken O
when O
coadministration O
is O
necessary O
. O

- O
Drugs O
with O
ototoxic O
potential O
: O
Especially O
in O
the O
presence O
of O
impaired O
renal O
function O
, O
the O
use O
of O
parenterally O
administered O
bumetanide B-drug
in O
patients O
to O
whom O
aminoglycoside B-group
antibiotics I-group
are O
also O
being O
given O
should O
be O
avoided O
, O
except O
in O
life-threatening O
conditions O
. O

However O
, O
severe O
reactions O
, O
such O
as O
hypotension O
requiring O
treatment O
, O
dyspnea O
requiring O
bronchodilators B-group
, O
angioedema O
, O
or O
generalized O
urticaria O
require O
immediate O
discontinuation O
of O
TAXOL B-brand
and O
aggressive O
symptomatic O
therapy O
. O

A O
30 O
to O
45 O
% O
increase O
in O
AUC O
and O
Cmax O
of O
nisoldipine B-drug
was O
observed O
with O
concomitant O
administration O
of O
cimetidine B-drug
400 I-drug
mg I-drug
twice O
daily O
. O

Drug O
interaction O
studies O
with O
other O
anticonvulsants B-group
have O
not O
been O
conducted O
. O

In O
the O
same O
study O
it O
was O
shown O
that O
didanosine B-drug
and O
stavudine B-drug
had O
no O
significant O
effect O
on O
the O
intracellular O
phosphorylation O
of O
zalcitabine B-drug
in O
peripheral O
blood O
mononuclear O
cells O
. O

A O
study O
of O
interaction O
between O
BREVIBLOC B-brand
and O
warfarin B-drug
showed O
that O
concomitant O
administration O
of O
BREVIBLOC B-brand
and O
warfarin B-drug
does O
not O
alter O
warfarin B-drug
plasma O
levels O
. O

In O
a O
study O
involving O
12 O
adult O
volunteers O
, O
TORADOLORAL O
was O
coadministered O
with O
a O
single O
dose O
of O
25 O
mg O
warfarin B-drug
, O
causing O
no O
significant O
changes O
in O
pharmacokinetics O
or O
pharmacodynamics O
of O
warfarin B-drug
. O

Patients O
receiving O
both O
indomethacin B-drug
and O
furosemide B-drug
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
diuretic O
and/or O
antihypertensive O
effect O
of O
furosemide B-drug
is O
achieved O
. O

Nonsteroidal B-group
Anti-inflammatory I-group
Drugs I-group
( O
NSAIDs B-group
) O
: O
The O
concomitant O
administration O
of O
a O
nonsteroidal B-group
anti I-group
inflammatory I-group
drug I-group
with O
a O
quinolone B-group
may O
increase O
the O
risks O
of O
CNS O
stimulation O
and O
convulsions O
. O

The O
effect O
of O
induction O
or O
inhibition O
of O
other O
pathways O
on O
exposure O
to O
alosetron B-drug
and O
its O
metabolites O
is O
not O
known O
. O

Drugs O
such O
as O
troleandomycin B-drug
and O
ketoconazole B-drug
may O
inhibit O
the O
metabolism O
of O
corticosteroids B-group
and O
thus O
decrease O
their O
clearance O
. O

In O
some O
patients O
, O
this O
may O
lead O
to O
reduced O
clearance O
, O
prolongation O
of O
plasma O
half-life O
, O
and O
enhanced O
effects O
of O
caffeine B-drug
and O
theobromine B-drug
. O

Effect O
of O
aprepitant B-drug
on O
the O
pharmacokinetics O
of O
other O
agents O

Hydrochlorothiazide B-drug
( O
HCTZ B-drug
) O
Alone O
or O
in O
Combination O
with O
Triamterene B-drug
: O
Concomitant O
use O
of O
HCTZ B-drug
alone O
or O
in O
combination O
with O
triamterene B-drug
is O
contraindicated O
. O

Salicylate B-group
levels O
have O
been O
found O
to O
be O
falsely O
elevated O
with O
some O
assay O
methods O
. O

Little O
or O
no O
change O
in O
the O
pharmacokinetics O
of O
either O
drug O
was O
observed O
when O
VIRACEPT B-brand
was O
coadministered O
with O
lamivudine B-drug
or O
stavudine B-drug
. O

Each O
group O
took O
either O
150 O
mg O
or O
75 O
mg O
of O
fluvoxamine B-drug
a O
day O
for O
5 O
days O
( O
day O
-3 O
to O
day O
2 O
) O
. O

- O
Chloroquine B-drug
( O
e.g. O
, O
Aralen B-brand
) O
or O

Indinavir B-drug
has O
been O
shown O
to O
increase O
plasma O
levels O
of O
combination B-group
hormonal I-group
contraceptives I-group
. O

In O
one O
controlled O
clinical O
study O
, O
the O
ureidopenicillins O
, O
including O
piperacillin B-drug
, O
were O
reported O
to O
prolong O
the O
action O
of O
vecuronium B-drug
. O

Of O
particular O
importance O
, O
sufficient O
time O
must O
elapse O
before O
initiating O
TCA O
treatment O
in O
a O
patient O
being O
withdrawn O
from O
fluoxetine B-drug
, O
given O
the O
long O
half-life O
of O
the O
parent O
and O
active O
metabolite O
( O
at O
least O
5 O
weeks O
may O
be O
necessary O
) O
. O

Thalidomide B-drug
: O
Co-administration O
with O
thalidomide B-drug
should O
be O
employed O
cautiously O
, O
as O
toxic O
epidermal O
necrolysis O
has O
been O
reported O
with O
concomitant O
use O
. O

In O
addition O
, O
studies O
in O
healthy O
volunteers O
have O
shown O
that O
TIKOSYN B-brand
does O
not O
affect O
the O
pharmacokinetics O
or O
pharmacodynamics O
of O
warfarin B-drug
, O
or O
the O
pharmacokinetics O
of O
propranolol B-drug
( O
40 O
mg O
twice O
daily O
) O
, O
phenytoin B-drug
, O
theophylline B-drug
, O
or O
oral O
contraceptives B-group
. O

- O
Medicinal O
or O
dietary O
iodine B-group
interferes O
with O
all O
in O
vivo O
tests O
of O
radio-iodine O
uptake O
producing O
low O
uptakes O
which O
may O
not O
be O
reflective O
of O
a O
true O
decrease O
in O
hormone O
synthesis O

The O
pressor O
effects O
of O
diethylpropion B-drug
and O
those O
of O
other O
drugs O
may O
be O
additive O
when O
the O
drugs O
are O
used O
concomitantly O
; O

Previous O
studies O
have O
demonstrated O
a O
significant O
reduction O
in O
the O
oral O
bioavailability O
of O
trovafloxacin B-drug
and O
ciprofloxacin B-drug
when O
administered O
concomitantly O
with O
an O
intravenous O
opiate B-group
such O
as O
morphine B-drug
. O

Digoxin B-drug
volume O
of O
distribution O
was O
not O
significantly O
changed O
. O

free O
T4 O
concentration O
is O
unaltered O

Serious O
anticholinergic O
symptoms O
( O
i.e. O
, O
severe O
dry O
mouth O
, O
urinary O
retention O
and O
blurred O
vision O
) O
have O
been O
associated O
with O
elevations O
in O
the O
serum O
levels O
of O
tricyclic B-group
antidepressant I-group
when O
cimetidine B-drug
therapy O
is O
initiated O
. O

there O
was O
no O
alteration O
in O
the O
pharmacokinetics O
of O
either O
drug O
. O

Patients O
taking O
disopyramide B-drug
phosphate I-drug
and O
erythromycin B-drug
concomitantly O
may O
develop O
increased O
serum O
concentrations O
of O
disopyramide B-drug
resulting O
in O
excessive O
widening O
of O
the O
QRS O
complex O
and/or O
prolongation O
of O
the O
Q-T O
interval O
. O

Since O
there O
have O
been O
isolated O
reports O
of O
patients O
with O
elevated O
digoxin B-drug
levels O
, O
it O
is O
recommended O
that O
digoxin B-drug
levels O
be O
monitored O
when O
initiating O
, O
adjusting O
, O
and O
discontinuing O
nifedipine B-drug
to O
avoid O
possible O
over- O
or O
under-digitalization O
. O

Valdecoxib B-drug
did O
not O
have O
a O
statistically O
significant O
effect O
on O
the O
pharmacokinetics O
of O
phenytoin B-drug
( O
a O
CYP O
2C9 O
and O
CYP O
2C19 O
substrate O
) O
. O

certain O
protease B-group
inhibitors I-group
e.g. O
, O
ritanovir O
; O

Three O
clinical O
trials O
have O
investigated O
Simulect B-brand
use O
in O
combination O
with O
triple-therapy O
regimens O
. O

adjust O
dosage O
of O
antidiabetic B-group
drug I-group
accordingly O
. O

Potent O
inhibitors O
of O
CYP3A4 O
( O
below O
) O
increase O
the O
risk O
of O
myopathy O
by O
reducing O
the O
elimination O
of O
lovastatin B-drug
. O

There O
have O
been O
inconsistent O
reports O
regarding O
the O
effects O
of O
other O
drugs O
( O
e.g. O
, O
quinine B-drug
, O
penicillamine B-drug
) O
on O
serum O
digoxin B-drug
concentration O
. O

Therefore O
, O
cyclosporine B-drug
serum O
levels O
should O
be O
monitored O
and O
appropriate O
cyclosporine B-drug
dosage O
adjustments O
made O
when O
these O
drugs O
are O
used O
concomitantly O
. O

These O
include O
probenecid B-drug
, O
cholestyramine B-drug
, O
and O
some O
antibiotics B-group
( O
e.g O
. O
erythromycin B-drug
, O
rifamipicin O
, O
ampicillin B-drug
and O
chloramphenicol B-drug
) O
. O

Thyroid O
Physiology O
: O
The O
following O
agents O
may O
alter O
thyroid O
hormone O
or O
TSH O
levels O
, O
generally O
by O
effects O
on O
thyroid O
hormone O
synthesis O
, O
secretion O
, O
distribution O
, O
metabolism O
, O
hormone O
action O
, O
or O
elimination O
, O
or O
altered O
TSH O
secretion O
: O
aminoglutethimide B-drug
, O
p-aminosalicylic B-drug
acid I-drug
, O
amiodarone B-drug
, O
androgens B-group
and O
related O
anabolic O
hormones O
, O
complex O
anions O
( O
thiocyanate B-drug
, O
perchlorate B-drug
, O
pertechnetate B-drug
) O
, O
antithyroid B-group
drugs I-group
, O
b-adrenergic B-group
blocking I-group
agents I-group
, O
carbamazepine B-drug
, O
chloral B-drug
hydrate I-drug
, O
diazepam B-drug
, O
dopamine B-drug
and O
dopamine B-group
agonists I-group
, O
ethionamide B-drug
, O
glucocorticoids B-group
, O
heparin B-drug
, O
hepatic O
enzyme O
inducers O
, O
insulin B-drug
, O
iodinated O
cholestographic O
agents O
, O
iodine-containing B-group
compounds I-group
, O
levodopa B-drug
, O
lovastatin B-drug
, O
lithium B-drug
, O
6-mercaptopurine B-drug
, O
metoclopramide B-drug
, O
mitotane B-drug
, O
nitroprusside B-drug
, O
phenobarbital B-drug
, O
phenytoin B-drug
, O
resorcinol B-drug
, O
rifampin B-drug
, O
somatostatin B-group
analogs I-group
, O
sulfonamides B-group
, O
sulfonylureas B-group
, O
thiazide B-group
diuretics I-group
. O

Given O
the O
possibility O
of O
extravasation O
, O
it O
is O
advisable O
to O
closely O
monitor O
the O
infusion O
site O
for O
possible O
infiltration O
during O
drug O
administration O
. O

Since O
INVIRASE B-brand
is O
coadministered O
with O
ritonavir B-drug
, O
the O
ritonavir B-drug
label O
should O
be O
reviewed O
for O
additional O
drugs O
that O
should O
not O
be O
coadministered O
. O

It O
is O
desirable O
to O
monitor O
TCA B-group
plasma O
levels O
whenever O
a O
TCA B-group
is O
going O
to O
be O
co-administered O
with O
another O
drug O
known O
to O
be O
an O
inhibitor O
of O
P450 O
2D6 O
. O

as O
measured O
by O
PBI O
, O
T4 O
by O
column O
, O
or O
T4 O
by O
radioimmunoassay O
. O

Sixty-two O
( O
94 O
% O
) O
of O
66 O
strains O
of O
Enterobacteriaceae O
and O
Pseudomonas O
aeruginosa O
were O
inhibited O
by O
6.2 O
mug O
or O
less O
of O
gentamicin B-drug
per O
ml O
. O

Anticonvulsants B-group
: O
carbamazepine B-drug
, O
phenobarbital B-drug
, O
phenytoin B-drug

Resveratrol B-drug_n
has O
been O
shown O
to O
induce O
vasorelaxation O
. O

prolonged B-group
narcotics I-group
; O

Risk O
of O
Anaphylactic O
Reaction O
: O
While O
taking O
beta-blockers B-group
, O
patients O
with O
a O
history O
of O
severe O
anaphylactic O
reaction O
to O
a O
variety O
of O
allergens O
may O
be O
more O
reactive O
to O
repeated O
challenge O
, O
either O
accidental O
, O
diagnostic O
, O
or O
therapeutic O
. O

Epinephrine B-drug
should O
not O
be O
administered O
concomitantly O
with O
other O
sympathomimetic B-group
drugs I-group
( O
such O
as O
isoproterenol B-drug
) O
because O
of O
possible O
additive O
effects O
and O
increased O
toxicity O
. O

Clinical O
studies O
have O
shown O
that O
INDOCIN B-brand
does O
not O
influence O
the O
hypoprothrombinemia O
produced O
by O
anticoagulants B-group
. O

Effect O
of O
other O
drugs O
on O
Sensipar B-brand
: O
Sensipar B-brand
is O
metabolized O
by O
multiple O
cytochrome O
P450 O
enzymes O
, O
primarily O
CYP3A4 O
, O
CYP2D6 O
, O
and O
CYP1A2 O
. O

therefore O
, O
drug O
interactions O
mediated O
by O
inhibition O
of O
hepatic O
metabolism O
are O
not O
expected O
to O
occur O
. O

In O
rheumatoid O
arthritis O
, O
concomitant O
medications O
besides O
MTX B-drug
were O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
, O
folic B-drug
acid I-drug
, O
corticosteroids B-group
and/or O
narcotics B-group
. O

Therefore O
, O
when O
Hydrochlorothiazide B-drug
and O
non-steroidal B-group
anti-inflammatory I-group
agents I-group
are O
used O
concomitantly O
, O
the O
patient O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
of O
the O
diuretic B-group
is O
obtained O
. O

In O
addition O
, O
steady O
state O
levels O
of O
racemic O
citalopram B-drug
were O
not O
significantly O
different O
in O
poor O
metabolizers O
and O
extensive O
CYP2D6 O
metabolizers O
after O
multiple-dose O
administration O
of O
citalopram B-drug
, O
suggesting O
that O
coadministration O
, O
with O
escitalopram B-drug
, O
of O
a O
drug O
that O
inhibits O
CYP2D6 O
, O
is O
unlikely O
to O
have O
clinically O
significant O
effects O
on O
escitalopram B-drug
metabolism O
. O

May O
interact O
anticoagulants B-group
( O
altered O
hypo-prothrombinemic O
effect O
) O
, O
barbiturates B-group
, O
rifampin B-drug
and O
other O
inducers O
of O
hepatic O
microsomal O
enzyme O
oxidation O
system O
( O
decreased O
effect O
of O
diethylstilbestrol B-drug
) O
, O
corticosteroids B-group
( O
increased O
effect O
of O
corticosteroids B-group
) O
. O

Effects O
of O
other O
Antiepilepsy O
Drugs O
( O
AEDs B-group
) O
on O
GABITRIL B-brand
: O
Carbamazepine B-drug
: O
Population O
pharmacokinetic O
analyses O
indicate O
that O
tiagabine B-drug
clearance O
is O
60 O
% O
greater O
in O
patients O
taking O
carbamazepine B-drug
with O
or O
without O
other O
enzyme- O
inducing O
AEDs B-group
. O

Diphenhydramine B-drug
: O
Diphenhydramine B-drug
is O
reported O
to O
be O
a O
weak O
inhibitor O
of O
aldehyde O
oxidase O
in O
rat O
liver O
, O
but O
its O
inhibitory O
effects O
in O
human O
liver O
are O
not O
known O
. O

Verapamil B-drug
produced O
a O
decrease O
of O
20 O
% O
[ O
90 O
% O
CI O
: O
18-27 O
] O
of O
the O
plasma O
levels O
of O
MHD B-drug_n
. O

serum O
magnesium O
levels O
may O
increase O
in O
uremic O
patients O
) O
Serum O
protein-bound O
iodine O
( O
PBI O
) O
levels O
( O
may O
be O
decreased O
) O
Thiazides B-group
should O
be O
discontinued O
before O
carrying O
out O
tests O
for O
parathyroid O
function O
. O

It O
is O
not O
known O
if O
fulvestrant B-drug
is O
excreted O
in O
human O
milk O
. O

Doses O
of O
vitamin B-drug
C I-drug
up O
to O
200 O
mg O
were O
allowed O
in O
clinical O
studies O
without O
negative O
consequences O
. O

- O
Drugs O
whose O
efficacy O
is O
impaired O
by O
phenytoin B-drug
include O
: O
anticoagulants B-group
, O
corticosteroids B-group
, O
coumarin B-group
, O
digitoxin B-drug
, O
doxycycline B-drug
, O
estrogens B-group
, O
furosemide B-drug
, O
oral O
contraceptives B-group
, O
rifampin B-drug
, O
quinidine B-drug
, O
theophylline B-drug
, O
vitamin B-group
D I-group
. O

Here O
we O
show O
that O
a O
combination O
of O
galangin B-drug
or O
3,7-dihydroxyflavone O
with O
vancomycin B-drug
may O
be O
used O
to O
sensitize O
resistant O
strains O
of O
Enterococcus O
faecalis O
and O
Enterococcus O
faecium O
to O
the O
level O
of O
vancomycin-sensitive O
strains O
. O

In O
vitro O
studies O
with O
human O
liver O
microsomes O
indicate O
that O
bortezomib B-drug
is O
primarily O
a O
substrate O
for O
cytochrome O
P450 O
3A4 O
, O
2C19 O
, O
and O
1A2 O
. O

Additionally O
, O
there O
is O
no O
evidence O
of O
circulating O
active O
metabolites O
or O
accumulation O
during O
chronic O
dosing O
. O

Therefore O
, O
there O
is O
a O
potential O
for O
an O
interaction O
with O
other O
drugs O
that O
are O
metabolized O
by O
CYP O
1A2 O
( O
e.g. O
, O
amitriptyline B-drug
, O
tacrine B-drug
, O
and O
zileuton B-drug
) O
. O

In O
vitro O
activity O
of O
KRM-1648 B-drug_n
, O
either O
singly O
or O
in O
combination O
with O
ofloxacin B-drug
, O
against O
Mycobacterium O
ulcerans O
. O

Coadministration O
of O
ethoxzolamide B-drug
with O
other O
diuretics B-group
, O
amphotericin B-drug
B I-drug
, O
and O
corticosteroids B-group
may O
cause O
hypokalemia O
. O

However O
, O
norepinephrine B-drug
may O
still O
be O
used O
effectively O
. O

haloperidol B-drug
; O

Absorption O
of O
fluvastatin B-drug
is O
virtually O
complete O
across O
all O
species O
, O
including O
man O
, O
and O
is O
not O
affected O
by O
the O
presence O
of O
food O
. O

. O

decreased O
pregnanediol O
excretion O
; O

Use O
of O
a O
nonhormonal B-group
contraceptive I-group
product I-group
is O
recommended O
. O

ritonavir I-drug
concentration O

Patients O
on O
thyroid O
replacement O
therapy O
may O
require O
higher O
doses O
of O
thyroid B-group
hormone I-group
. O

Enoxacin B-drug
interferes O
with O
the O
metabolism O
of O
theophylline B-drug
resulting O
in O
a O
42 O
% O
to O
74 O
% O
dose-related O
decrease O
in O
theophylline B-drug
clearance O
and O
a O
subsequent O
260 O
% O
to O
350 O
% O
increase O
in O
serum O
theophylline O
levels O
. O

Prostatic O
epithelium O
proliferates O
in O
a O
defined O
medium O
consisting O
of O
basal O
medium O
RPMI1640 O
containing O
transferrin B-drug_n
( O
1 O
microgram/ml O
) O
, O
EGF B-drug_n
( O
10 O
ng/ml O
) O
, O
and O
insulin B-drug
( O
3.7 O
micrograms/ml O
or O
0.1 O
IU/ml O
) O
. O

Amantadine B-drug
, O
tricyclic B-group
antidepressants I-group
, O
and O
MAOIs B-group
may O
increase O
anticholinergic O
effect O
of O
clidinium B-drug
. O

In O
these O
patients O
whose O
hypertension O
was O
controlled O
with O
nifedipine B-drug
, O
Vardenafil B-drug
20 O
mg O
produced O
mean O
additional O
supine O
systolic/diastolic O
blood O
pressure O
reductions O
of O
6/5 O
mm O
Hg O
compared O
to O
placebo O
. O

- O
Oral O
contraceptives B-group
( O
birth O
control O
pills O
) O
containing O
estrogen B-group
or O

meprobamate B-drug
; O

Morphine B-drug
prolonged O
gastrointestinal O
transit O
time O
from O
69 O
to O
103 O
minutes O
( O
P O
= O
.005 O
) O
; O

Hematopoietic O

It O
is O
unknown O
how O
the O
effect O
seen O
in O
these O
in O
vitro O
studies O
translates O
into O
clinical O
consequences O
. O

Corticosteroids B-group
: O
Dexamethasone B-drug
: O
Aprepitant B-drug
, O
when O
given O
as O
a O
regimen O
of O
125mg O
with O
dexamethasone B-drug
coadministered O
orally O
as O
20 O
mg O
on O
Day O
1 O
, O
and O
Aprepitant B-drug
when O
given O
as O
80 O
mg/day O
with O
dexamethasone B-drug
coadministered O
orally O
as O
8 O
mg O
on O
Days O
2 O
through O
5 O
, O
increased O
the O
AUC O
of O
dexamethasone B-drug
, O
a O
CYP3A4 O
substrate O
by O
2.2-fold O
, O
on O
Days O
1 O
and O
5 O
. O

ii O
. O

Drug/Laboratory O
Test O
Interactions O
The O
following O
drugs O
or O
moieties O
are O
known O
to O
interfere O
with O
laboratory O
tests O
performed O
in O
patients O
on O
thyroid B-group
hormone I-group
therapy O
: O
androgens B-group
, O
corticosteroids B-group
, O
estrogens B-group
, O
oral O
contraceptives B-group
containing O
estrogens B-group
, O
iodine-containing B-group
preparations O
and O
the O
numerous O
preparations O
containing O
salicylates B-group
. O

Ketamine B-drug
: O
Marked O
hypertension O
and O
tachycardia O
have O
been O
reported O
in O
association O
with O
concomitant O
administration O
of O
levothyroxine B-drug
sodium I-drug
and O
ketamine B-drug
. O

This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
NSAIDs B-group
concomitantly O
with O
ACE B-group
inhibitors I-group
. O

There O
have O
been O
greater O
than O
2-fold O
increases O
in O
previously O
stable O
plasma O
levels O
of O
other O
antidepressants B-group
, O
including O
nortriptyline B-drug
, O
when O
fluoxetine B-drug
hydrochloride I-drug
has O
been O
administered O
in O
combination O
with O
these O
agents O
. O

No O
confirmed O
interactions O
have O
been O
reported O
between O
ZOLADEX B-brand
and O
other O
drugs O

Strong O
inducers O
of O
cytochrome O
P450 O
enzymes O
( O
i.e O
. O
carbamazepine B-drug
, O
phenytoin B-drug
and O
phenobarbital B-drug
) O
have O
been O
shown O
to O
decrease O
the O
plasma O
levels O
of O
MHD B-drug_n
( O
29-40 O
% O
) O
. O

Tolbutamides B-drug
conversion O
to O
inactive O
metabolites O
has O
been O
shown O
to O
be O
catalyzed O
by O
xanthine O
oxidase O
from O
rat O
liver O
. O

For O
example O
, O
since O
cholestyramine B-drug
may O
reduce O
the O
gastrointestinal O
absorption O
of O
both O
the O
oral O
anticoagulants B-group
and O
vitamin B-group
K I-group
, O
the O
net O
effects O
are O
unpredictable O
. O

It O
is O
recommended O
that O
if O
CASODEX B-brand
is O
started O
in O
patients O
already O
receiving O
coumarin B-group
anticoagulants I-group
, O
prothrombin O
times O
should O
be O
closely O
monitored O
and O
adjustment O
of O
the O
anticoagulant B-group
dose O
may O
be O
necessary O
. O

Anticonvulsants B-group
( O
Phenytoin B-drug
) O
: O
Steady O
state O
plasma O
exposure O
( O
AUC O
) O
of O
valdecoxib B-drug
( O
40 O
mg O
BID O
for O
12 O
days O
) O
was O
decreased O
by O
27 O
% O
when O
co-administered O
with O
multiple O
doses O
( O
300 O
mg O
QD O
for O
12 O
days O
) O
of O
phenytoin B-drug
( O
a O
CYP O
3A4 O
inducer O
) O
. O

Quinolones B-group
, O
including O
norfloxacin B-drug
, O
may O
enhance O
the O
effects O
of O
oral O
anticoagulants B-group
, O
including O
warfarin B-drug
or O
its O
derivatives O
or O
similar O
agents O
. O

Felbamate B-drug
treatment O
resulted O
in O
a O
42 O
% O
decrease O
in O
the O
gestodene B-drug
AUC O
0-24 O
, O
but O
no O
clinically O
relevant O
effect O
was O
observed O
on O
the O
pharmacokinetic O
parameters O
of O
ethinyl B-drug
estradiol I-drug
. O

Drug/Laboratory O
Test O
Interactions O
As O
with O
cephalothin B-drug
, O
high O
concentrations O
of O
cefoxitin B-drug
( O
100 O
micrograms/mL O
) O
may O
interfere O
with O
measurement O
of O
serum O
and O
urine O
creatinine O
levels O
by O
the O
Jaff O
reaction O
, O
and O
produce O
false O
increases O
of O
modest O
degree O
in O
the O
levels O
of O
creatinine O
reported O
. O

aureus O
, O
to O
survive O
in O
pentazocine B-drug
and O
tripelennamine B-drug
may O
explain O
in O
part O
a O
shift O
from O
S O
. O

In O
addition O
to O
the O
interactions O
noted O
above O
, O
chronic O
( O
2 O
weeks O
) O
oral O
Cordarone B-drug
administration O
impairs O
metabolism O
of O
phenytoin B-drug
, O
dextromethorphan B-drug
, O
and O
methotrexate B-drug
. O

. O

A O
review O
is O
presented O
of O
some O
of O
the O
problems O
that O
may O
arise O
in O
association O
with O
anaesthesia O
for O
epileptic O
patients O
. O

Special O
care O
is O
required O
if O
this O
drug O
is O
given O
to O
patients O
receiving O
ganglion B-group
blocking I-group
compounds I-group
because O
a O
critical O
fall O
in O
blood O
pressure O
may O
occur O
. O

Tetracyclines B-group
: O
Concomitant O
treatment O
with O
Accutane B-brand
and O
tetracyclines B-group
should O
be O
avoided O
because O
Accutane B-brand
use O
has O
been O
associated O
with O
a O
number O
of O
cases O
of O
pseudotumor O
cerebri O
( O
benign O
intracranial O
hypertension O
) O
, O
some O
of O
which O
involved O
concomitant O
use O
of O
tetracyclines B-group

No O
drug O
interaction O
data O
are O
available O
on O
concomitant O
administration O
of O
Panretin B-brand
gel O
and O
systemic O
anti-KS O
agents O
. O

A O
drug-drug O
interaction O
study O
with O
rifampin B-drug
in O
healthy O
volunteers O
has O
shown O
a O
30 O
% O
decrease O
in O
caspofungin B-drug
trough O
concentrations O
. O

To O
find O
out O
whether O
this O
observation O
is O
related O
to O
the O
increased O
regional O
perfusion O
in O
diabetes O
longitudinal O
studies O
on O
patients O
with O
Type O
I O
( O
insulin-dependent O
) O
diabetes O
mellitus O
are O
needed O
. O

Carbamazepine B-drug
- O
Combined O
administration O
of O
racemic O
citalopram B-drug
( O
40 O
mg/day O
for O
14 O
days O
) O
and O
carbamazepine B-drug
( O
titrated O
to O
400 O
mg/day O
for O
35 O
days O
) O
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
carbamazepine B-drug
, O
a O
CYP3A4 O
substrate O
. O

Levetiracetam B-drug
circulates O
largely O
unbound O
( O
10 O
% O
bound O
) O
to O
plasma O
proteins O
; O

Therefore O
, O
when O
INSPRA B-brand
and O
NSAIDs B-group
are O
used O
concomitantly O
, O
patients O
should O
be O
observed O
to O
determine O
whether O
the O
desired O
effect O
on O
blood O
pressure O
is O
obtained O
. O

Caution O
should O
be O
exercised O
when O
treating O
patients O
with O
either O
of O
these O
drugs O
or O
other O
highly O
protein-bound O
drugs O
and O
Atromid-S B-brand
. O

The O
clinical O
relevance O
of O
this O
finding O
is O
unclear O
. O

Carbamazepine B-drug
: O
Carbamazepine B-drug
causes O
an O
approximate O
50 O
% O
increase O
in O
the O
clearance O
of O
Felbatol B-brand
at O
steady O
state O
and O
, O
therefore O
, O
the O
addition O
of O
carbamazepine B-drug
results O
in O
an O
approximate O
40 O
% O
decrease O
in O
the O
steady-state O
trough O
concentrations O
of O
Felbatol B-brand
as O
compared O
to O
the O
same O
dose O
of O
Felbatol B-brand
given O
as O
monotherapy O
. O

Saquinavir B-drug

Less O
than O
the O
usual O
amounts O
of O
these O
medicines O
should O
be O
used O
. O

In O
clinical O
studies O
, O
Tilade B-brand
has O
been O
co-administered O
with O
other O
anti-asthma O
medications O
, O
including O
inhaled O
and O
oral O
bronchodilators B-group
, O
and O
inhaled O
corticosteroids B-group
, O
with O
no O
evidence O
of O
increased O
frequency O
of O
adverse O
events O
or O
laboratory O
abnormalities O
. O

- O
Methyldopa B-drug
( O
e.g. O
, O
Aldomet B-brand
) O
Use O
of O
methyldopa B-drug
with O
sulfapyridine B-drug
may O
increase O
the O
chance O
of O
side O
effects O
affecting O
the O
liver O
and/or O
the O
blood O

Consideration O
should O
be O
taken O
in O
patients O
being O
treated O
with O
antidiabetic B-drug
agents O
. O

However O
, O
the O
pharmacodynamic O
effect O
increased O
by O
197 O
% O
( O
QTc O
increase O
over O
time O
) O
and O
by O
95 O
% O
( O
maximum O
QTc O
increase O
) O
. O

No O
drug/drug O
interaction O
studies O
have O
been O
performed O
. O

Insulin B-drug
or O
Oral O
Hypoglycemics B-group
: O
Initiating O
thyroid O
replacement O
therapy O
may O
cause O
increases O
in O
insulin B-drug
or O
oral O
hypoglycemic B-group
requirements O
. O

Although O
the O
occurrence O
has O
not O
been O
reported O
with O
Cefizox B-brand
, O
nephrotoxicity O
has O
been O
reported O
following O
concomitant O
administration O
of O
other O
cephalosporins B-group
and O
aminoglycosides B-group
. O

Serotonin O
release O
by O
platelets O
plays O
an O
important O
role O
in O
hemostasis O
. O

. O

Sumatriptan B-drug
- O
There O
have O
been O
rare O
postmarketing O
reports O
describing O
patients O
with O
weakness O
, O
hyperreflexia O
, O
and O
incoordination O
following O
the O
use O
of O
a O
selective B-group
serotonin I-group
reuptake I-group
inhibitor I-group
( O
SSRI B-group
) O
and O
sumatriptan B-drug
. O

reliable O
estimates O
of O
the O
prevalence O
of O
reduced O
P450 O
2D6 O
isozyme O
activity O
among O
Asian O
, O
African O
and O
other O
populations O
are O
not O
yet O
available O
. O

. O

An O
individual O
who O
is O
stable O
on O
a O
given O
dose O
of O
TCA B-group
may O
become O
abruptly O
toxic O
when O
given O
one O
of O
these O
inhibiting O
drugs O
as O
concomitant O
therapy O
. O

Fluoxetine B-drug
and O
moclobemide B-drug
increased O
blood O
glucose B-drug
at O
different O
times O
after O
the O
glucose O
overload O
. O

Cyclosporine B-drug
, O
tacrolimus B-drug
and O
digoxin B-drug
concentrations O
should O
be O
monitored O
at O
the O
initiation O
of O
Itraconazole B-drug
therapy O
and O
frequently O
thereafter O
, O
and O
the O
dose O
of O
these O
three O
drug O
products O
adjusted O
appropriately O
. O

Probenecid B-drug
: O
Concomitant O
administration O
of O
TORADOL B-brand
ORAL O
and O
probenecid B-drug
resulted O
in O
decreased O
clearance O
of O
ketorolac B-drug
and O
significant O
increases O
in O
ketorolac B-drug
plasma O
levels O
( O
total O
AUC O
increased O
approximately O
threefold O
from O
5.4 O
to O
17.8 O
m O
g/h/mL O
) O
and O
terminal O
half-life O
increased O
approximately O
twofold O
from O
6.6 O
to O
15.1 O
hours O
. O

Therefore O
, O
it O
is O
advisable O
to O
be O
particularly O
cautious O
in O
patients O
whose O
plasma O
digoxin B-drug
levels O
are O
above O
or O
suspected O
to O
be O
above O
the O
usual O
therapeutic O
range O
. O

Pediatric O
Use O

Thus O
, O
the O
interaction O
observed O
between O
erythromycin B-drug
and O
terfenadine B-drug
is O
not O
expected O
for O
dirithromycin B-drug
. O

The O
reported O
dose O
used O
for O
L-glutamine B-drug
was O
21 O
grams O
daily O
taken O
in O
divided O
doses O
three O
times O
a O
day O
. O

Due O
to O
its O
potential O
to O
cause O
neutropenia O
and O
lymphopenia O
, O
proper O
monitoring O
of O
patients O
is O
required O
if O
Rebif B-brand
is O
given O
in O
combination O
with O
myelosuppressive O
agents O
. O

Since O
blood O
level O
of O
calcitriol/ergocalcitriol B-drug
will O
be O
reduced O
, O
higher O
doses O
of O
Rocaltrol B-brand
may O
be O
necessary O
if O
these O
drugs O
are O
administered O
simultaneously O
. O

Most O
of O
the O
above O
effects O
concerning O
diuretics B-group
have O
been O
attributed O
, O
at O
least O
in O
part O
, O
to O
mechanisms O
involving O
inhibition O
of O
prostaglandin O
synthesis O
by O
INDOCIN B-brand
. O

Warfarin B-drug
- O
Administration O
of O
40 O
mg/day O
racemic O
citalopram B-drug
for O
21 O
days O
did O
not O
affect O
the O
pharmacokinetics O
of O
warfarin B-drug
, O
a O
CYP3A4 O
substrate O
. O

Concomitant O
use O
of O
bromocriptine B-drug
mesylate I-drug
with O
other O
ergot B-group
alkaloids I-group
is O
not O
recommended O
. O

Antifungals B-group
: O
Itraconazole B-drug
Ketoconazole I-drug

Blood O
samples O
were O
drawn O
at O
0 O
, O
0.5 O
, O
1 O
, O
1.5 O
, O
2 O
, O
3 O
, O
4 O
, O
6 O
, O
8 O
, O
12 O
, O
18 O
, O
and O
24 O
hours O
for O
Cmax O
, O
tmax O
, O
and O
AUC O
determinations O
. O

In O
some O
patients O
, O
the O
administration O
of O
a O
non-steroidal B-group
anti-inflammatory I-group
agent I-group
can O
reduce O
the O
diuretic B-group
, I-group
natriuretic O
, O
and O
antihypertensive O
effects O
of O
loop O
, O
potassium-sparing O
and O
thiazide B-group
diuretics I-group
. O

These O
facts O
should O
be O
considered O
when O
evaluating O
plasma O
renin O
activity O
in O
hypertensive O
patients O
. O

Onset O
of O
the O
interaction O
began O
within O
five O
days O
of O
beginning O
concurrent O
therapy O
. O

Antacids B-group
: O
Enteric O
Coated O
Aspirin B-brand
should O
not O
be O
given O
concurrently O
with O
antacids B-group
, O
since O
an O
increase O
in O
the O
pH O
of O
the O
stomach O
may O
effect O
the O
enteric O
coating O
of O
the O
tablets O
. O

Naproxen B-drug
had O
no O
effect O
on O
plasma O
levels O
of O
diflunisal B-drug
. O

It O
is O
desirable O
to O
monitor O
TCA B-group
plasma O
levels O
whenever O
a O
TCA B-group
is O
going O
to O
be O
coadministered O
with O
another O
drug O
known O
to O
be O
an O
inhibitor O
of O
P450 O
2D6 O
. O

To O
study O
the O
pancreatic O
effects O
of O
other O
agents O
, O
dynamic O
insulin O
and O
glucagon O
release O
was O
measured O
from O
the O
in O
vitro O
perfused O
pancreases O
of O
normal O
and O
diabetic O
Chinese O
hamsters O
in O
response O
to O
various O
combinations O
of O
arginine B-drug
( O
20mM O
) O
, O
glucose B-drug
( O
100 O
or O
150 O
mg. O
per O
100 O
ml O
. O
) O
, O
and O
theophylline B-drug
( O
10 O
mM O
) O
. O

MAO B-group
Inhibitors I-group
: O
Studies O
in O
animals O
demonstrate O
that O
the O
acute O
toxicity O
of O
bupropion B-drug
is O
enhanced O
by O
the O
MAO B-group
inhibitor I-group
phenelzine B-drug
. O

Ethopropazine B-drug
may O
interact O
with O
alcohol B-drug
or O
other O
CNS B-group
depressants I-group
, O
causing O
increased O
sedative O
effects O
. O

The O
blood O
pressure O
effect O
of O
SULAR B-brand
tended O
to O
be O
greater O
in O
patients O
on O
atenolol B-drug
than O
in O
patients O
on O
no O
other O
antihypertensive B-group
therapy O
. O

Digoxin B-drug
: O
In O
controlled O
studies O
in O
healthy O
volunteers O
, O
bepridil B-drug
hydrochloride I-drug
either O
had O
no O
effect O
( O
one O
study O
) O
or O
was O
associated O
with O
modest O
increases O
, O
about O
30 O
% O
( O
two O
studies O
) O
in O
steady-state O
serum O
digoxin B-drug
concentrations O
. O

Four O
educational O
messages O
advise O
on O
over O
60 O
% O
of O
the O
PICR O
detected O
. O

Racemic O
citalopram B-drug
did O
not O
alter O
the O
mean O
AUC O
or O
Cmax O
of O
pimozide B-drug
. O

Antigout B-group
medications I-group

Because O
warfarin B-drug
is O
metabolized O
by O
CYP2C9 O
and O
CYP3A4 O
, O
patients O
who O
require O
anticoagulation O
should O
receive O
low-molecular O
weight O
or O
standard O
heparin B-drug
. O

Lupus-like O
syndrome O

Other O
binding O
proteins O
may O
be O
elevated O
in O
serum O
, O
i.e. O
, O
corticosteroid O
binding O
globulin O
( O
CBG O
) O
, O
sex O
hormone-binding O
globulin O
( O
SHBG O
) O
, O
leading O
to O
increased O
total O
circulating O
corticosteroids B-group
and O
sex B-group
steroids I-group
, O
respectively O
. O

Toxicity O
of O
cadmium O
and O
zinc B-drug
to O
encystment O
and O
in O
vitro O
excystment O
of O
Parorchis O
acanthus O
( O
Digenea O
: O
Philophthalmidae O
) O
. O

Although O
clinical O
evidence O
to O
date O
has O
not O
demonstrated O
renal O
precipitation O
of O
oxypurines O
in O
patients O
either O
on O
allopurinol B-drug
alone O
or O
in O
combination O
with O
uricosuric B-group
agents I-group
, O
the O
possibility O
should O
be O
kept O
in O
mind O
. O

( O
Concurrent O
use O
with O
thiazide B-group
diuretics I-group
may O
intensify O
electrolyte O
imbalance O
, O
particularly O
hypokalemia O
. O
) O

Diphenoxylate B-drug
HCl I-drug
and O
atropine B-drug
sulfate I-drug
may O
interact O
with O
MAO B-group
inhibitors I-group
In O
studies O
with O
male O
rats O
, O
diphenoxylate B-drug
hydrochloride I-drug
was O
found O
to O
inhibit O
the O
hepatic O
microsomal O
enzyme O
system O
at O
a O
dose O
of O
2 O
mg/kg/day O
. O

The O
following O
similar O
changes O
may O
be O
expected O
with O
larger O
doses O
of O
estrogen B-group
: O
- O
Increased O
sulfobromophthalein O
retention O

Corticosteroids B-group
, O
ACTH B-drug
: O
intensified O
electrolyte O
depletion O
, O
particularly O
hypokalemia O
. O

Flucytosine B-drug
: O
while O
a O
synergistic O
relationship O
with O
amphotericin B-drug
B I-drug
has O
been O
reported O
, O
concomitant O
use O
may O
increase O
the O
toxicity O
of O
flucytosine B-drug
by O
possibly O
increasing O
its O
cellular O
uptake O
and/or O
impairing O
its O
renal O
excretion O
. O

reduced O
response O
to O
metyrapone O
test O
; O

Quinidine B-drug
, O
verapamil B-drug
, O
amiodarone B-drug
, O
propafenone B-drug
, O
indomethacin B-drug
, O
itraconazole B-drug
, O
alprazolam B-drug
, O
and O
spironolactone B-drug
raise O
the O
serum O
digoxin B-drug
concentration O
due O
to O
a O
reduction O
in O
clearance O
and/or O
in O
volume O
of O
distribution O
of O
the O
drug O
, O
with O
the O
implication O
that O
digitalis B-group
intoxication O
may O
result O
. O

Aminoglutethimide B-drug
: O
May O
increase O
CYP O
metabolism O
of O
progestins B-group
leading O
to O
possible O
decrease O
in O
contraceptive O
effectiveness O
. O

There O
are O
case O
reports O
of O
patients O
who O
developed O
increased O
BUN O
, O
serum O
creatinine O
and O
serum O
potassium O
levels O
, O
and O
weight O
gain O
when O
furosemide B-drug
was O
used O
in O
conjunction O
with O
NSAIDs B-group
. O

A O
drug O
interaction O
study O
was O
performed O
in O
which O
ERBITUX B-brand
was O
administered O
in O
combination O
with O
irinotecan B-drug
. O

Clinically O
significant O
effects O
have O
been O
reported O
with O
the O
warfarin B-group
anticoagulants I-group
; O

Phenobarbital B-drug
or O
Primidone B-drug
: O
No O
formal O
pharmacokinetic O
studies O
have O
been O
performed O
examining O
the O
addition O
of O
tiagabine B-drug
to O
regimens O
containing O
phenobarbital B-drug
or O
primidone B-drug
. O

. O

Interconversion O
between O
caffeine B-drug
and O
theophylline B-drug
has O
been O
reported O
in O
preterm O
neonates O
. O

therefore O
, O
the O
use O
of O
dofetilide B-drug
does O
not O
necessitate O
an O
adjustment O
in O
digoxin B-drug
dose O
to O
maintain O
therapeutic O
digoxin O
levels O
. O

Spermine B-drug
promotes O
the O
translocation O
of O
phosphatidate O
phosphohydrolase O
from O
the O
cytosol O
to O
the O
microsomal O
fraction O
of O
rat O
liver O
and O
it O
enhances O
the O
effects O
of O
oleate O
in O
this O
respect O
. O

The O
steady O
state O
plasma O
concentrations O
of O
imipramine B-drug
and O
desipramine B-drug
have O
been O
reported O
to O
be O
increased O
an O
average O
of O
31 O
% O
and O
20 O
% O
, O
respectively O
, O
by O
the O
concomitant O
administration O
of O
alprazolam B-drug
tablets O
in O
doses O
up O
to O
4 O
mg/day O
. O

There O
is O
insufficient O
experience O
to O
assess O
the O
safety O
and O
efficacy O
of O
ORENCIA B-brand
administered O
concurrently O
with O
anakinra B-drug
, O
and O
therefore O
such O
use O
is O
not O
recommended O
. O

however O
, O
it O
adversely O
affected O
response O
duration O
suggesting O
that O
pyridoxine B-drug
should O
not O
be O
administered O
with O
HEXALEN B-brand
and/or O
cisplatin.1 B-drug

Nursing O
Mothers O
It O
is O
not O
known O
whether O
peginterferon B-drug
or O
ribavirin B-drug
or O
its O
components O
are O
excreted O
in O
human O
milk O
. O

Antiretroviral B-group
plasma O
and O
urine O
sampling O
were O
conducted O
on O
Days O
1 O
, O
7 O
, O
and O
21 O
for O
zidovudine B-drug
and O
on O
Days O
7 O
and O
21 O
for O
dideoxyinosine B-drug
. O

. O

In O
order O
to O
provide O
information O
for O
the O
appropriate O
package O
insert O
labeling O
of O
progestin-only B-group
oral I-group
contraceptives I-group
( O
POC B-group
) O
in O
the O
US O
, O
a O
comprehensive O
review O
was O
made O
of O
norgestrel B-drug
( O
0.075 O
mg O
) O
and O
norethindrone B-drug
( O
0.35 O
mg O
) O
, O
with O
the O
clinical O
differences O
indicated O
where O
applicable O
. O

Drug-Laboratory O
Test O
Interactions O
There O
are O
no O
known O
interactions O
between O
ELLENCE B-brand
and O
laboratory O
tests O
. O

None O
known O
. O

Valproate B-drug
: O
The O
addition O
of O
tiagabine B-drug
to O
patients O
taking O
valproate B-drug
chronically O
had O
no O
effect O
on O
tiagabine B-drug
pharmacokinetics O
, O
but O
valproate B-drug
significantly O
decreased O
tiagabine B-drug
binding O
in O
vitro O
from O
96.3 O
to O
94.8 O
% O
, O
which O
resulted O
in O
an O
increase O
of O
approximately O
40 O
% O
in O
the O
free O
tiagabine O
concentration O
. O

The O
successive O
application O
of O
glycine B-drug
( O
5 O
or O
10 O
mg/kg O
egg O
weight O
( O
e.w O
. O
) O
and O
glutamate B-drug
( O
15 O
mg/kg O
e.w O
. O
) O
in O
a O
10 O
min O
interval O
significantly O
increased O
the O
activation O
of O
spontaneous O
motility O
of O
17-day-old O
chick O
embryos O
in O
comparison O
with O
the O
effect O
of O
glutamate B-drug
alone O
. O

Propranolol B-drug
: O
May O
decrease O
aspirins B-brand
anti-inflammatory O
action O
by O
competing O
for O
the O
same O
receptors O
. O

with O
sucralfate B-drug
; O

Some O
quinolones B-group
, O
including O
ciprofloxacin B-drug
, O
have O
been O
associated O
with O
transient O
elevations O
in O
serum O
creatinine O
in O
patients O
receiving O
cyclosporine B-drug
concomitantly O
. O

twice O
the O
human O
dose O
on O
BSA O
) O
and O
non-ossification O
of O
the O
odontoid O
and O
ventral O
tubercle O
of O
the O
first O
cervical O
vertebra O
at O
doses O
0.1 O
mg/kg/day O
IM O
( O
approximately O
one-tenth O
of O
the O
human O
dose O
on O
BSA O
) O
when O
administered O
during O
the O
period O
of O
organogenesis O
. O

Thus O
there O
was O
a O
tendency O
toward O
a O
more O
pronounced O
inhibition O
of O
the O
4-hydroxylation O
during O
treatment O
with O
150 O
mg/d O
of O
fluvoxamine B-drug
compared O
with O
75 O
mg/d O
, O
but O
the O
difference O
was O
not O
statistically O
significant O
. O

Amiodarone B-drug
is O
also O
known O
to O
be O
an O
inhibitor O
of O
CYP3A4 O
. O

Concomitant O
administration O
of O
Mefloquine B-drug
and O
other O
related O
compounds O
( O
eg O
, O
quinine B-drug
, O
quinidine B-drug
and O
chloroquine B-drug
) O
may O
produce O
electrocardiographic O
abnormalities O
and O
increase O
the O
risk O
of O
convulsions O
. O

Clinical O
studies O
of O
the O
effect O
of O
strong O
CYP O
3A4 O
inhibitors O
on O
the O
pharmacokinetics O
of O
fulvestrant B-drug
have O
not O
been O
performed O
. O

The O
natriuretic O
effect O
of O
furosemide B-drug
has O
been O
reported O
to O
be O
inhibited O
by O
some O
drugs O
of O
this O
class O
. O

Interference O
of O
biocytin O
with O
opioid-evoked B-group
hyperpolarization O
and O
membrane O
properties O
of O
rat O
spinal O
substantia O
gelatinosa O
neurons O
. O

tricyclic B-group
antidepressants I-group
. O

Coadministration O
of O
digoxin B-drug
did O
not O
have O
effects O
on O
either O
the O
safety O
or O
efficacy O
of O
ibutilide B-drug
in O
the O
clinical O
trials O
. O

reliable O
estimates O
of O
the O
prevalence O
of O
reduced O
P450 O
2D6 O
isozyme O
activity O
among O
Asian O
, O
African O
and O
other O
populations O
are O
not O
yet O
available O
. O

In O
an O
effort O
to O
screen O
compounds O
for O
antipsychotic O
activity O
, O
preclinical O
researchers O
have O
investigated O
whether O
these O
compounds O
block O
PCP-induced B-drug_n
behaviors O
in O
animals O
. O

Other O
compounds O
that O
are O
substrates O
of O
CYP3A4 O
may O
have O
decreased O
plasma O
concentrations O
when O
coadministered O
with O
SUSTIVA B-brand
( O
efavirenz B-drug
) O
. O

Only O
at O
the O
highest O
concentration O
tested O
( O
171 O

No O
carcinogenicity O
or O
fertility O
studies O
were O
conducted O
. O

Estazolam B-drug
: O
Interaction O
with O
Drugs O
that O
Inhibit O
Metabolism O
via O
Cytochrome O
P450 O
3A O
( O
CYP3A O
) O
: O
The O
metabolism O
of O
estazolam B-drug
to O
the O
major O
circulating O
metabolite O
4-hydroxy-estazolam B-drug_n
and O
the O
metabolism O
of O
other O
triazolobenzodiazepines B-group
is O
catalyzed O
by O
CYP3A O
. O

A O
daily O
dose O
of O
2 O
mg O
of O
coumaphos/kg B-drug_n
of O
body O
weight O
for O
6 O
days O
did O
not O
affect O
the O
plasma O
enzymes O
or O
the O
antiprothrombinemic O
effect O
of O
bishydroxy-coumarin B-drug
in O
wethers O
. O

The O
incidence O
of O
cardiovascular O
morbidity O
and O
mortality O
is O
not O
higher O
among O
users O
of O
sildenafil B-drug
. O

- O
Primaquine B-drug
or O

There O
have O
been O
reports O
of O
theophylline-related B-drug
side O
effects O
in O
patients O
on O
concomitant O
therapy O
with O
norfloxacin B-drug
and O
theophylline B-drug
. O

Since O
entecavir B-drug
is O
primarily O
eliminated O
by O
the O
kidneys O
, O
coadministration O
of O
BARACLUDE B-brand
with O
drugs O
that O
reduce O
renal O
function O
or O
compete O
for O
active O
tubular O
secretion O
may O
increase O
serum O
concentrations O
of O
either O
entecavir B-drug
or O
the O
coadministered O
drug O
. O

Naproxen B-drug
: O
Coadministration O
( O
N=18 O
) O
of O
naproxen B-drug
sodium I-drug
capsules O
( O
250 O
mg O
) O
with O
Neurontin B-brand
( O
125 O
mg O
) O
appears O
to O
increase O
the O
amount O
of O
gabapentin B-drug
absorbed O
by O
12 O
% O
to O
15 O
% O
. O

Therefore O
, O
COLESTlD B-brand
Tablets O
may O
delay O
or O
reduce O
the O
absorption O
of O
concomitant O
oral O
medication O
. O

PEGANONE B-brand
used O
in O
combination O
with O
other O
drugs O
known O
to O
adversely O
affect O
the O
hematopoietic O
system O
should O
be O
avoided O
if O
possible O
. O

Drug O
Interactions O
with O
Antacids B-group
Administration O
of O
120 O
mg O
of O
fexofenadine B-drug
hydrochloride I-drug
( O
2 O
x O
60 O
mg O
capsule O
) O
within O
15 O
minutes O
of O
an O
aluminum B-drug
and O
magnesium B-drug
containing O
antacid B-group
( O
Maalox B-brand
) O
decreased O
fexofenadine B-drug
AUC O
by O
41 O
% O
and O
cmax O
by O
43 O
% O
. O

Somatrem/Somatropin B-drug
: O
Excessive O
concurrent O
use O
of O
thyroid B-group
hormone I-group
may O
accelerate O
epiphyseal O
closure O
. O

Drugs O
whose O
absorption O
is O
sensitive O
to O
pH O
may O
be O
negatively O
impacted O
by O
concomitant O
administration O
of O
omeprazole B-drug
and O
valdecoxib B-drug
. O

No O
information O
available O
. O

Arginine B-drug
, O
in O
the O
absence O
of O
glucose B-drug
or O
theophylline B-drug
, O
caused O
excessive O
glucagon O
release O
in O
the O
diabetics O
and O
undetectable O
insulin O
release O
in O
either O
diabetics O
or O
normals O
. O

These O
agents O
should O
not O
be O
taken O
for O
8 O
hours O
before O
or O
for O
2 O
hours O
after O
enoxacin B-drug
administration O
. O

During O
amiodarone B-drug
administration O
, O
systemic O
clearance O
of O
digoxin B-drug
was O
reduced O
from O
234 O
+/- O
72 O
ml/min O
( O
mean O
+/- O
standard O
deviation O
) O
to O
172 O
+/- O
33 O
ml/min O
( O
p O
less O
than O
0.01 O
) O
. O

Drug O
interactions O
: O
How O
to O
identify O
them O
. O

. O

injection O
of O
vehicle O
( O
corn O
oil O
, O
0.1 O
mL/day O
) O
, O
estradiol B-drug
( O
10 O
microg/kg/day O
or O
4 O
mg/kg/day O
) O
and/or O
progesterone B-drug
( O
20 O
mg/kg/day O
) O
, O
for O
eight O
days O
. O

This O
may O
indicate O
that O
they O
could O
enhance O
the O
toxicity O
of O
methotrexate B-drug
. O

Inhibitors O
of O
CYP3A4 O
( O
eg O
, O
ketoconazole B-drug
) O
or O
CYP2D6 O
( O
eg O
, O
quinidine B-drug
, O
fluoxetine B-drug
, O
or O
paroxetine B-drug
) O
can O
inhibit O
aripiprazole B-drug
elimination O
and O
cause O
increased O
blood O
levels O
. O

The O
mechanism O
underlying O
many O
of O
these O
events O
is O
unknown O
, O
but O
may O
represent O
increased O
hypotension O
. O

It O
is O
therefore O
necessary O
to O
be O
well O
acquainted O
with O
the O
clinical O
and O
paraclinical O
pattern O
of O
magnesium B-drug
deficit O
and O
to O
discriminate O
between O
magnesium B-drug
deficiency O
due O
to O
an O
insufficient O
magnesium B-drug
intake O
which O
only O
requires O
oral O
physiological O
supplementation O
and O
magnesium B-drug
depletion O
related O
to O
a O
dysregulation O
of O
the O
control O
mechanisms O
of O
magnesium B-drug
status O
which O
requires O
more O
or O
less O
specific O
regulation O
of O
its O
causal O
dysregulation O
. O

Therefore O
, O
the O
concomitant O
administration O
of O
TRACLEER B-brand
and O
glyburide B-drug
is O
contraindicated O
, O
and O
alternative O
hypoglycemic B-group
agents I-group
should O
be O
considered O
. O

